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Tong Wu 
THE EXPLORATION OF AN EFFECTIVE MEDICAL COUNTERMEASURE 
ENHANCING SURVIVAL AND HEMATOPOIETIC RECOVERY AND 
PREVENTING IMMUNE INSUFFICIENCY IN LETHALLY-IRRADIATED MICE 
There is an urgent demand for effective medical countermeasures (MCM) in the 
event of high-dose radiation exposure ranging from nuclear plant disasters to potential 
nuclear warfare. Victims of lethal-dose radiation exposure face multi-organ injuries 
including the hematopoietic acute radiation syndrome (H-ARS) and the delayed effects of 
acute radiation exposure (DEARE) years after irradiation. Defective lymphocyte 
reconstitution and its subsequent immune insufficiency are some of the most serious 
consequences of H-ARS and DEARE. In order to investigate potential MCMs to protect 
or mitigate these radiation injuries, the prolonged tissue-specific immunosuppression at 
all levels of lymphocyte development in established murine H-ARS and DEARE models 
was defined, along with unique sex-related and age-related changes present in some 
tissues but not others. The “double hits” of irradiation and age-related stress on 
lymphopoiesis led to significant myeloid skew and long-term immune involution. 
Different kinds and different combinations of hematopoietic growth factors, some in 
combination with angiotensin converting enzyme inhibitor, were administered to lethally 
irradiated mice. These radiomitigators were found to significantly increase survival and 
enhance hematopoiesis in H-ARS, but they did little to alleviate the severity of DEARE 
including immune insufficiency. 16,16 dimethyl-prostaglandin E2 (dmPGE2), a long-
acting formulation of PGE2 with similar biological effects as PGE2, was found to 
enhance survival and hematopoiesis in lethal-irradiated mice when used as radiomitigator 
viii 
or radioprotectant. The optimum time window for administration of radioprotectant and 
radiomitigator dmPGE2 was defined, which is -3hr to -15min prior to irradiation and 
+6hr to +30hr post irradiation. Significant survival efficacy of radioprotectant dmPGE2 
was also demonstrated in pediatric and geriatric mice. Using specific PGE2 receptor (EP) 
agonists, the EP4 receptor was defined as the PGE2 receptor potentially responsible for 
dmPGE2 radioprotection. Radioprotectant dmPGE2 was also found to prevent radiation-
induced thymic involution and to ameliorate the long-term immune suppression in 
radiation survivors in the DEARE phase via promoting hematopoietic stem cell 
differentiation towards to the lymphoid lineage. This is the first report of an effective 
MCM for H-ARS which also targets long-term thymic involution and lymphoid lineage 
reconstitution. 
 
Christie M. Orschell Ph.D., Chair 
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Chapter 1. Introduction 
1.1. Rationale and Overview 
There is an urgent demand for effective medical countermeasures (MCM) in the 
event of high-dose radiation exposure ranging from nuclear plant disasters to potential 
nuclear warfare. The first and only use of nuclear weapons to date occurred in Japan in 
1945, when US forces dropped the atomic bombs “Little Boy” and “Fat Man” over 
Hiroshima and Nagasaki, respectively. While this act ended the Second World War, it 
resulted the deaths of over 200,000 people, over 80% of whom were civilians. This 
culminated in a loss of 28% of the population of Hiroshima, and 39% of the population of 
Nagasaki. Approximately 35,000 people in Nagasaki and 70,000 people in Hiroshima 
were killed instantly. The remaining victims died as a result of high-dose radiation 
exposure, typically within 20-30 days. At the time, the symptoms of high-dose radiation 
exposure were unknown, and were referred to as “atomic bomb disease” or “radiation 
poisoning”. Infection, hemorrhage, and multiple-organ failure were the main causes of 
death. Antibiotics and repeated blood transfusions were given, with limited success [1, 2]. 
Survivors suffered long-term effects of radiation exposure, including malignancies, birth 
defects in their offspring, cataracts, and cognitive decline [3, 4]. 
 
Nuclear reactors are another source of radiation threat. Explosions followed by 
core meltdown at Chernobyl (1986) and Fukushima (2011) nuclear power plants exposed 
employees and firefighters to high-dose radiation at the reactor site, and civilians to 
radiation from contaminated air, water, and soil. The Chernobyl accident released over 
four hundred times the amount of radioactive material in comparison with the atomic 
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bombs in Japan; however, due to the relative underpopulation of the surrounding area, 
mortality was significantly lower [5].Two hundred people in Chernobyl suffered acute 
complications similar to the atomic bombing victims, with 31 deaths within the first three 
months. Over 200,000 emergency workers, police, soldiers, firefighters, and volunteers 
responsible for clean-up after the Chernobyl accident experienced negative effects from 
radiation exposure at varying doses. The nearby city of Pripyat was evacuated the day 
after the accident, and an exclusion zone of 30 km radius around the site was instituted in 
the following years. The accident displaced over 300,000 people. However, people 
residing nearby were exposed to repeated low-dose radiation, and according to 
epidemiological studies, 4,000 cancer deaths occurred in the next 30 years among this 
population. This cancer rate is significantly higher than the global average [6, 7]. In the 
Fukushima accident, less radioactive material was released as the plant’s radioactive 
cores remained largely intact. No immediate deaths occurred; however, it was confirmed 
that a worker died from radiation-related cancer in 2018. The impact of the release of 
radioactive material into the sea is still unknown, as are long-lasting health implications 
for people in the area surrounding the plant [4, 8]. 
 
During the Cold War years that followed World War II, the United States and the 
then Soviet Union stockpiled around 125,000 nuclear warheads between them. Most 
sovereign states participated in the 1970 Treaty on the Non-Proliferation of Nuclear 
Weapons, and the Soviet Union dissolved in 1991, resulting in a dramatic decrease of 
global nuclear warheads to under 15,000 among nine nations [9]. However, the threat 
from nuclear war to mankind is still a possibility. The use of nuclear energy presents the 
 3 
most credible risk of radiation exposure through nuclear plant accidents. Over 100 
serious nuclear accidents have been recorded since the first use of nuclear power. Two-
thirds of these occurred in the USA [10]. Technological and safety advances have 
minimized risk; however, unpredictable factors such as the earthquake and tsunami 
responsible for the Fukushima accident pose a threat to these nuclear facilities. The 
development of interventions for people exposed to high-dose radiation is required to 
reduce mortality after nuclear accidents and warfare globally. This motivated me in Dr. 
Orschell's laboratory to study MCMs in response to high-dose radiation exposure.  
 
1.2. Types of Ionizing Radiation 
There are five types ionizing radiation: alpha, beta, gamma, x-ray, and neutron 
(Figure 1). Alpha, beta, and neutron radiation consists of small particles; gamma 
radiation and x-rays are high-energy photon waves. Alpha particles are ejected from 
unstable nuclei during alpha decay and are identical to the nucleus of helium, with the 
absence of surrounding electrons. These particles can travel only a few centimeters in air, 
thus their penetrating capacity is weak and can be blocked by clothing. Beta particles are 
high-energy electrons released during radioactive decay, with a smaller mass than alpha 
particles. They can travel approximately one meter in air, and have a higher penetrating 
capacity than alpha particles, though can be blocked by a thin aluminum plate. Beta 
particles are capable of penetrating the skin to the germinal layer, potentially resulting in 
injury. Alpha and beta radiation generally do not pose a serious risk to human health 
unless inhaled or ingested.  
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Figure 1 
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Figure 1. Types of ionizing radiation.  
In the five types of ionizing radiation, alpha, beta and neutron radiation are small 
particles; gamma and x radiation are photon waves. Alpha radiation travels only a short 
distance with weak penetrating ability. Beta radiation travels longer and has higher 
penetrating ability than alpha radiation but still easily be blocked by a thin aluminum 
plate. Gamma and x radiation travels far in air and easily penetrate body tissue, which 
could be blocked by dense material such as lead. Neutron, which has excellent 
penetration ability, its effect is dependent on ionizing other atoms. Only hydrogen-rich 
material such as water can effectively block neutron radiation. The main radiation source 
in this thesis is gamma radiation. Figure adapted from Wikipedia contributors. (2020, 
June 21). Ionizing radiation. In Wikipedia, The Free Encyclopedia. Retrieved July 14, 
2020, from https://en.wikipedia.org/wiki/Ionizing_radiation. 
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The fission of radioactive atoms results in the emission of numerous neutrons, 
which are uncharged. Neutron radiation is indirectly ionizing as a result of subsequent 
ionization of other atoms when the free neutrons react with other nuclei. Neutrons can 
travel hundreds or even thousands of meters in air and have high penetration ability -- 
only hydrogen-rich material can effectively block neutron radiation. Nuclear reactors are 
surrounded by meter-thick concrete or water outer layers for this reason [11, 12].  Alpha, 
beta, and neutron particles are either low-penetrating or hard to control, and thus are 
unlikely to be used in warfare, unlike gamma and x-rays, which pose a more significant 
threat (Figure 1).  
 
Gamma and x-rays are electromagnetic radiation, with waves similar to visible 
light in form, but higher in energy. Both travel far in air and are high-penetrating, capable 
of reaching bodily tissue. This results in electron displacement and energy release 
sufficient to burn surrounding tissues. Gamma and x-rays are blocked only by extremely 
dense material such as lead. Common gamma radiation sources are 137Cs, 131I, 60Co, 
226Ra, and 99mTc. The 137Cs source was used in following studies. The difference between 
gamma and x-ray is controversial, though it is generally accepted that gamma radiation is 
emitted from the atom’s nucleus, whereas x-rays are emitted from the electron cloud. 
Gamma radiation has a shorter wavelength and higher photon energy than x-rays [13, 
14]. 
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1.3. Radiation Quantities 
The U.S. Nuclear Regulatory Commission (NRC) defines four radiation dose 
units: radioactivity, exposure, absorbed dose, and dose equivalent. The dose unit for 
radioactivity is the curie (Ci, British) or becquerel (Bq, international) and represents the 
number of decayed atoms in a material over a specific time. The does unit for exposure is 
roentgen (R), representing the amount of ionization in the air. The absorbed dose is the 
amount of energy absorbed by a defined mass of tissue, and its dose unit is gray (Gy) or 
radiation absorbed dose (Rad). The dose equivalent measures the clinical effect of 
radiation on the body as a product of the absorbed dose and tissue weighting factor, 
which varies depending on tissue sensitivity to radiation. It is expressed as roentgen 
equivalent man (REM) or Sievert (Sv) [11, 15]. The Gy or cGy (1 Gy = 100 cGy = 100 
Rad) are used as the radiation unit in following studies.  
 
The dose rate in the following studies refers to the rate of radiation dose exposure, 
measured in cGy per minute. Higher dose rates are associated with a more severe 
response to the radiation and increased carcinogenic risk [15].  Dose rate allows us to 
calculate the time necessary for whole-body irradiation. E.g. if the target dose for a 
mouse is 8.72 Gy, and the dose rate is 89.14 cGy/minute, the exposure time is 9 minutes 
and 47 seconds (8.72 Gy/89.14 cGy/minute = 9.78 minutes).    
 
1.4. Biological Effects of Ionizing Radiation 
The biological effects of ionizing radiation lead to the symptoms of radiation 
sickness. Absorbed radiation affects multiple cellular organelles. It disrupts atomic bonds 
 8 
directly or indirectly via water radiolysis, which produces reactive oxygen species (ROS) 
and reactive nitrogen species (RNS). 137Cs gamma radiation causes 60 nmol/L ROS per 
nanogram of tissue within one microsecond post- irradiation (post-IR) [16]. ROS 
metabolites produced via water radiolysis are predominantly O2•−, •OH, and H2O2, causing 
deoxyribonucleic acid (DNA) damage via the induction of abasic sites and base 
oxidation, contributing to carcinogenic mutagenesis [17, 18]. These free radicals also 
oxidize accessory structures such as histone, which is critical for gene regulation and 
DNA packaging (Figure 2), and cause protein carbonylation and lipid peroxidation in 
non-nuclear organelles. The mitochondria are particularly affected as they produce most 
of the intracellular ROS. The mitochondria are responsible for energy production and 
oxidation-reduction balance [19-21], and persistent increased mitochondrial oxidative 
stress and heritable mitochondrial DNA (mtDNA) damage post-IR contributes to 
accelerated aging [17, 22].  
 
Radiation-induced mitochondrial DNA damage occurs through several 
mechanisms. Firstly, radiation-induced lipid peroxidation disrupts the mitochondrial 
membrane, which is the location of the electron transport chain (ETC) [23]. Subsequent 
electron leakage from the ETC reduces O2, producing more superoxide, leading to 
mitochondrial dysfunction, mitochondrial DNA mutation, and apoptosis [24]. Secondly, 
radiation damages protein translocation machinery, impairing the import of cytosolic 
proteins required for mitochondrial biogenesis into the mitochondria [25, 26]. Thirdly, 
radiation damages mtDNA in the same way as it does nuclear DNA, inducing abasic sites 
and base oxidation. This damage is heritable and transmitted to new mitochondria   
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Figure 2. Direct and indirect effects of ionizing radiation.  
There are two types of biological effects of ionizing radiation: the direct effect and the 
indirect effect. The disruption of DNA structure by indirect effect is mainly mediated by 
the production of ROS and RNS. The indirect damage is generally more severe than the 
direct damage since indirect effect also brings damage to other organelles as shown in 
Figure 3. Figure adapted from Hall, E. J. and Giaccia, A. J., Radiobiology for the 
Radiologist. 2012 [27]. 
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generated post-IR [17, 28].  Finally, fragments of damaged mtDNA can migrate into the 
nucleus and insert into the nuclear genome during DNA double strand break (DSB) 
repair, which is induced by radiation. These insertions further increase radiation-induced 
genomic instability, heightening the potential for carcinogenesis [17] (Figure 3).   
 
Another characteristic of radiation is the bystander effect, in which non-irradiated 
(NI) cells are affected by radiation through communication with irradiated cells. Several 
possible mechanisms have been proposed. Free radicals and cytokines produced by 
irradiated cells may impact non-irradiated cells via paracrine signaling [29]. Epigenetic 
alteration may also occur as a result of non-coding ribonucleic acid (RNA, such as 
miRNA or siRNA, which silence gene expression) detaching from irradiated cells and 
altering gene expression in non-irradiated cells [30]. mtDNA fragments also contribute to 
the bystander effect by migrating to non-irradiated cells [17]. Understanding of the 
biological effects of ionizing radiation helps delineate the short- and long-term effects of 
radiation, and the pharmacological mechanism of treatments. 
 
1.5. Illnesses and Treatments Related to Radiation Exposure  
1.5.1. Acute radiation syndrome  
Less than 24 hours after exposure to high doses of ionizing radiation, victims 
develop a continuum of multi-system symptoms referred to as acute radiation syndrome 
(ARS). Different tissues have different radio-sensitivity; less-differentiated and actively-
proliferating cells are the most sensitive (Law of Bergonié and Tribondeau) [11, 31].  
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Figure 3. Biological effects of ionizing radiation.  
Ionizing radiation causes direct damage to DNA structure, or indirect damage to DNA 
and mitochondrion by the free radicals produced from water radiolysis. The free radicals, 
mainly ROS and RNS, oxidize and permanently change the structure of lipids, proteins, 
nuclear DNA and mtDNA. Figure adapted from Azzam, E.I., Jay-Gerin, J.P. and Pain, 
D., Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. 
Cancer Lett, 2012 [17].  
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There are four stages of ARS: the prodromal phase, latent phase, manifestation 
phase and recovery/death phase (Figure 4). When the radiation dose is extremely high 
(>50 Gy), victims quickly progress into unconsciousness and hypotension, and death will 
occur within 48 hours as a result of neurologic and cardiovascular collapse (Figure 5) 
[32]. When the radiation does is less than 1 Gy, although there is sub-clinical damage to 
hematological system, the victim is generally asymptomatic. At a dose higher than 1 Gy 
but not at a level considered extremely high (e.g. 2-10 Gy), digestive tract symptoms 
appear first, including nausea, vomiting, and anorexia. This results from radiation-
induced damage to the vomiting center of the chemoreceptor trigger zone (CTZ) in the 
medulla oblongata, as opposed to direct digestive tract damage. Typically, these 
symptoms persist no longer than 48 hours [15], and are followed by a short latent phase 
in which the victim appears to recover before live cell numbers decrease below the 
clinical threshold. The latent phase period varies and is inversely proportional to radiation 
dose. The subsequent manifestation phase results from cell depletion and dysfunction of 
the hematopoietic, gastrointestinal, and central nervous systems. This phase can last from 
days to months. If victims receive sub-lethal irradiation dose, the recovery phase will 
follow; without treatment, death is highly probably in victims exposed to a lethal dose 
(LD). LD××/×× days is used to define a lethal dose, representing number of deaths over 
time, i.e. LD70/30 means at this dose, 70% of the irradiated population will die within 30 
days [11, 33].   
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Figure 4  
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Figure 4. Stages of acute radiation syndrome.  
The prodromal syndrome develops first, followed by a latent period and then symptoms 
of illness shows up. The severity of symptoms at prodromal syndrome stage and 
symptoms of illness stage is directly proportional to radiation dose. The time of the latent 
period is inversely proportional to radiation dose. Figure adapted from Hall, E. J. and 
Giaccia, A. J., Radiobiology for the Radiologist. 2012 [27]. 
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Figure 5. Acute radiation syndrome in different organs.  
Neurovascular system is one of the most radio-resistant system and victims will quickly 
progress death once the neurovascular symptoms develop. Hematological system is one 
of the most radio-sensitive system where the low radiation dose even as 1 Gy could 
induce sub-clinical damages and the recovery phase is late at around days 20-30 post-
irradiation. If victims received lethal dose of radiation, there will be no recovery phase 
and will progress to death earlier. The radio-sensitivity of the gastrointestinal system is in 
the middle of neurovascular system and hematological system. Figure adapted from 
Seedhouse, E., Space Radiation and Astronaut Safety. 2018 [34]. 
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1.5.1.1. Gastrointestinal acute radiation syndrome  
The epithelial cells lining the gastrointestinal (GI) tract are highly sensitive to 
radiation as they slough and replenish on a regular basis. In humans, Gastrointestinal 
acute radiation syndrome (GI-ARS) occurs following exposure to radiation >5 Gy. In 
addition to the nausea, vomiting, and anorexia observed in the prodromal phase, victims 
experience abdominal cramps, watery diarrhea, hematemesis, and melena. This results 
from compromise of the GI barrier, impairing the balance of absorption, secretion, and 
excretion. Associated dehydration and electrolyte imbalance can be lethal. The 
breakdown of GI integrity also increases the movement of normal or pathogenic bacteria 
from the GI into blood, leading to bacteremia and sepsis. Because the hematopoietic 
system is also inhibited, severe infection can lead to septic shock, multiple organ 
dysfunction syndromes (MODS), and death [32, 33, 35]. 
 
1.5.1.2. Cerebrovascular acute radiation syndrome 
Compared to the digestive and hematopoietic systems, the central nerve system 
(CNS) is relatively radioresistant. Although low-dose irradiation can disturb the vomiting 
center in the prodromal phase and induce some functional disorders, these effects are 
transient and no measurable damage occurs in the brain until the radiation dose reaches 
10 Gy. The typical symptoms at total-body irradiation (TBI) doses >20 Gy include 
nausea, vomiting, dizziness, headache, disorientation, hypo- or hyper-reflexia, ataxia, 
seizure, delirium and dementia. The mechanism is believed to be due to direct nerve cell 
damage and indirect capillary circulation damage. The latter compromises blood-brain 
barrier integrity and leads to interstitial edema and intracerebral hemorrhage, contributing 
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to intracranial hypertension, brain herniation, and circulatory collapse. Most 
cerebrovascular damages are irreversible and severe symptoms generally represent poor 
prognosis [11, 15, 32]. 
 
1.5.1.3. Hematopoietic acute radiation syndrome  
Hematopoietic cells are the most proliferative cell type and the majority of bone 
marrow (BM) cells are immature progenitors. Thus, the hematopoietic system is one of 
the most radiosensitive, and a dose as low as 0.2 Gy can induce cell cycle arrest. 
Transient, mild cytopenia occurs at 0.2 - 2 Gy without significant clinical manifestations. 
Victims may experience prodromal symptoms such as nausea and fatigue. Clinical 
hematopoietic acute radiation syndrome (H-ARS) occurs when the absorbed dose is 
above 2 Gy [11, 33], and symptoms will not be apparent until circulating cell numbers 
have dropped significantly. The symptoms of H-ARS are due to leukopenia, which leads 
to susceptibility to infection and poor wound healing; erythropenia, leading to anemia, 
fatigue, and heart failure; and thrombocytopenia, leading to petechiae, purpura, and 
hemorrhage [15]. The radiosensitivity of blood cells varies by type. Lymphocytes (LY) 
are the most sensitive, despite being terminally-differentiated, and are the first population 
to be depleted in H-ARS [11]. LY depletion is positively proportional to the absorbed 
dose. The lymphocyte depletion rate (LDR) is used as a biodosimetry method. 
Biodosimetry is the measure of biological parameters to estimate the radiation dose a 
person has received (Figure 6). LDR is more accurate than observing clinical symptoms 
and less complicated than other biodosimetry, such as dicentric chromosome analysis or 
fluorescence in situ hybridization [11, 36]. LY depletion begins in the first 6-24 h after  
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Figure 6. Classical Andrews lymphocyte depletion kinetics and accompanying 
clinical severity ranges.  
Lymphocyte decreasing rate and degree of the decline is positively proportional to the 
absorbed radiation dose. The lymphocyte depletion rate is used as a biodosimetry 
method. Curves 1 to 4 roughly represent the following does of TBI: (1): 3.1 Gy; (2): 4.4 
Gy; (3): 5.6 Gy; (4): 7.1 Gy. Figure adapted from Christensen, D.M., Iddins, C.J. and 
Sugarman, S.L., Ionizing radiation injuries and illnesses. Emerg Med Clin North Am, 
2014 [11]. 
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exposure and reaches nadir at 3-6 days, depending on the radiation dose. Neutrophils 
(NE) deplete to their lowest level 1- 2 weeks after TBI dosage greater than 2 Gy in 
human, which is later than LY [37, 38]. Neutropenia and lymphocytopenia render victims 
immunocompromised and highly susceptible to infection in the nadir phase. Red blood 
cells (RBC) and platelets (PLT) are considerably less radiosensitive than white blood 
cells (WBC). RBC typically renew every 120 days; PLT every 8-9 days; and they are 
non-nucleated end-product cells with terminal differentiation. Thus, RBC depletion is 
slow and nadir is not remarkable [11]. The decline pattern of PLT is similar to NE, 
reaching nadir 1- 2 weeks after exposure to a lethal dose. The time to nadir and the nadir 
level is inversely proportional to radiation dose, whereas nadir duration is positively 
proportional to the absorbed dose. The lower the nadir level and the longer its duration is, 
the risk of infection and hemorrhage risk increases, thus increasing the mortality risk 
[32]. 
 
1.5.1.4. Other ARS sub-syndromes 
Due to the limitations of this study, further ARS sub-syndromes are not discussed 
in detail. However, radiation also damages the eyes, skin, endocrine system, urogenital 
system, etc., some of which show specific ARS symptoms [11]. Additionally, inhalation 
or digestion of alpha and beta particles causes internal exposure and subsequent ARS in 
exposed organs, which may be more severe than ARS resulting from external exposure 
[15].  
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1.5.2. Deterministic and stochastic effects of ionizing radiation 
Most of the discussed ARS are deterministic effects of ionizing radiation, 
meaning that the dose of radiation determines the severity of the effect. There are two 
characteristics of deterministic effect. Firstly, the severity of the effect is proportional to 
the absorbed dose. Secondly, there is a dose threshold and symptoms occur only when the 
dose is at or above this threshold. It is due to the damage of many cells by radiation. The 
shape of the curve is sigmoid (Figure 7). The effects on testis and bone marrow are the 
examples of the deterministic effect, which have the lowest thresholds of body tissue 
(0.15 Gy for testis and 0.5 Gy for bone marrow) [33]. 
 
In contrast, stochastic effects occur by chance. The probability of occurrence is 
proportional to the dose of radiation, but there is no obvious threshold, and the effect can 
occur even if only one cell is damaged. The shape of the curve is linear. Malignancy 
induced by irradiation an example of stochastic effect [15, 39] (Figure 7). 
 
1.5.3. Delayed effects of acute radiation exposure  
Delayed effects of acute radiation exposure (DEARE) is a spectrum of chronic 
illnesses involving multiple systems after years post-IR, which is the result of oxidative 
stress, inflammation, fibrosis, and loss of stem cell self-renewal in the ARS survivors [40, 
41]. Little is known about DEARE in comparison with ARS, and most knowledge are 
gleaned from observing atomic bomb survivors and post-radiotherapy cancer survivors.  
There are three types of DEARE: somatic, genetic (hereditable), fetal (in utero). In 
following studies, somatic effect is the focus.  
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Figure 7. Deterministic effects and stochastic effect of radiation.  
Deterministic effect occurs when victim exposes to radiation exceeding a certain level 
(threshold). The higher the radiation dose, the more severe deterministic effect will be. 
The reason for deterministic effect is the cell killing/death. Stochastic effect does not 
have a threshold and does not happen at everyone exposed to radiation. The higher the 
radiation dose, the higher probability of certain stochastic effect (such as cancer) will be. 
It is due to accumulated damage to DNA and malignant proliferation. Figure adapted 
from Chouker, A., Stress Challenges and Immunity in Space. 2020 [42]. 
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1.5.3.1. Non-cancer diseases 
According to the Life Span Study (LSS) and Adult Health Study (AHS) of the 
Hiroshima and Nagasaki atomic bomb survivors, cataract, thyroid disease, 
hyperparathyroidism, chronic liver disease and cirrhosis, uterine myoma, hypertension, 
myocardial infarction, stroke, chronic kidney diseases, pneumonia/influenza [3, 43] are 
significantly associated with radiation. Cancer survivors who received radiotherapy of the 
abdomen or pelvis have been reported to develop delayed radiation enteropathy, 
presenting as featured as malabsorption or dysmotility [44]. The risk for late-onset 
chronic kidney disease is increased significantly in patients receiving >16 Gy TBI before 
hematopoietic stem cell transplantation [45]. In patients receiving thoracic radiotherapy, 
around 5-15% develop symptomatic pneumonitis and 43% experience radiation-induced 
pneumonitis or pulmonary fibrosis 6-24 months after treatment [46, 47]. Neurocognitive 
deficits occur several months to years after treatment in 30-50% of patients who received 
radiotherapy for brain tumors [48, 49]. Some of the effects seen after radiotherapy were 
not reported in atomic bomb survivors as the TBI they received was much lower than 
targeted dose administered to specific organs during radiotherapy. According to the 
stochastic effect rule, the higher the dose, the higher possibility of a late effect occurs. 
The LD50 for humans is 4 Gy in TBI, but the dose required to eradicate an epithelial 
tumor is 60-80 Gy. This dose is achieved by providing multiple fractionated irradiations 
directed at the target organ. 
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1.5.3.2. Solid tumors and hematopoietic malignancies 
Unlike in radiotherapy, atomic bomb survivors received penetrating TBI, and 
their risk for developing malignancies increased in multiple organs and systems as a 
consequence. Over the years following radiation exposure, the risk for solid tumor 
development gradually increases at a greater extent than the age-related risk of tumors in 
non-irradiated humans (Figure 8). There is a significant linear dose-response relationship 
to tumor development in cancers of the oral cavity, esophagus, stomach, colon, liver, 
lung, etc. Other factors also increase risk, such as gender, age at exposure, time after 
exposure, and lifestyle. The relative risk for total solid tumors is 50% higher in females 
than males, and two-fold higher in survivors irradiated at a younger age than at an older 
age [3, 50, 51]. 
 
The latent period for hematopoietic malignancies is much shorter than for solid 
tumors. Leukemia is the predominant radiation-related cause of death in the early years 
post-exposure. The first instance of radiation-induced leukemia was reported 7 years after 
the atomic bombing of Japan[52]. In atomic bomb survivors, the risk for developing 
leukemia peaked 8-10 years after exposure and then rapidly decreased [53]. Risk for 
myelodysplastic syndromes (MDS) is also associated with radiation; unlike leukemias, 
these develop later in life [54]. There is little evidence to indicate that radiation exposure 
increases risk for lymphomas or multiple myeloma [55]. 
 
1.5.3.3. Residual bone marrow damage  
DEARE effects on the hematopoietic system are known as residual bone marrow 
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Figure 8. Life Span Study (LSS) radiation-associated deaths per year.  
Around 120,000 Hiroshima and Nagasaki atomic bomb survivors and control subjects 
were included in the LSS. Mortality data for solid tumor, leukemia and benign diseases 
were followed up through the year of 2002. Leukemia is the first radiation-associated 
long-term health effect observed in the LSS. Risk assessment of leukemia for the period 
1945-1950 is not possible since victims had to be alive in 1950 to be in the cohort, the 
estimated leukemia deaths during this period are shown as green dotted line. Figure 
adapted from Douple, E.B., et al., Long-term radiation-related health effects in a unique 
human population: lessons learned from the atomic bomb survivors of Hiroshima and 
Nagasaki. Disaster medicine and public health preparedness, 2011 [50].  
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damage (RBMD), a latent condition characterized prolonged inhibition of hematopoiesis 
leading to immunosuppression and increased infection risk [4, 40, 56]. As previously 
described, radiation-induced apoptosis of hematopoietic stem cell (HSC) causes H-ARS. 
This damage to the hematopoietic system can persist long-term [40], though this 
phenomenon has been largely ignored due to seemingly-complete recovery of peripheral 
blood (PB) cell counts, BM cellularity, and number of colony-forming unit (CFU) early 
after exposure [57, 58]. 
 
There are three proposed mechanisms of RBMD: 1) exhaustion of the HSC pool; 
2) HSC senescence; 3) HSC niche damage. First, radiation increases ROS level, which in 
turn induces DNA DSBs. Ataxia-telangiectasia mutated kinase (ATM) recognizes, and is 
activated by, DSBs and phosphorylates downstream p53 and PUMA, which inhibits the 
anti-apoptotic Bcl-2 and activates pro-apoptotic Bax and Bak [59, 60]. Bax and Bak open 
the voltage-dependent anion channel in mitochondria, leading to the release of 
cytochrome C, which activates caspase-9 and induces apoptosis. This is one possible 
mechanism of HSC pool depletion; however, quiescent, metabolically inactive HSC have 
few mitochondria and rely on glycolysis vs. aerobic metabolism [61],  and the role of 
apoptosis in RBMD is still controversial.  
 
The second proposed mechanism, HSC senescence, is based on ROS or p53-
mediated activation of p38 and downstream p16. Activation of p16 results in irreversible 
cell cycle arrest and senescence [62, 63]. Increased ROS in HSC may occur through 
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endogenous oxygen consumption mediated by nicotinamide adenine dinucleotide 
phosphate oxidase (NOX) [64]. There are five isoforms of NOX (1-5), and NOX4 has 
been implicated in radiation-induced chronic oxidative stress in HSC [56, 65]. 
 
The third proposed mechanism is based on the role of the HSC niche in HSC self-
renewal and differentiation. Radiation can induce senescence in bone marrow stromal 
cells via the p38/p16 pathway and this is at least partially responsible for RBMD [66]. 
Sinusoidal endothelial cells have also been known to be affected by radiation-induced 
senescence [67]. It is not clear if osteoblasts contribute to HSC senescence. Other niche 
cells may impact HSC self-renewal and differentiation via altered secretion of cytokines 
or cell-cell contact post-IR. 
 
1.5.4. Medical management of radiation injury 
In the event of unexpected atomic activity and radiation accidents, triage should 
be applied. Physicians must identify victims exposed to life-threatening doses and 
provide treatment prior to decontamination, such as removal of clothing. The priorities in 
triage of victims are based on their injuries, estimated radiation dose, and clinical 
symptoms [15, 68]. The following studies focused solely on the management of radiation 
injury to the hematopoietic system.  
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1.5.4.1. Standard management of H-ARS 
1.5.4.1.1. Transfusion and supportive care 
Blood transfusions are typically administered 10-30 days post-IR. These include 
blood component transfusion or irradiated whole blood transfusion. Antibiotics should be 
given to mitigate the effect of bacterial translocation from the GI system to the blood as 
GI tract barrier impairment and myelosuppression greatly increase infection risk in H-
ARS patients. In the H-ARS mouse model, treatment with antibiotics and acidified water 
from day 4 to 30 post-TBI increases the survival rate and decreases infection risk [69]. In 
leukopenic patients, broad-spectrum antibiotics plus antiviral and antifungal agents 
should be provided prophylactically until the granulocyte number has recovered.  
 
1.5.4.1.2. Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) is an effective treatment for 
hematopoietic malignancies such as multiple myeloma or leukemia, and for benign 
hematopoietic diseases such as aplastic anemia. Aplastic anemia shares similarities with 
H-ARS, such as bone marrow failure. HSCT appears to be a promising option for H-ARS 
treatment; however, many obstacles prevent HSCT following a radiation event.  
 
In the event of an atomic bomb detonation or large-scale radiation accident, the 
number of victims is likely to be disproportionately higher than the number of available 
HSC for transplantation. Human leukocyte antigen (HLA)-matched donors are required, 
and finding these in sufficient numbers is a significant complication. Additionally, the 
process of HLA typing takes 1-2 weeks, which is too long to wait for treatment [15]. It is 
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also difficult to determine radiation dose and whether the radiation dose a victim received 
was partial or whole-body. In mice, partial irradiation is associated with increased 
survival in comparison with mice receiving total-body irradiation (TBI) at the same dose 
[11]. Partially-irradiated victims and TBI victims exposed to a dose <3 Gy generally do 
not experience fatal hematological effects, so HSCT in these patients is unnecessary. The 
lethal TBI dose is 7-8 Gy, and victims exposed to >10 Gy die of CNS complications 
before H-ARS appears. The therapeutic window for HSCT, 7-10 Gy, is difficult to 
estimate immediately after exposure [15].  Finally, though available data are limited, 
HSCT has not produced favorable results. After the Chernobyl disaster, of 29 victims 
receiving HSCT, only three survived, and despite transient donor engraftment, 
autologous reconstitution eventually took over the bone marrow. The remaining 26 
victims died with a median survival of 33 days [15, 68]. This evidence collectively 
indicates that HSCT is a suboptimal intervention following adverse radiation events. 
 
1.5.4.1.3. Growth factor therapy 
Growth factor treatment is a more practical and economic therapy than HSCT. 
Currently, the Food and Drug Administration (FDA) has approved recombinant 
granulocyte colony-stimulating factor (G-CSF), recombinant granulocyte macrophage 
colony-stimulating factor (GM-CSF), and pegylated G-CSF to address neutropenia after 
radiation exposure. G-CSF binds to its receptors and subsequently activates the 
downstream signal pathways, Jak/Stat, Ras/MAPK, and phosphoinositide 3-kinase 
(PI3K) /Akt. This mediates the proliferation of myeloid progenitors and increases the 
number of circulating mature neutrophils [70, 71]. The mechanism of GM-CSF is similar, 
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but with a broader target, including monocyte-macrophages and eosinophils [72, 73]. LY, 
RBC, and PLT recovery is accelerated following growth factor treatment due to induction 
of HSC differentiation. However, this stimulating effect is short-lived and may expedite 
HSC pool exhaustion and exacerbate RBMD [65]. No MCM approved for treatment post-
IR is effective in RBMD, highlighting a critical need to develop new strategies for 
RBMD/DEARE intervention.  
 
1.5.4.2. Potential new therapeutics of H-ARS and DEARE 
Although current FDA-approved MCMs increase survival and complete blood 
count in H-ARS victims, survivors are plagued with long-term hematopoietic 
insufficiency; in particular, defective lymphocyte reconstitution [74]. These MCMs are 
myeloid lineage stimulators leading to early- and long-term myeloid reconstitution, but 
not long-term lymphoid reconstitution. No complete reconstitution of T-cells has been 
observed [75]. Long-term T-cell deficiencies include decreased T-cell number, 
imbalanced CD4/CD8 ratio, and compromised T-cell receptor diversity due to thymic 
involution [15]. Victims of radiation exposure often experience frequent infections and 
cancer in later life, which may be related to deficient T-cell surveillance [76, 77].  
 
The application of growth factors and cytokines capable of enhancing T-cell 
reconstitution and thymic recovery are a promising new direction in therapeutic strategies 
for H-ARS. These include interleukin-7 (IL-7), keratinocyte growth factor (KGF), and 
fetal liver tyrosine kinase 3 (Flt3) ligand, which aid lymphocyte reconstitution in both H-
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ARS and DEARE. Drugs such as lisinopril, which enhance the radio-mitigating effect of 
colony-stimulating factors, are another interesting therapeutic avenue. 
 
1.5.4.2.1. IL-7 
While IL-7 efficacy in H-ARS has yet to be investigated, it has been reported that 
IL-7 accelerates thymopoiesis and increases CD4 and CD8 T-cell number following 
chemotherapy and bone marrow transplantation [78]. IL-7 induces cyclin-dependent 
kinase 2 (Cdk2) or Cdk4 activity, thus increasing cyclin E levels in lymphoid progenitors 
and promoting the proliferation of both T and B lymphocytes [79].  IL-7 administration 
also promotes homeostatic T-cell expansion in normal NI mice [15]. 
 
1.5.4.2.2. KGF    
KGF is known to protect epithelial cells from radiation damage [15, 80].  Its 
receptors are expressed on the surface of thymic epithelial cell (TEC), which produce IL-
7 and promote thymopoiesis. KGF may protect TEC from radiation damage. Min et al. 
[81] demonstrated that administration of KGF for three consecutive days prior to 
allogeneic bone marrow transplant enhanced thymic cellularity for at least three months, 
and increased the number of donor-derived T-cells in recipient spleens.   
 
1.5.4.2.3. Flt3 ligand    
Flt3 is an important surface marker for identifying lymphoid-primed multipotent 
progenitor (LMPP) and common lymphoid progenitor (CLP), which are the common 
progenitors of LY. Binding of FMS-like tyrosine kinase 3 ligand (FLT3L) to Flt3 
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dimerizes Flt3 and subsequently activates downstream PI3K and Ras pathways. This 
promotes the survival and growth of hematopoietic progenitors [82].  FLT3L has minimal 
biological effect when used alone; however, it exhibits synergy with other hematopoietic 
growth factors (HGF) including G-CSF, GM-CSF, interleukin-3 (IL-3), stem cell factor, 
or as an engineered protein containing both FLT3L and another colony-stimulating factor 
[83, 84]. Combination therapies and the engineered protein both accelerate granulocyte 
and immune recovery in mice whether administrated before or after irradiation [85, 86]. 
 
1.5.4.2.4. Angiotensin converting enzyme inhibitor (ACEI) 
The renin-angiotensin system (RAS) is known for its role in regulating blood 
pressure and hydro-electrolyte homeostasis [87].  Renin from the kidney cleaves and 
activates the angiotensinogen from the liver to form angiotensin I (Ang I). Angiotensin 
converting enzyme (ACE), abundant in the lung and blood vessel endothelium, converts 
Ang I into angiotensin II (Ang II). Ang II binds angiotensin receptors on arterial smooth 
muscle, inducing vasoconstriction and increasing blood pressure. Ang II also increases 
hypothalamic production of antidiuretic hormone (ADH) and aldosterone production in 
the zona glomerulosa of the adrenal cortex. Together, these hormones increase sodium 
and water retention in arteries and veins, further elevating blood pressure [88].  ACEI 
inhibits ACE activity and decreases the conversion of Ang I to Ang II, thus down-
regulating blood pressure. Angiotensin II receptor blockers (ARB) is a competitive 
inhibitor of Ang II receptor, directly binding angiotensin receptors [87, 89]. ACEI and 
ARB are widely used for controlling hypertension and coronary artery disease. 
Angiotensin (1-7) is the metabolite of Ang I, catalyzed by neprilysin; or the metabolite of  
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Ang II, catalyzed by ACE2 [90]. Angiotensin (1-7) mediates vasodilation, and is also 
degraded by ACE. Therefore ACEI, as an inhibitor of ACE, increases angiotensin (1-7). 
This contributes to blood pressure control via mediation of vasodilation (Figure 9). 
 
The RAS system may play a role in the regulation of hematopoiesis. Ang II 
receptors present on bone marrow CD34+CD38- cells, stromal cells, erythroid 
progenitors, and mature lymphocytes [91, 92]. Mas is the receptor of angiotensin (1-7), 
which presents on BM hematopoietic stem and progenitor cells and its expression is 
enhanced during hematopoietic stress [93]. Ang II and angiotensin (1-7) may have direct 
effects on hematopoiesis. The Ang II receptor and Mas receptor also present on bone 
marrow endothelial cells, an important component of the bone marrow niche, indicating 
that Ang II and angiotensin (1-7) may regulate hematopoiesis indirectly through altering 
the bone marrow microenvironment [94]. Ang II and angiotensin (1-7) may also 
stimulate hematopoietic progenitors indirectly by modulating HGF such as erythropoietin 
(EPO) in kidney cells [95].  Both in vitro and in vivo experiments show that Ang II or 
angiotensin (1-7) enhances hematopoiesis only under hematopoietic stress, such as in 
myelosuppression following chemo- or radiotherapy. Ang II or angiotensin (1-7) are 
generally given along with other stimulating factors such as G-CSF or erythropoietin to 
facilitate the stimulating effect [93, 94, 96].  
 
ACEI induces anemia and leukopenia when given at high dose [97, 98].  
Paradoxically, however, ACE inhibition has been found to enhance hematopoiesis and 
mitigate hematopoietic injury after radiation in a time-dependent manner [95, 99-101]. 
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Figure 9. The renin-angiotensin system.  
Renin from kidney cleaves and activates the angiotensinogen from liver which turns into 
Ang I. ACE, which abounds in endothelium of lung and blood vessels, then converts Ang 
I into Ang II. Ang II regulates blood pressure by binding to angiotensin receptors and by 
regulating ADH production. ACEI inhibits ACE activity and ARB blocks the angiotensin 
receptors, which down-regulate blood pressure. The metabolite of Ang I and Ang II, 
angiotensin (1-7), has opposite effect on blood pressure, which down-regulates blood 
pressure by causing vasodilation. Figure adapted from Conti, S., Cassis, P. and Benigni, 
A., Aging and the renin-angiotensin system. Hypertension, 2012 [102].  
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When given for 7 consecutive days before irradiation, ACEI sensitizes the hematopoietic 
system to radiation damage by increasing the number of short-term HSC (ST-HSC) and 
hematopoietic progenitor cell (HPC) in the G2/M phase at the time of irradiation. This 
leads to severe pancytopenia and 100% lethality. When ACEI is given 1-48 hr after 
irradiation, and for 14 to 30 consecutive days, hematopoietic recovery is significantly 
increased, along with survival rate. There is no significant difference in survival between 
early (1 hr) and late (48 hr), short regimens (14 days) and longer regimens (30 days) of 
ACEI. This radiomitigating effect likely results from transient quiescence of ST-HSC and 
HPC, allowing for DNA damage repair and, thus, increased cellular survival [101, 103].  
In NI mice, ACEI treatment induces quiescence after 2 days and proliferation after 7 days 
of administration. In NI humans, patients may experience one or multiple-lineage 
cytopenia.  The tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is the 
natural substrate of ACE and a negative regulator of hematopoiesis. ACE inhibition 
would decrease AcSDKP degradation and thus increase its plasma level [104]. Inhibition 
of Ang II formation and increase of AcSDKP explains the transient anemia and 
leukopenia resulting from ACE inhibition in non-irradiated scenario [99]. Administration 
of AcSDKP at peri-irradiation (both before and after TBI) does not decrease mortality, 
while Ang II-receptor antagonists does. Therefore, blocking the Ang II pathway, rather 
than increasing AcSDKP, and thus stopping the HSC from entering the cell cycle [105], 
is thought to be the mechanism of protection effect of ACEI and ARB, in which 
angiotensin (1-7)-Mas signal pathway might also involve [99]. 
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Drugs targeting the Ang II receptor or Mas receptor also attenuate lung, cardiac 
and renal fibrosis in DEARE mice. Many reports of this phenomenon exist, but the 
mechanism remains unknown [103, 106, 107]. 
 
1.5.4.2.5. Prostaglandin E2 (PGE2) 
Arachidonic acid (AA) is a component of the inner cell lipid membrane. It is 
released by phospholipase A2 (PLA2) and converted to prostaglandins (PG) by 
cyclooxygenases (COX) and tissue-specific synthases.  PGs have a short half-life and act 
as autocrine or paracrine factors on different systems with overlapping functions [108]. 
The rate of PG synthesis depends on local expression and activity of COX, which has two 
isozymes, COX-1 and COX-2. COX-1 is constitutively expressed in most tissues under 
physiological conditions. COX-2 expression is induced by inflammation, injury, or 
cytokines, and is the dominant source of PGs in pathological conditions. The products of 
COX-1 and COX-2 are different, but overlapping, as they are capable of interacting with 
different tissue-specific synthases, yet not mutually exclusive preferences. COX-1 
primarily interacts with thromboxane synthase, prostaglandin F synthase, and the 
cytosolic prostaglandin E synthase. COX-2 prefers prostaglandin I synthase and 
microsomal prostaglandin E synthase [109, 110]. The main products of COX-1 are 
prostaglandin I2 (PGI2), thromboxane A2 (TXA2), and PGE2. PGI2 protects the gastric 
mucosa. TXA2 is a coagulant and a vasoconstrictor. PGE2 regulates renal blood flow and 
natriuresis [111, 112]. The main product of COX-2 is PGE2, which mediates many 
pathological processes, including pain, fever, and inflammation [113] (Figure 10). PGE2 
is unstable with a half-life of 30 seconds and is rapidly catabolized by 15-
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hydroxyprostaglandin dehydrogenase (15-PGDH) and 15- ketoprostaglandin D13-
reductase (13-PGR) [114, 115]. 
 
The physiological and pathological effects of PGE2 are heterogeneous, including 
labor induction, bone resorption, vasodilation, anti-inflammation, and fever onset [108]. 
PGE2 interacts with four specific G-protein coupled receptor (GPCR) isoforms (EP1, 
EP2, EP3 and EP4) [115]. EP1 and EP2 are low-affinity receptors requiring high PGE2 
levels for activation, whereas EP3 and EP4 are high-affinity receptors. EP2 and EP4 
couple with Gαs, EP3 couples with Gαi, and EP1 couples with Gαq [116] (Figure 11). 
PGE2 binding to EP1 activates Gαq and phospholipase C (PLC), which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diglyceride (DAG) and inositol 
trisphosphate (IP3). IP3 releases Ca2+ from endoplasmic reticulum and increases 
intracellular Ca2+ concentrations. DAG activates protein kinase C (PKC). PGE2 binding 
to EP2 or EP4 activates Gαs and adenylate cyclase, which stimulates cyclic adenosine 
monophosphate (cAMP) dependent protein kinase A (PKA), or directly stimulates the 
cAMP-independent PI3K signal pathway. Both PKA and PI3K activate Akt kinase, 
which inhibits glycogen synthase kinase-3 (GSK-3). GSK-3 inhibits the activation of β-
catenin. The stimulation of EP2 or EP4 pathways therefore activates and translocates β-
catenin into the nucleus [115, 117]. The nuclear translocation of β-catenin triggers 
transcription and translation of downstream proteins, including Survivin and Cyclin D, 
promoting cellular survival and proliferation. EP3 has multiple splice variants. Most 
couple with Gαi, and a few with Gαs. The Gαi subunit inhibits adenylate cyclase and 
decreases cAMP [118] (Figure 12). Susceptibility to desensitization also regulates PGE2 
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Figure 10. Eicosanoid biosynthesis from arachidonic acid.  
Arachidonic acid is released from cell membrane by PLA2 and is converted to 
prostaglandins by COX, or to leukotrienes and lipoxins by lipoxygenase. COX-1 
constitutively express in most tissues under physiological condition, and COX-2 is 
induced by pathological conditions such as inflammation and injury. The main products 
of COX-1 are PGI2, TXA2 and PGE2. The main product of COX-2 is PGE2, which 
mediates many pathological processes such as pain, fever and inflammation. Figure 
adapted from Harizi, H., Corcuff, J.B. and Gualde, N., Arachidonic-acid-derived 
eicosanoids: roles in biology and immunopathology. Trends Mol Med, 2008 [108].  
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Figure 11. Prostaglandin E2 receptors.  
PGE2 receptors are G-protein-coupled receptors, which have four isoforms (EP1, EP2, 
EP3 and EP4). EP1 couples to Gαq in which the activation results in the increase of 
intracellular Ca2+. EP2 and EP4 couple to Gαs in which the activation results in the 
increase of intracellular cAMP. EP3 couples to Gαi in which the activation results in the 
decrease of intracellular cAMP.  Figure adapted from Dey, I., Lejeune, M., and Chadee, 
K., Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J 
Pharmacol, 2006 [117]. 
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Figure 12. Prostaglandin E2 signaling.  
Binding of PGE2 with EP2 or EP4 activates Gαs and adenylate cyclase, which stimulates 
cAMP dependent PKA through the increase of cAMP; or directly stimulates cAMP 
independent PI3K pathway. Both PKA and PI3K activate Akt kinase which inhibits 
GSK-3. GSK-3 inhibits the activation of β-catenin. So, the stimulation of EP2 or EP4 
pathways eventually activates and translocates β-catenin into nucleus. The nuclear 
translocation β-catenin triggers the transcription and translation of downstream proteins 
such as Survivin and Cyclin D, which correspond to the final results of EP2/EP4 
activation, such as pro-survival and proliferation. Most of EP3 variants couple to Gαi 
which decrease the intracellular cAMP and thus have opposite effects to EP2/EP4. 
Activation of EP1 increases intracellular Ca2+ concentrations and activates PKC. The 
effects of PGE2 are pleiotropic. Figure adapted from Dey, I., Lejeune, M. and Chadee, 
K., Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J 
Pharmacol, 2006 [117]. 
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responsiveness. After agonist stimulation, GPCRs can become desensitized and 
internalized, and signal intensity decreases. EP4 is more rapidly desensitized after PGE2 
binding compared with EP2, which is resistant to PGE2-induced desensitization [115, 
117, 119].  EP4 and EP3 isoform-I are more rapidly internalized than EP2, EP3 isoform-
III, and EP3 isoform-IV [117, 120]. To summarize, the different EP receptor pathways 
are both alternative and overlapping; therefore, PGE2 effects are diverse and depend on 
tissue-specific receptor expression and G protein coupling [118].  
 
The effects of PGE2 on hematopoiesis are pleiotropic. Different timing, 
concentration, and formulation of PGE2 may lead to different results. Nanomolar levels 
of PGE2 exposure in vitro inhibits granulocyte-macrophage progenitor cell (colony-
forming unit - granulocyte/macrophage, CFU-GM) growth, indicating myeloid progenitor 
inhibition [121, 122]. In vivo, injected PGE2 inhibited CFU-GM growth [123].  PGE2 
also enhanced erythroid progenitor cell (burst-forming unit-erythroid, BFU-E) and 
multipotential progenitor cell (colony-forming unit granulocyte/erythrocyte/macrophage/ 
megakaryocyte, CFU-GEMM) growth. This may result from direct stimulation or indirect 
mediation via increased renal EPO production [124-126]. 
 
PGE2 synthesis is indispensable for HSC formation and hematopoietic 
development in zebra fish embryogenesis [127]. For adult human HSC, two-hour ex vivo 
exposure to 16,16 dimethyl-prostaglandin E2 (dmPGE2) (1 µM) increases Survivin and 
decreases caspase-3, inhibiting HSC apoptosis. Short-term exposure to dmPGE2 also 
initiates cell cycle activation in long term-HSC (LT-HSC) but not in progenitor cells 
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[128].  In a competitive transplantation study, short-term dmPGE2 exposure increased 
chimerism in the peripheral blood 20 weeks post-transplantation and increased homing to 
bone marrow within 16 hr due to increased self-renewal and proliferation of LT-HSC 
[128]. Conversely, in another study, bone marrow cells from mice treated with 6 mg/kg 
dmPGE2 twice daily for 16 days were used for competitive transplantation and 
demonstrated superior lymphomyeloid reconstitution that was lost at 16 weeks post-
transplantation, indicating that ST-HSCs were predominantly stimulated [129]. These 
discrepancies may be due to different concentration of dmPGE2 treatment, different 
treatment duration, and different stimulatory effect on HSC between ex vivo and in vivo 
dmPGE2 exposure. The effects of dmPGE2 on both HSC and HSC niche in vivo vs. the 
effect of dmPGE2 on HSC alone ex vivo may also contribute to the discrepancies. 
 
Short term ex vivo exposure to dmPGE2 increases HSC homing to the bone 
marrow via increased expression of C-X-C chemokine receptor type 4 (CXCR4), which 
promotes chemotactic migration to stromal cell-derived factor 1 α (SDF1α) in the stem 
cell niche. This effect is blocked by the CXCR4 antagonist AMD3100 [128]. This 
supports the finding that HSC engraftment is enhanced following short-term ex vivo 
dmPGE2 exposure [130]. In contrast, endogenous PGE2 enforces HSC marrow retention 
through the activation of EP4 receptor and independent of the SDF-1-CXCR4 axis, 
highlighting the difference in mechanisms on HSC between in vivo and ex vivo 
experiment [131]. Recently, another CXCR4/SDF1-independent, osteopontin-dependent 
axis was found to mediate nonsteroidal anti-inflammatory drug (NSAID)-induced HSC 
trafficking through inhibiting PGE2-EP4 signaling pathway [131]. 
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As dmPGE2 appears to promote HSC survival and self-renewal, it was considered 
to be a potential MCM, either as a radioprotectant or radiomitigator. Since nuclear attacks 
and accidents cannot be predicted in advance, first responders and military personnel 
facing radiation threats need radioprotectant MCM, whereas civilian victims need 
radiomitigator MCM. Hanson et al. [132, 133] demonstrated that dmPGE2 protected 
intestinal clonogenic cells from radiation damage in B6D2F1 mice when used as a 
radioprotectant one hour prior to radiation exposure. Walden TL et al. [134] found that 
dmPGE2 increased the LD50/30 survival rate of CD2F1 mice when administrated 30 min 
prior to radiation. Recently, Hoggatt J et al. [135] demonstrated that dmPGE2 
significantly increases the day 30 survival rate of C57Bl/6 mice in a radiomitigating 
manner when administered 6 or 24 hr post-IR, potentially by enhancing HSC survival and 
self-renewal. These studies were performed in adult mice with different genetic 
backgrounds, encouraging researchers to evaluate the efficacy and optimal time window 
of dmPGE2, either as radioprotectant or radiomitigator, in a well-defined animal model 
[69]. Since there is no effective MCM against DEARE, the potential for dmPGE2 to 
alleviate DEARE in H-ARS survivors was investigated. 
 
1.6. Hematopoiesis 
1.6.1. Colony assays and competitive transplantation assays 
The adverse impacts on hematopoietic stem and progenitor cell (HSPC) and 
hematopoiesis from radiation exposure are the main causes of H-ARS and RBMD. 
Investigation into the extent of damage and which cell compartment is targeted by a 
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specific treatment are crucial to develop and evaluate MCM. Thus, in this section, the 
concept of hematopoiesis and methods to evaluate hematopoiesis will be introduced. 
HSC is at the top of the hematopoietic hierarchy and continuously gives rise to all mature 
blood cells, including neutrophils, eosinophils, basophils, monocytes, macrophages, 
lymphocytes, red blood cells, and platelets. The two key characteristics of HSC are self-
renewal, either symmetric or asymmetric; and differentiation, which gives rise to mature 
progenies (Figure 13). The idea of HSC originated in the 1950s when it was  
discovered that shielding the spleen or injecting bone marrow cells prevented the death in 
mice with radiation-induced bone marrow failure mice [136]. In the 1960s, Till & 
McCulloch further hypothesized that there existed common progenitors in the bone 
marrow, and that a single cell may be capable of reconstituting hematopoiesis after 
radiation - the colony forming unit-spleen (CFU-S) [137]. They later confirmed that 
CFU-S is clonal after identifying the same unique chromosomal aberrations between the 
irradiated donor cells and CFU-S cells [138]. With the advent of in vitro hematopoietic 
cell culture system, the colony forming cell (CFC) assay was developed as a method for 
quantifying multi-potent or committed HPC. HPC is lineage-restricted, meaning that it 
can only differentiate into certain types of mature blood cells [139].  CFC assays in solid 
methylcellulose-based medium can be used to quantify HPC of myeloid, erythroid and 
megakaryoid lineages. Terminology for colony forming units are: BFU-E, colony-
forming unit-erythroid (CFU-E), CFU-GM and CFU-GEMM [139-142]. Lymphoid 
lineage progenitor culture methodology was developed much later. B-lymphoid 
progenitor cells (colony-forming unit-pre-B, CFU-pre-B) can be detected by adding IL-7 
into the medium or on special medium such as Whitlock-Witte culture [143]. 
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Figure 13. Hierarchy of hematopoietic tree.  
The classic view of hematopoietic tree uses phenotypical markers to identify multipotent 
HSC and bi-/oligopotent and unipotent progenitors where HSC is at the top of the 
hematopoietic tree with self-renewal ability. The HSCs give rise to CLP and CMP, which 
then give rise to all lymphoid and myeloid cells. The hematopoietic growth factors which 
are used as MCMs to radiation damage mimic the endogenous cytokine pathways. Figure 
adapted from Reya, T., et al., Stem cells, cancer, and cancer stem cells. Nature, 2001 
[144]. 
  
 56 
The aforementioned CFC assay was initially thought to measure HSC; however, it 
actually measures multi-potent progenitors with limited self-renewal. The true 
measurement of HSC is the ability to recapitulate hematopoiesis in a transplant recipient 
where endogenous hematopoiesis has be ablated. Competitive bone marrow 
transplantations is a commonly used variant [145, 146], in which a mixture of donor and 
competitor bone marrow cells are transplanted into lethally irradiated mice. Cell surface 
markers for donor cells, competitor cells and host cells are all different, which allows 
these markers to be used to determine the source of mature blood cells. Donor cell ability 
to produce multi-lineage reconstitution relative to the standard competitor is evaluated. In 
following studies, donor mice are C57Bl/6 (CD45.2+), and the recipient and competitor 
mice are B6.SJL-PtrcAPep3B/BoyJ mice (B6.BoyJ; CD45.1+) or the F1 hybrid mice of 
C57Bl/6 and BoyJ mice (CD45.1+CD45.2+) [147].  CD45 expression on the white blood 
cells of these congenic mice differs and can be distinguished by flow cytometry. 
Chimerism is estimated from the percentage of CD45.2+CD45.1- cells in recipient mice 
and is evaluated monthly post-transplantation. 
 
HSC is a heterogeneous group of cells with various levels of “stemness”. There 
are 3 subgroups of HSC with different self-renewal capacities and multipotent 
differentiation: ST-HSC, intermediate-term HSC (IT-HSC) and LT-HSC with capability 
to reconstitute <16 weeks, 16-32 weeks, and >32 weeks, respectively [148, 149]. To 
demonstrate LT-HSC potential, serial transplantations are required in which primary 
donor cells are transplanted from the primary recipient into secondary recipients. This 
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may be repeated in tertiary and quaternary recipients and beyond. Secondary 
transplantation is typically carried out 4-6 months after the primary transplantation [150]. 
 
1.6.2. HSPC phenotype 
Fluorescence-activated cell sorting (FACS) is used to quantify, separate, or sort 
subpopulations of blood cells, including HSPCs and mature peripheral blood cells. The 
immunophenotypic assay determines the percentage or frequency of a specific 
subpopulation of blood cells by using the fluorophore-conjugated antibodies to probe 
antigens expressed on the cell surface or inside the cell. Lineage-specific antigens present 
on the surface of mature cells. Different mouse blood cells express different lineage 
markers, for example, Ter119 for erythroid cells, Gr1 for myeloid cells, CD3 for T 
lymphocytes, B220 for B lymphocytes, and CD11b for monocytes/macrophages and 
natural killer (NK) cells. Using a combination of these antibodies allows for negative 
selection of cells that do not express these lineage markers. The lineage negative (Lin-, 
Ter119- CD3- Gr1-B220- CD11b-) population is enriched for immature hematopoietic 
cells. The stem cell antigen-1 (Sca-1) and stem cell factor receptor (c-kit, CD117) further 
define the HSPC population in the Lin- population. Lin- c-kit hi Sca-1hi (LSK) cells are 
enriched for HSC, whereas the Lin- c-kit hi Sca-1lo cells are enriched for myeloid-
erythroid HPC and Lin- c-kit intermediate Sca-1intermediate cells (Lin- c-kit int Sca-1int) are 
enriched with lymphoid HPC. CD16/32 and CD34 further divide the myeloid-erythroid 
HPCs in Lin- c-kit hi Sca-1lo population into common myeloid progenitor (CMP, 
CD34+CD16/32-), granulocyte monocyte progenitor (GMP, CD34+CD16/32+) and 
megakaryocyte erythrocyte progenitor (MEP, CD34-CD16/32-) [151, 152]. Flt3 and IL-7 
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receptor (IL7R, CD127) further define lymphoid HPC (CLP) in the Lin- c-kit int Sca-1int 
population as Lin- c-kit int Sca-1int Flt3 hi IL7R+ [153, 154]. 
 
LSK cells are heterogeneous, including both HSC and HPC. There are two gating 
strategies to sub-divide LSK cells, one is based on the introduction of two signaling 
lymphocyte activation molecule (SLAM) family markers (CD150 and CD48) with or 
without CD34; and another one is based on the introduction of CD34 and Flt3. The first 
method subdivides the LSK cells into HSC (SLAM LSK, CD150+CD48-), multipotent 
progenitor (MPP, CD150-CD48-), HPC-1 (CD150-CD48+) and HPC-2 (CD150+CD48+) 
[155, 156]. By adding the CD34, the HSC can be further subdivided into LT-HSC 
(CD34-) and ST-HSC (CD34+) [149]. The second method subdivides the LSK cells into 
LMPP (Flt3hiCD34+), MPP (Flt3intCD34+), LT-HSC (Flt3-CD34-) and ST-HSC (Flt3-
CD34+) [82, 157, 158]. There is no standard criterion on the phenotype of HSPC and 
there are many overlaps between these two methods.  
 
Flt3 is a type III receptor tyrosine. Binding of FLT3L with Flt3 plays an important 
role in B and T cell lymphopoiesis. Flt3 expression on different HSPC compartments is 
variable. LT-HSC and ST-HSC express low levels of Flt3 (5%-8%), whereas 60% of 
MPP are Flt3 positive. Thirty percent of CMP express Flt3 on their surface and have the 
potential to differentiate into granulocytes/erythrocytes/megakaryocytes but with limited 
potential to lymphocytes. HPC-1 and LMPP express the highest level of Flt3 (60%-
100%) and preferentially differentiate to lymphocytes/granulocytes. LMPP/HPC-1 give 
rise to the lymphoid lineage-restricted CLP and the myeloid lineage-restricted GMP. 
 59 
More than 80% of CLP and only 15% of GMP express Flt3 on their surface. Rare HPC-2 
(<10%) and MEP (<1%) express Flt3 and HPC-2 and almost exclusively differentiate 
into erythrocytes and megakaryocytes [159-162]. Other growth factor receptors such as 
receptors for MCSF (MCSFR) and EPO (EpoR) are involved in myeloid lineage 
differentiation, but are not widely accepted as markers [82]. In summary, Flt3 expression 
is confined to myeloid-lymphoid progenitors as opposed to megakaryoid-erythroid 
progenitors. 
 
Hematopoiesis is not deficient in Flt3-/- mice [159]; however, Flt3L-/- mice 
demonstrate a severe deficiency in myeloid and B-lymphoid progenitors [161]. MPP, 
LMPP, CLP, and early thymic progenitor (ETP) are affected in this knockout model, 
either due to decrease in number or decrease in differentiation potential [163]. This 
suggests that the Flt3 signal promotes lymphoid development, possibly at the expense of 
myelopoiesis [164]. There are controversies regarding whether Flt3 is the sole deciding 
factor in the fate choice between myeloid and lymphoid lineages, but there is no doubt 
that lymphoid development is dependent on Flt3 expression [82, 163, 164]. Myelopoiesis 
may depend on the combined action of Flt3 and MCSFR or EpoR [82, 158].  
 
1.6.3. Hematopoietic differentiation tree 
HSC are at the top of the hematopoietic differentiation tree and have the capacity 
to divide into all mature peripheral blood cells. The microscope-dependent and 
morphology-based classification of HSPC is limited in its ability to differentiate between 
HSC and early HPC, which lack of distinguishable morphological characteristics. 
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Initially, the more advanced colony-forming assay and single cell bone marrow 
transplantation assays identified the first branch point at MPP, followed by the separation 
of myeloid and lymphoid potential identified by CMP and CLP [144]. MPP do not have 
self-renewal ability and their differentiation ability is increased in comparison with HSC. 
CLP give rise to B-, T- and NK cells. CMP give rise to MEP and GMP, which give rise 
to red blood cells and platelets, and neutrophils, monocytes/macrophages, and 
eosinophils respectively (Figure 14 A). This model of hematopoiesis was later revised 
with the identification of LMPP which expresses high level of Flt3 and preferentially 
generates lymphoid lineages, while retains myeloid potential [158, 165]. This challenged 
the classic model as the separation between the myeloid and lymphoid potential is not 
defined as previously thought. Later, it was proposed that GMP are heterogeneous, 
containing eosinophil/basophil progenitors (EoBP) associated with erythrocyte and 
megakaryocyte fate (erythro-myeloid progenitor) but not with granulocytes precursors 
[166-169]. It has also been reported that HSC is functionally and molecularly 
heterogeneous, containing myeloid-biased (MPP2), balanced (MPP3) and lymphoid-
biased (MPP4) HSC [170-172]. These progenitors are downstream of “true” HSC and 
have self-renewal ability and are referred to collectively as the “HSC pool” (Figure 14 
B).  
 
Recently, a group of von Willebrand factor (vWF)-positive, platelet-primed HSCs 
was identified, which differentiates into megakaryocytes independently from any other 
lineages. This suggests that the separation of megakaryoid-erythroid potential may be the 
earliest lineage commitment [171, 173] (Figure 15).  Additionally, recent single-cell  
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Figure 14. Classic hematopoietic differentiation tree.  
At earlier era, it is generally accepted that the first branch point separating the myeloid 
and lymphoid lineages in differentiation tree is via the separation of CMP and CLP 
populations. The primitive cells differentiate from multipotent to bipotent and then to 
unipotent progenitor cells. HSCs are homogeneous, which consist of LT-HSC and ST-
HSC (panel A). But later on, HSCs were found functionally and molecularly 
heterogeneous which contain at least myeloid-biased (MPP2), balanced (MPP3) and 
lymphoid-biased (MPP4) groups. Myeloid and lymphoid separation is not as strict as 
researchers previously thought and the myeloid and lymphoid potentials remain coupled 
in the LMPP. GMPs are phenotypically homogenous but are functionally heterogeneous 
which contain the eosinophil/basophil progenitor (panel B). Figure adapted from 
Laurenti, E. and Gottgens B., From haematopoietic stem cells to complex differentiation 
landscapes. Nature, 2018 [165].  
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Figure 15 
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Figure 15. Revised hematopoietic differentiation tree.  
Platelet-biased stem cells were found at the apex of the hematopoietic stem-cell hierarchy 
which suggest that the first branch point in the differentiation tree is much more 
complicated than a simple segregation of myeloid and lymphoid lineages. Lineage choice 
occurs earlier than previously thought. Multipotent and unipotent progenitors dominate 
adult BM, whereas the oligopotent progenitors are rare or absent, or transient exist. 
Lineage fate choice is a continuous process where the low-primed undifferentiated 
hematopoietic stem and progenitor cells gradually differentiate to unilineage-restricted 
cells. A consensus on the revised model of hematopoiesis has not been reached. Figure 
adapted from Laurenti, E. and Gottgens B., From haematopoietic stem cells to complex 
differentiation landscapes. Nature, 2018 [165]. 
 
 
 
 
 
 
 
 
 
 
 
  
 65 
transcriptome analysis revealed that lineage fate choice may be a continuous process, 
where low-primed undifferentiated HSPC gradually differentiates to unilineage-restricted 
cell without a multipotent or bipotent progenitor (Figure 15) [174-176].  The 
hematopoietic differentiation model is therefore not yet fully understood, and is 
continuously evolving as new findings reveal that hematopoietic differentiation is more 
sophisticated than previously thought. 
 
1.6.4. T cell hematopoiesis 
T cell hematopoiesis is relatively unique compared with other lineages as T cells 
mature in the thymus, a specialized primary lymphoid organ critical to the adaptive 
immune system. Other hematopoietic cells mature in the bone marrow. In the bone 
marrow, after MPP differentiates into LMPP and CLP, a portion of LMPP and CLP cells 
termed thymus-seeding progenitors (TSP) enter the thymus via postcapillary venules at 
the cortico-medullary junction (CMJ) [177]. In the thymus, BM TSP differentiate into 
ETP, then differentiate into double negative (DN) cells, which gives rise to double 
positive (DP) cells and further differentiate into either CD4 or CD8 single positive (SP) T 
cells. DN thymocytes can be further divided into DN1, DN2, DN3 and DN4 cells based 
on the expression of CD44 and CD25 (DN1: CD44+CD25-; DN2: CD44+CD25+; DN3: 
CD44-CD25+; DN4: CD44-CD25-). As thymocytes differentiate from DN1 to DN4, they 
progressively migrate from the CMJ toward the subcapsular zone (SCZ) [178, 179]. 
 
The T cell receptor (TCR) consists of an alpha (α) and a beta (β) chain [180]. The 
major histocompatibility complex (MHC) is a group of cell surface molecules that 
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present foreign epitopes to TCR and thus trigger T-cell activation [181, 182].  In order to 
recognize the foreign epitope presented by MHC, TCR must go through α and β 
rearrangement. The TCRβ chain is rearranged at the DN3 stage and then paired with the 
pre-Tα to form the pre-TCR. This step is called β-selection [183].  Cells that do not 
produce functional pre-TCR are eliminated by apoptosis. Cells that successfully traverse 
through β-selection undergo TCRα rearrangement, resulting in complete TCR and 
transition into the DP stage [184].  DP thymocytes undergo positive selection, which 
means that they will be eliminated if their complete TCRs are unable to bind MHCs 
[179].  CD8 is a coreceptor that binds MHC class I molecule and CD4 is a coreceptor for 
MHC class II molecule. Cell receiving signal from TCR/MHC I binding develops into SP 
CD8+ T cell and likewise, cell receiving signal from TCR/MHC II binding develops into 
SP CD4+ T cell. SP thymocytes then migrate from thymic cortex to medulla [185]. In the 
medulla, SP thymocytes go through negative selection in order to eliminate autoreactive 
thymocytes. The SP thymocytes which have high affinity for self-peptides presented on 
MHC molecules are driven to apoptosis through upregulating the pro-apoptotic molecules 
[186]. Non-autoreactive thymocytes that have appropriate affinity for MHC molecules 
enter into the peripheral blood and become mature T cells. These recent thymic emigrants 
(RTEs) are naïve cells expressing CD62 ligand (CD62L) [187]. After encountering novel 
foreign antigens, naïve T cells proliferate and produce inflammation to eliminate the 
pathogens [188, 189]. A protective memory effect mediated by memory T cells will 
forms during the latter phase of inflammation. There are two types of memory T cells 
circulating in the peripheral blood and lymphoid organs: effector memory T cell (TEM) 
which can be identified as CD44+CD62L-, and central memory T (TCM) cell as 
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CD44+CD62L+ [190, 191]. The T cell developmental pathway from bone marrow to 
peripheral blood is summarized in Figure 16.  
 
TEC cells are the main component of thymic niche, which support T-cell 
development and maturation as “nursing cells”. TECs reside in specialized anatomical 
regions, and are defined as cortical TEC (cTEC) or medullary TEC (mTEC) [192]. 
Markers commonly associated with cTEC include cytokeratin 8/18 (K8/K18), Ly51, 
CD205, and the proteasomal subunit β5t and delta‐like (DL) 4. Markers commonly 
associated with mTEC include cytokeratin 5/14 (K5/K14), the lectin ulex europaeus 
agglutinin 1 (UEA1), CD80, autoimmune regulator (Aire), MTS10, ERTR5, and the tight 
junction components claudin-3/claudin-4 [192, 193]. The ratio of cTEC/mTEC quantified 
by K8/K5 by fluorescent immunohistochemistry (IHC) is 1.78 in the neonatal mouse 
thymus and 0.56 in adults [12]. LMPP and CLP express CCR7 and CCR9, and interact 
with their ligands, CCL21/CCL19 and CCL25, which mainly express on endothelial cell 
and TEC in thymus [194-196]. Progenitors settling in the thymus are exposed to the 
cytokines IL-7 and Notch ligand DL4, which are highly expressed by cTEC [197]. mTEC 
is indispensable in establishing central tolerance with the expression of Aire gene and in 
promoting the development of CD4+CD25+Foxp3+ T regulatory and NK cells [192, 198]. 
The T cell development from bone marrow to thymus then to peripheral blood is 
summarized in Figure 16 [178]. 
 
In this chapter, I introduce the concept and biological effects of ionizing radiation; 
describe the clinical syndromes of radiation damages and potential treatments  
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Figure 16. T cell development from bone marrow to thymus.  
A portion of LMPPs and CLPs enters the thymus via postcapillary venules at CMJ and 
differentiates into DN cells and then to DP cells and follow with CD4 and CD8 SP cells. 
DN cells can be further divided into DN1, DN2, DN3 and DN4 cells based on their 
expression of CD44 and CD25. As thymocytes differentiate from DN1 to DN4, they 
progressively migrate from the CMJ toward SCZ. Mature thymocytes, which have 
appropriate affinity for MHC molecules, enter into the peripheral blood and become 
naïve T cells (RTE, recent thymic emigrant). After encountering novel foreign antigens, 
naïve T cells proliferate and produce effector T cells to eliminate the pathogens. A 
protective memory effect mediated by memory T cells forms during the latter phase of 
inflammation. Figure adapted from Aifantis, I., Raetz, E. and Buonamici, S., Molecular 
pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol, 2008 [199].  
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currently available for these damages, especially focusing on the damage of 
hematopoietic system; and characterize the hematopoietic development and research 
methods in hematopoiesis. In chapter two to chapter five, the hematopoietic irradiation 
damages by a well-established mouse model, both in short-term and long-term, will be 
defined; and the radioprotective and radiomitigative effects of several promising MCMs 
will be presented. The hypothesis will be proposed as the hematopoietic recovery, 
including the immune recovery, would be severely impaired in survivors of H-ARS 
through interference on HSPC differentiation; and this defect can be corrected or 
prevented by the optimized administration of MCM. The following specific aims were 
planned in order to test the hypothesis: Aim 1. Characterize the hematopoietic and 
immune suppression during the H-ARS phase and the recovery of different lymphoid 
compartments in H-ARS survivors. Aim 2.  Evaluate the impact of different MCMs on 
the hematopoietic and immune systems during H-ARS and DEARE phases; and 
investigate the potential intrinsic and extrinsic mechanisms responsible for the 
effectiveness of these MCMs. The research is expected to pave the road for more 
extensive and efficient MCM screening to combat the threat of radiation damage in the 
future. 
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Chapter 2. Immune Reconstitution and Thymic Involution in the Acute and Delayed 
Hematopoietic Radiation Syndromes 
2.1. Introduction 
H-ARS and DEARE are serious and potentially lethal outcomes of exposure to 
high-dose radiation. Treatments for H-ARS include the recently approved MCM 
including Neupogen (G-CSF), Neulasta (pegylated G-CSF) and Leukine (GM-CSF) 
[200], which stimulate primitive hematopoietic progenitor cells to produce life-saving 
blood elements, primarily of the myeloid lineage [69, 201-204]. Although these MCM 
significantly increase survival from H-ARS, they do little to alleviate the morbidity of 
DEARE and its devastating multi-organ dysfunction, including long-term hematopoietic 
insufficiency. 
One of the most serious consequences of hematopoietic DEARE is defective 
lymphocyte reconstitution and its subsequent immune insufficiency. Survivors of H-ARS 
often suffer from long-term T-cell deficiencies that dampen robust protective immune 
responses, including decreased T cell number, imbalanced CD4/CD8 ratio, and 
compromised naive T cell receptor diversity [15]. Long-term survivors, as well victims of 
the atomic bombings of Hiroshima and Nagasaki [4, 205] and cancer patients that have 
received radiotherapy [206], also experience increased incidence of infections and cancer, 
likely due to deficient T cell surveillance [76]. Many of these immune perturbances also 
occur to a lesser degree during normal aging in association with thymic involution. 
Thymic involution, the age-related loss of thymic mass and reduction of naïve T cell 
output, correlates with reduced immune surveillance and onset of cancers, autoimmunity, 
 72 
and infectious diseases in aging [186]. Age-related thymic involution and its associated 
immune dysfunction are exacerbated by previous radiation exposure, further 
compounding the immune deficiencies in hematopoietic DEARE.  
While immune dysfunction has been well characterized in normal aging [207], as 
well as in the acute phase of radiation exposures, little is known regarding the immune 
suppression that occurs during DEARE. Generation of functional immunity is a complex 
process. Briefly, BM LT-HSC differentiate into MPP, followed by LMPP, and then CLP. 
LMPP and CLP emigrate from the BM to the thymus where they differentiate into CD4-
CD8- DN cells, followed by CD4+CD8+ DP cells, and finally single positive CD4+ or 
CD8+ T cells, remaining CLP in the BM develop into mature B cells [178, 179], as 
described in Chapter 1. Mature CD4+ and CD8+ T cells migrate from the thymus into 
peripheral blood and secondary lymphoid organs, where they initiate 
immunosurveillance. Due to the rapid proliferation and turnover of thymocytes, the 
thymus is highly radiosensitive.  
Dr. Orschell’s laboratory has previously developed a well characterized murine 
model of H-ARS and DEARE in young adult C57BL/6 mice, and have used this model to 
study mechanisms and efficacy of MCM against radiation for licensure and treatment 
strategies [41, 69, 107, 135, 147, 201, 208-215]. Herein, the prolonged 
immunosuppression is characterized, at all levels of lymphocyte development in these 
acute and chronic radiation models. Data presented here aims to increase understanding 
of the severe immune dysfunction that occurs in radiation survivors, with the ultimate 
goal of generating a mouse model suitable for assessing the efficacy of potential MCM 
and therapeutic strategies.  
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2.2. Materials and Methods  
2.2.1. Mice and husbandry 
Specific pathogen-free C57BL/6 mice (50:50 male:female; Jackson Laboratory, 
Bar Harbor, ME) were received at 10-week-old (w/o) and acclimatized for 2-week prior 
to irradiation. Husbandry and health status monitoring were carried out as previously 
described [147, 210]. All studies were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee.  
 
2.2.2. Irradiation, dosimetry and monitoring 
Irradiation and dosimetry were performed as previously described [147, 210]. In 
sum, mice were placed in single chambers of a Plexiglas irradiation apparatus and rotated 
horizontally (thus irradiated posterior-anteriorly) with a single uniform TBI doses of 8.72 
(estimated LD70/30) or 9.04 Gy (estimated LD90/30) gamma radiation from a 137Cs 
radiation source (Mark 1 Irradiator, JL Shepherd, San Fernando, CA) at an exposure rate 
of 0.93-1.03 Gy/min. Inflight OSL nanodosimeters (Landauer Inc, Glenwood, IL) were 
used to verify homogeneity of exposure. Between day (d) 1-30 post-TBI, mice were 
provided with autoclaved acidified water and wet feed ad libitum.  In H-ARS phase, 
irradiated mice were observed twice daily and scored for signs meeting the criteria for 
early euthanasia as Dr. Orschell’s laboratory described [69]. Surviving mice at day 30 
post-TBI were allowed to age for the study of DEARE and fed with regular extruded 
chow. Since there were no differences in the experimental outcomes assessed in these 
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studies between the LD70/30 and LD90/30, data from mice exposed to either dose were 
combined.    
2.2.3. Complete blood cell count (CBC) 
Around 2-3 mm was snipped from the tail of randomly selected male and female 
mice and 40 µl of peripheral blood was collected into an ethylenediaminetetraacetic acid 
(EDTA)-coated capillary tube. Stiptic stick containing silver nitrate was applied to the 
tail to stop the bleeding. Complete blood cell counts with differentials were performed at 
baseline and on various days after irradiation, using a validated HEMAVET® 950FS 
Hematology System (Drew Scientific, Waterbury, CT), as previously described [69, 147, 
211]. To minimize stress effects, mice were bled no less than 14 days apart during H-
ARS phase.  
 
2.2.4. Tissue harvest and single cell suspension 
All tissues were harvested following euthanasia by CO2 inhalation. Thymi were 
carefully cleared of fat and connective tissue under a dissecting microscope to eliminate 
contamination with non-thymic tissue. Thymus and spleen weights were obtained using a 
Mettler Toledo Balance XS204 (Mettler-Toledo LLC, Columbus, OH). Single cell 
suspensions of thymocytes and splenocytes were generated by macerating tissues 
between the frosted ends of two microscope slides or with the blunt end of a syringe 
plunger, respectively. PB was collected from tail snips and BM cells were flushed from 
femurs, tibias, pelvis, and humeri. Single cells were suspended in Hank's balanced salt 
solution (HBSS, Lonza, Walkersville, MD) with 20U/ml heparin (Hospira Inc., Lake 
 75 
Forest, IL). Erythrocytes were removed from samples by ammonium chloride lysis 
(0.16M NH4Cl, 0.01M KHCO3) [40].  
 
2.2.5. Tissue fixation, histological staining, and imaging 
Thymi and spleens were fixed in neutral buffered formalin (NBF) overnight. 
Formalin-fixed tissues were paraffin embedded and sectioned, then stained with 
hematoxylin/eosin (H&E) and Picrosirius red. For H&E sections, digital images were 
acquired using an Aperio Scan Scope CS system (Aperio, Inc., Vista, CA). For 
Picrosirius red sections, digital images were acquired using a Leica DM 5000B 
microscope (Leica Microsystems, Inc., Buffalo Grove, IL) with a Diagnostic Instruments 
Spot RTKE camera (SPOT Imaging Solutions, Sterling Heights, MI) [41, 216]. For 
quantifying the Picrosirius red stained thymus tissue, 4-6 images were obtained randomly 
per slide at 5× magnification. All images were analyzed using ImageJ (version 1.50v; 
National Institutes of Health). Red, green, and blue (RGB) images were converted to 
grayscale then percentage of red-stained collagen in the background of pale-stained 
medullar area was measured. The measurement follows the guidance at 
https://imagej.nih.gov/ij/docs/examples/stained-sections/index.html.  
 
2.2.6. Antibody staining and flow cytometric analyses 
B220+ B cells were identified using B220-PE-Texas Red or APC, CD4+ T cells by 
CD4-APC or PECY5, and CD8+ T cells by CD8a-PE or Pacific Blue. Naïve CD4+ and 
CD8+ T cells (CD44lo CD62Lhi) were detected using the additional antibodies CD44-
APCCY7 and CD62L- PerCPCY5-5. DN thymocytes were defined as CD4- CD8- cells 
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and subdivided into DN1, DN2, DN3, and DN4 cells based on expression of CD44 and 
CD25 as follows: DN1: CD44+ CD25-; DN2: CD44+ CD25+; DN3: CD44-CD25+; DN4: 
CD44-CD25- using CD4-PerCPCY5-5, CD8-PE or Pacific Blue, CD44-APC or APCCY7 
and CD25-PECY7 antibodies. BM LMPP (Lin- c-Kithi Sca-1hi Flt3hi CD34+) and CLP 
(Lin- c-Kitint Sca-1int IL7R+ Flt3hi) were identified using CD11b-FITC, Ter119-FITC, 
CD3-FITC, Gr1-FITC, B220-FITC, Sca-1-PECY7 or BV650, c-Kit-APC, CD34-Pacific 
Blue or BV421, IL7R-APCCY7 and FLT3-PE or PECY5 antibodies. All antibodies were 
purchased from BD Biosciences (San Jose, CA), Biolegend (San Diego, CA), 
eBiosciences (San Diego, CA) or R&D Systems (Minneapolis, MN).  The staining 
processes were carried out for 20 min at 4°C in the dark, followed by washing with 1% 
bovine calf serum (BCS)/phosphate buffered saline (PBS). Samplers were acquired using 
BD LSRII system (Becton Dickinson Immunocytometry Systems, San Jose, CA) and 
analyzed using FlowJo Software (FlowJo LLC, Ashland, OR). 
 
2.2.7. Statistical analysis 
Unpaired Student’s t-tests were performed to compare the following parameters: 
CBC, thymus and spleen weight and cellularity, thymic collagen deposition, and 
lymphoid cell types. If no sex differences were observed, data from males and females 
were combined. While many parameters measured over time were also significantly 
different at individual time-points, a single asterisk denoting significance comparing all 
mice over a specific time range was used rather than multiple asterisks at individual time-
points, for the ease of the reader. Data are expressed as mean ± standard error of the 
mean (SEM). P<0.05 was considered significant. 
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2.3. Results 
2.3.1. Reconstitution and involution of peripheral blood cells 
Dr. Orschell’s laboratory has previously documented significantly decreased 
numbers of all blood elements in the PB of aged H-ARS survivors compared to NI age-
matched controls [147]. To investigate male / female differences in the decreased blood 
production in H-ARS survivors, as well as in normal aging in NI age-matched controls, 
PB CBC from males and females were examined separately. The fluctuation in animal 
number during the course of the study is due to the fact that these are retrospective 
analyses that combined data from several studies, and also because mortality increases 
with age, especially in radiation survivors, leaving fewer aged mice available for analyses 
at later time-points. When CBC from NI male or NI female mice of multiple ages 
between 3- and 24-month-old (m/o) were compared, WBC, NE, LY, and PLT were all 
found to be significantly higher in NI males compared to females. In IR mice, all blood 
parameters were significantly reduced during the H-ARS phase, as Dr. Orschell's 
laboratory and others have reported [69, 211, 217], and did not differ between males and 
females. However, sex differences in CBC became again apparent as H-ARS survivors 
aged. When data from IR males or IR females between 6 and 21 months post-TBI were 
compared, all blood elements were found to be significantly decreased in IR females 
compared to IR males (Figure 17 A-E). NE gradually increased in the DEARE phase in 
both IR males and IR females (Figure 17 B), whereas LY declined over time, most 
dramatically in IR females (Figure 17 C). A similar trend was observed in NI mice during 
aging, in which NE increased and LY decreased, indicative of myeloid skew. The 
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enhanced radiosensitivity of LY compared to other blood elements is evidenced by the 
sustained lymphopenia at the end of the H-ARS phase (day 30 post-TBI) compared to the 
nearly complete recovery of most other blood elements (Figure 17 A-E).  
 
2.3.2. Reconstitution and involution of thymus and spleen  
Lymphocytes originate in the BM from the LT-HSC and migrate as LMPP and 
CLP to the thymus, where they continue maturation to become mature CD4+ and CD8+ T 
lymphocytes. Given the high degree of radiosensitivity of the thymus [218, 219], and 
potential impact of radiation-induced thymic damage on long-term T cell maturation, 
thymus weight and cellularity in IR mice were examined during the H-ARS and DEARE 
phases in comparison to NI age-matched controls.  
 
Thymus weight and cellularity were found to be significantly greater in young 12 
w/o NI female mice compared to young males (Figure 17 F & G), in agreement with 
others [220, 221]. However, as NI mice aged, thymus weight and cellularity gradually 
decreased in both sexes, and sex differences in geriatric mice lessened with age, similar 
to other reports [220, 222]. 
 
During the H-ARS phase, thymic weight and cellularity changed in a biphasic 
pattern, with nadirs at day 3 and day 20 post-IR and a transient peak at day 10 which 
reached 60% and ~32% of the NI baseline value, respectively (Figure 17 F & G). Due to 
the higher baseline values in NI females, radiation-induced thymic suppression was 
proportionally greater in females than males. Similar to CBC shown in Figure 17 A-E, 
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there were no sex differences in thymic weight or cellularity during H-ARS. By day 30, 
thymus weight in IR males and females combined was 40% of that in NI mice (p<0.01, 
Figure 17 F). Thymus weights in both NI and IR mice continued to decrease as mice 
aged, with values from IR mice remaining significantly less than those in NI mice 
throughout the DEARE phase (p<0.01). Parallel trends were observed for thymic 
cellularity (Figure 17 G).  
 
Naïve T cells migrate from the thymus to the spleen where they encounter foreign 
antigens and undergo activation. Spleen weight and cellularity reached their nadirs by 
day 3 post-IR, followed by a partial recovery by day 20 (Figure 17 H & I). Similar to 
peripheral blood, the reconstitution of spleen in the H-ARS phase was monophasic. 
Spleen weight and cellularity from both NI and IR survivors did not change drastically as 
mice aged, unlike the age-related involution observed in thymus (Figure 17 F-I). 
 
2.3.3. Histological analyses of thymus and spleen 
Thymi and spleens from NI and IR mice at different ages were stained by H&E to 
evaluate histological changes throughout the H-ARS and DEARE phases. Young (3 m/o) 
NI thymi were characterized by a large cortex:medulla ratio of 3:1-4:1 with a distinct 
cortico-medullary junction (CMJ) (Figure 18 A). The cortex thinned significantly after 
irradiation, such that by day 20 post-IR (second nadir) the cortex:medulla ratio dropped 
to 1:1-2:1 and the CMJ became blurry. Thymi from aged NI mice (15 m/o) also displayed 
a thin cortex but with a clear CMJ, as well as focal fibrous proliferation. Aged thymi 
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from H-ARS survivors [12 months (mo.) post-IR] demonstrated a large mass of adipose 
tissue and reticular connective tissue surrounding a small, hypocellular thymus with  
Figure 17 
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Figure 17. Reconstitution and involution in peripheral blood, thymus and spleen 
post-IR.  
Peripheral blood, thymi, and spleens were harvested from C57Bl/6 mice that had received 
a single TBI dose of 8.72 or 9.04 Gy gamma radiation at 12 w/o (IR) and from age-
matched NI controls at various time-points. NI and IR mice were evaluated for WBC 
(panel A), NE (panel B), LY (panel C), RBC (panel D), PLT (panel E), thymus weight 
(panel F), thymus cellularity (panel G), spleen weight (panel H) and spleen cellularity 
(panel I) and analyzed separately by gender. Data are mean ± SEM. Asterisk (*) indicates 
p<0.05 comparing female (F) with male (M) in NI group. Triangle (∆) indicates p<0.05 
comparing F with M in IR group. All data are significantly different between NI and IR 
mice and thus not indicated on each graph. Time post-IR, age, and number of mice 
analyzed for CBC, thymus and spleen at each time-point are given below panels E, G and 
I, respectively.  
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undistinguishable CMJ. The cortex:medulla ratio of aged thymus ranged between 1.1-2.1. 
Photographs of thymi from NI and IR mice at different ages in Figure 18 A illustrate the 
vast differences in size.   
 
To further confirm that radiation induces fibrous proliferation in the thymus early 
post-IR, thymi at 30 days post-IR were stained with Picrosirius red to identify collagen 
deposition, which was found to be localized to the medulla (Figure 18 B). Quantification 
with ImageJ revealed 20-30% more collagen deposition in the medulla of IR mice in 
comparison with NI mice as early as day 30 post-IR (Figure 18 B).  
 
2.3.4. Phenotypic analyses of lymphoid compartments 
Dr. Orschell’s laboratory has previously documented significantly decreased PB 
lymphocytes in H-ARS survivors, which correlated with significant myeloid skew [147] 
and decreased number of functional BM-derived lymphoid progenitors [40]. To better 
understand the effects of lethal radiation exposure on specific lymphoid subpopulations, 
lymphocyte populations were phenotypically defined and enumerated in PB, thymus, 
spleen, and BM of aged H-ARS survivors in comparison to age-matched NI controls and 
young NI mice. Aged H-ARS survivors exhibited significantly decreased numbers of PB 
B220+ B cells, CD4+ T cells, CD4+ naïve cells, and CD8+ naïve T cells compared to age-
matched NI controls (Figure 19 A, B, D & E). PB CD8+ cells of aged H-ARS survivors 
also had similar trend but not significantly different comparing to aged NI controls 
(Figure 19 C), as were CD4+ memory and CD8+ memory cells (non-significantly; data 
not shown). Normal aging in NI mice resulted in non-significant reductions in all PB T  
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Figure 18. Images and histology of thymi and spleens in NI and IR mice.  
Panel A shows representative photographs of thymi from NI and IR mice at various time-
points, and thymi that were fixed in formalin, embedded in paraffin and stained for 
hematoxylin and eosin. Panel B shows representative micrographs of thymic sections 
from 4 m/o NI mice and IR mice 30 days post-IR stained with Picrosirius red. Collagen 
deposition is presented as the percentage of Picrosirius red positive area in the medullary 
area using ImageJ software. Data are mean ± SEM. n=6 mice per group (2 females and 4 
males per group), with one tissue section stained per mouse. *p<0.05 comparing IR and 
NI mice. Panel C shows spleens from 3 and 15 m/o NI mice and IR mice 20 days and 12 
mo. post-IR. Tissues were fixed in formalin, embedded in paraffin and stained for 
hematoxylin and eosin. Dr. George E. Sandusky and Jennifer Stashevsky provided the 
histological staining. 
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Figure 19 
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Figure 19. Lymphocyte subsets in young and aged NI mice and aged H-ARS 
survivors.  
C57Bl/6 mice were exposed to a single TBI dose of 8.72 or 9.04Gy gamma radiation at 
12 w/o and euthanized at 15 m/o, along with 3 m/o and 15 m/o NI mice. Peripheral blood, 
splenocytes, thymocytes and bone marrow cells were processed and stained with 
antibodies as described in Materials and Methods. Flow cytometric analyses identifies 
peripheral blood B220+ cells (panel A), CD4+ T cells (panel B), CD8+ T cells (panel C), 
CD4 naïve T cells (panel D) and CD8 naïve T cells (panel E); splenic CD4+ T cells 
(panel F), CD8+ T cells (panel G), CD4 naïve T cells (panel H), and CD8 naïve T cells 
(panel I); thymic DN (panel J), DP (panel K), CD4+ (panel L), CD8+ (panel M), DN1 
(panel N), DN2 (panel O), DN3 (panel P) and DN4 (panel Q) cells; and  percentages of 
BM LMPP (panel R) and CLP cells (panel S), and absolute number of LMPP (panel T) 
and CLP cells (panel U). Data from male and female PB, spleen, and BM were not 
significantly different and thus combined. Data are mean ± SEM. n=4-6 mice per group. 
* p<0.05 compared to 15-month-old NI; ∆ p<0.05 compared to 3-month-old NI group in 
panels A-I and R-U. Brackets (⊓) in panels J-Q indicate p<0.05 comparing F and M 
combined data to other groups, and dagger (†) indicates p<0.05 comparing F to M within 
each NI or IR group.  
 
  
 87 
lymphocyte populations examined in comparison to 3 m/o NI mice (Figure 19 B-E), with 
an apparent increase in B cells (Figure 19 A). There were no sex differences in numbers 
of PB lymphocyte subpopulations in any group, so male and female data were combined.  
 
In the spleen, a similar pattern of decreased numbers of CD4+, CD4+ naïve, and 
CD8+ naïve cells was observed in H-ARS survivors versus NI age-matched controls as in 
PB, but differences did not reach significance (Figure 19 F, H & J). More prominent was 
a significant age-related decrease in CD8+, CD4+ naïve, and CD8+ naïve splenocytes in 
aged NI mice compared to young NI mice (Figure 19 G-I). There was no difference in the 
number of CD8+ lymphocytes between aged NI and IR mice, similar to PB (Figure 19 G), 
and there were no sex differences in splenocyte T cell subgroups. 
 
The age-related and radiation-related decrease in total thymocytes presented in 
Figure 19 G was also found to exist when thymic subpopulations were examined: DN, 
DP, CD4+, CD8+, DN1, DN2, DN3, and DN4 were all significantly decreased in H-ARS 
survivors compared to NI age-matched controls. Likewise, all these populations were 
significantly decreased in aged NI mice compared to young NI mice, illustrating the 
normal age-related thymic involution (Figure 19 J-Q, male and female data combined). 
Of interest, sex differences in thymic subpopulations were found to exist. In agreement 
with others [223], 3 m/o females had more DP cells than males (Figure 19 K). In 
addition, all thymic subpopulations trended higher in male H-ARS survivors compared to 
females, similar to the increased PB CBC in males versus females, and these differences 
reached significance for DN, DP, CD4+, and DN3 cells (Figure 19 J-L & P).  
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Peripheral lymphocytes originate from primitive BM progenitors termed LMPP 
and CLP, which originate from multi-potent HSC. To better understand BM involvement 
in immune deficiencies, BM LMPP and CLP were enumerated in H-ARS survivors in 
comparison to age-matched NI mice and young NI controls. Both frequency (as a 
percentage of LSK cells or Lin- Sca-1int c-Kitint cells) and absolute number of LMPP and 
CLP were significantly decreased in H-ARS survivors compared to age-matched controls 
(Figure 19 R-U). In NI mice, LMPP and CLP frequencies were also found to decrease 
significantly with age (Figure 19 R & S), as previously reported [224, 225]. However, 
when calculated as a percentage of whole BM, the percentages of both LMPP and CLP 
were found to be two-fold higher in aged NI mice compared to young NI (LMPP of old 
vs. young: 0.04 ± 0.009% vs. 0.02 ± 0.005%, p=0.02; CLP of old vs. young: 0.013 ± 
0.0029 vs. 0.007 ± 0.0015%, p=0.06). Similarly, absolute numbers of LMPP and CLP 
were 5-fold and 6-fold increase in old vs. young NI mice, respectively (Figure 19 T & U). 
This apparent dichotomy between decreased frequency and increased number can be 
explained by the significant phenotypic expansion of LT-HSC with age, as Dr. Orschell’s 
laboratory [147] and others [226] have reported, despite declining functional potential 
[40, 147, 227-234]. No sex differences were observed in the frequency or number of BM 
lymphoid progenitors.  
 
2.4. Discussion 
Lymphoid organs and lymphocytes are highly radiosensitive [235] due in part to 
their propensity toward rapid apoptosis when exposed to radiation. The acute effects of 
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radiation exposure on the lymphoid system are well known, but the late effects and long-
term immune suppression in survivors of H-ARS are less well characterized [147, 236, 
237]. In this report, radiation damage was investigated at all levels of lymphopoiesis in 
both male and female long-term H-ARS survivors, and was found to be characterized by 
significant tissue-specific reconstitution and involution patterns, age-related differences, 
and noteworthy male/female differences, especially in the thymus. 
 
Dr. Orschell’s laboratory previously reported persistent long-term dysfunction in 
competitive transplantation assays of phenotypically defined BM LT-HSC isolated from 
H-ARS survivors. Of note, lymphoid reconstitution in recipients of these BM LT-HSC 
transplants was severely diminished [40, 147], illustrating the loss of multi-lineage 
reconstitution potential of LT-HSC from DEARE mice. Herein, the primitive BM 
progenitors LMPP and CLP, progenies of LT-HSC, were enumerated and found to be 
significantly decreased in frequency and absolute number in DEARE mice, strongly 
implicating LT-HSC dysfunction as a significant contributor to the diminished lymphoid 
reconstitution in DEARE mice.   
 
Peripheral blood reconstitution in long-term H-ARS survivors was marked by 
significant myeloid skew, as previously reported [147, 237], and found herein to be 
present in both males and females. Of interest, myeloid skew was found to be more 
severe in IR females compared to males, and was characterized by a steady decline in 
lymphocyte number beginning around 9 months of age. Declining PB LY numbers in IR 
females paralleled observations in the thymus, which also showed worse recovery of 
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most classes of thymocytes (DN, DP, CD4+, CD8+ cells) in females, illustrating curious 
sex differences in immune reconstitution in the DEARE phase. Phenotypic analyses of 
PB LY subpopulations of DEARE mice revealed that the loss of LY was primarily due to 
significant loss of B cells, CD4+ T cells, and both CD4+ and CD8+ naïve T cells 
compared to NI age-matched controls. The LY subpopulation least affected by radiation 
exposure was CD8+ T cells, which are known to undergo homeostatic peripheral 
expansion (HPE) in lymphopenic environments [238, 239]. Similar trends in these LY 
subpopulations were also present in spleen. 
 
A biphasic recovery pattern of thymocytes was documented during the H-ARS 
phase with recovery to only ~40% of baseline values, similar to other reports [218, 219]. 
The first spike of cellularity in the biphasic recovery pattern is thought to be due to 
proliferation of remaining thymocytes [240, 241], which eventually deplete [242, 243]. 
This depletion, along with lack of BM support [244], leads to the second nadir. Thymic 
precursors migrating from the bone marrow to the thymus are responsible for eventual 
reconstitution [241, 245]. However, in H-ARS mouse model with high dose radiation, 
BM insufficiency is evident [40, 147], leading to long-term thymic insufficiency. The 
observed increase in medullary fibrosis in the thymus also likely contributes to thymic 
dysfunction in long-term H-ARS survivors. Thymic fibrosis early post-IR has also been 
reported in non-human primate radiation models [246]. 
 
Interesting male/female differences were also documented in normal NI C57BL/6 
mice. First, males possessed significantly increased numbers of most PB CBC parameters 
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compared to females (WBC, NE, LY, and PLT), and these sex differences persisted into 
old age. For LY, these differences intensified as mice aged, leading to more severe 
myeloid skew in NI geriatric females than in males. The presence of myeloid skew in 
both NI aged mice and H-ARS survivors illustrates similarities between normal aging and 
radiation damage on hematopoiesis [147, 247]. The decrease in LY in aged NI mice was 
primarily due to a decline in all classes of T cells, while B cells increased, as previously 
shown [248, 249]. Evidence of homeostatic peripheral expansion of PB CD8+ T cells was 
also present in aged NI mice. While most thymus parameters (mass, cellularity and T cell 
subpopulations) were increased in young NI females compared to males (in agreement 
with others [223, 250] and consistent with human data [251]), these differences 
diminished as mice aged. Spleen also showed decreased numbers of T cell 
subpopulations with age in both genders, but significantly increased spleen mass in NI 
aged females. Sex differences in PB and thymus parameters were both abolished after 
radiation exposure.  
 
Sex differences in lymphoid organs [250] and age-related thymic involution [252] 
have been postulated to be due to sex hormones, which may be further exacerbated by 
radiation damage to sex organs. Other factors independent of sex hormones, such as sex 
chromosomes, may also contribute to the observed sex differences. Many genes 
implicated in immune function are located on the X chromosome, including 
theinterleukin-2 receptor gamma chain gene [253] which participates in signal 
transduction of a number of cytokines, and FOXP3 gene which is involved in regulatory 
T cell development [254]. The X chromosome in general imparts an immunological 
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advantage to females in the face of various immune challenges, but can also lead to 
increased autoimmune diseases [255]. In addition, radiation-induced epigenetic changes 
in the murine thymus have been shown to differ between males and females [256], which 
may also contribute to sex-related differences in the radiation response and immune 
reconstitution. 
 
Taken together, this study has defined the prolonged immunosuppression at all 
levels of lymphocyte development in established murine H-ARS and DEARE models. 
These data build upon previous work by others and add to the understanding of the severe 
immune dysfunction that occurs in radiation survivors, with the hope that they will be 
useful for development of potential MCM and therapeutic strategies for radiation-induced 
long-term immune deficiency. 
 
In conclusion, immune suppression is a serious health risk in individuals exposed 
to myelosuppressive or ablative radiation, and has not been well-defined in long term 
survivors of H-ARS. Herein radiation-induced changes in primitive and mature lymphoid 
cells at all levels of lymphopoiesis were delineated in mice exposed to potentially lethal 
doses of radiation. Tissue-specific reconstitution and involution patterns were 
documented in PB, thymus, spleen, and BM tissues, along with unique sex-related and 
age-related changes present in some tissues but not others. The “double hits” of 
irradiation and age-related stress on lymphopoiesis lead to significant myeloid skew and 
long-term immune involution. These H-ARS and DEARE mouse model provide useful 
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tools for developing and evaluating medical countermeasures against the immune-
suppressing effects of irradiation. 
Chapter 3. Optimizing and Profiling Prostaglandin E2 as a Medical 
Countermeasure for the Hematopoietic Acute Radiation Syndrome 
3.1. Introduction 
Terrorist activities, nuclear warfare, and radiation accidents have the potential to 
expose humans to dangerous levels of radiation. Victims of exposure to a lethal dose of 
radiation face acute and chronic organ injuries, including H-ARS and DEARE. H-ARS 
and DEARE have been characterized by Dr. Orschell's laboratory in Chapter 2.  
 
MCM can be radioprotectant, when used pre-exposure for protection, or 
radiomitigator, when used post-exposure for mitigation [257]. Current FDA-approved 
radiomitigators including Neupogen (G-CSF), Leukine (GM-CSF), and Neulasta 
(pegylated G-CSF) are effective in increasing the survival rate and ameliorating H-ARS 
in victims of civilian radiation accident [200]. However, for first responders and military 
personnel who work in the radioactive-material contaminated environment, no 
radioprotectant has been approved [258]. Amifostine is approved for tissue protection in 
patients undergoing with chemotherapy and/or radiotherapy, but has not been approved 
as radioprotectant for H-ARS [259]. An effective radioprotectant for H-ARS is a 
significant, unmet medical need. 
 
PGE2 is one of the most abundant eicosanoids and mediates diverse physiological 
and pathological processes, including hematopoiesis [130, 260], bone metabolism [261], 
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blood pressure regulation [262], and pain and inflammation [263, 264]. The 
radioprotective and radiomitigating properties of dmPGE2, a long-acting analogue of 
PGE2 with similar biological effects as PGE2 but with a longer half-life, have been 
investigated. Hanson et al. [132, 265] indicated that dmPGE2 protected intestinal 
clonogenic cells from radiation damage in B6D2F1 mice when used as radioprotectant 1 
hr prior to radiation exposure. Walden et al. [134] demonstrated that dmPGE2 increased 
the LD50/30 survival rate of CD2F1 mice when administrated -30 min prior to radiation. 
Hoggatt J et al. [135] investigated dmPGE2 as a radiomitigator at +6 and +24 post-IR, 
demonstrating significantly enhanced day 30 survival rate and accelerated hematopoietic 
recovery in C57Bl/6 mice, possibly due to enhanced HSC survival and self-renewal 
(Figure 20). These early studies were performed on adult mice with different genetic 
backgrounds.  
 
The FDA Animal Rule (AR) is a set of FDA guidance about drug development 
when human studies are unethical, such as studies on lethal radiation exposure. Besides 
expecting the drug response in animal model could predict the response in human, FDA 
AR also encourages researchers to investigate the efficacy of MCMs in special 
populations, including pediatric and geriatric populations. In order to develop dmPGE2 
as an effective MCM, the efficacy of dmPGE2 was evaluated in the well-defined animal 
model [69] to investigate the optimal time window of dmPGE2 treatment and age-related 
effects on its radioprotective and radiomitigative properties. Additionally, the potential 
PGE2 receptor that might play a role in mediating dmPGE2 protection was identified, 
and the hematopoietic recovery and bone marrow environment changes post-IR were 
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evaluated. These findings may contribute to the possibility of stockpiling and widely 
distributing dmPGE2 as an MCM for H-ARS in the future. 
Figure 20 
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Figure 20. Effect of dmPGE2 as radiomitigator given at +6 hr or +24 hr post-TBI on 
day 30 survival and hematopoietic recovery of lethal-irradiated mice.  
Mice were exposed to 7.96 Gy (LD70/30) TBI at 12 w/o. DmPGE2 was injected 
subcutaneously single dose of 40 µg per mouse at +6 hr (panel A) or +24 hr (panel B) 
post-TBI. The survival in each group was monitored daily for consecutive 30 days after 
TBI. Thirty-day survival rates between the dmPGE2 and Veh group were compared using 
the Kaplan-Meier method and log-rank test. n=20-40 per group. * p<0.05 comparing to 
Veh group. For the +6 hr group, WBC, NE and LY were analyzed at various days post-
TBI (panel C-E). n=3 per group per time-point. Reproduced from Hoggatt J, Singh P, 
Stilger KN, et al. Recovery from hematopoietic injury by modulating prostaglandin E (2) 
signaling post-irradiation. Blood Cells Mol Dis. 2013 Mar;50(3):147-53. 
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3.2. Materials and Methods 
3.2.1. Mice, husbandry, monitoring and irradiation  
Male and female young adult C57BL/6 mice were purchased from Jackson 
laboratory (Bar Harbor, ME) at 10 w/o and acclimated with acidified water for 2-week 
prior to irradiation. In accordance with pilot studies, the adult mice were irradiated at 12 
w/o, an age analogous to a “young adult” human at 20 years old [266], with an 
unfractionated TBI dosage of 8.53 Gy (LD50/30), 8.72 Gy (LD70/30), or 9.04 Gy 
(LD90/30). Geriatric mice were aged in-house to 23.5 months and then provided acidified 
water for 2-week prior to irradiation. The geriatric mice were irradiated at 24 m/o 
(analogous to human at 70 years old [266]) with 10.08 Gy for male mice and 9.47 Gy for 
female mice. The pediatric mice were received from in-house breeding colony at the 
Indiana University Melvin and Bren Simon Cancer Center In Vivo Therapeutics Core 
(Indianapolis, IN), and were not provided acidified water until after TBI. The pediatric 
mice were irradiated at 6 w/o (analogous to human at 11.5 years old [266]) with 7.41 Gy 
for male mice and 8.01 Gy for female mice. Husbandry, health status monitoring, 
irradiation, and dosimetry were carried out as previously described in Chapter 2 and in 
earlier paper [69, 267]. The irradiation dosages for pediatric and geriatric mice were 
chosen based on previous dose response relationship (DRR) probit plots to reach lethality 
around LD70/30 in Veh group (data not shown). Males and females were exposed 
separately since the sex-specific LD70/30 at this pediatric or geriatric age differs by 0.6 
Gy, much greater than the difference in young adult (12 w/o) mice which is only 0.1 Gy 
(unpublished data). All studies were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee.  
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3.2.2. Compounds 
DmPGE2 in methyl acetate was purchased from Cayman Chemicals (Cayman 
Chemicals, Ann Arbor, MI), and evaporated on ice under N2 then reconstituted in 100% 
ethanol (EtOH) at a final concentration of 0.1 M. DmPGE2 was injected subcutaneously 
at one dose of 35 µg or two doses of 20 µg as indicated in Figures and Legends. Vehicle 
(Veh; 1.75% EtOH/PBS solution) was injected at the same time as dmPGE2, 
respectively. In PGE2 receptor activation study, the EP agonists are EP1+3 dual agonist 
(17-phenyl trinor PGE2, Cayman Chemical, Ann Arbor, MI), EP2 selective agonist 
(butaprost free-acid, Cayman Chemical, Ann Arbor, MI) and EP4 selective agonist 
(L902-688, Cayman Chemical, Ann Arbor, MI). EP receptor agonists (10 µg or 35 µg per 
mouse) were injected subcutaneously -30 min prior to TBI [131, 268]. The volume of all 
compounds to deliver per mouse per injection was 200 µl.  
 
3.2.3. CBC 
Complete blood count was performed on peripheral blood of mouse on a validated 
HEMAVET 950FS Hematology System (Drew Scientific, Waterbury, CT). The 
procedures of blood collection and HEMAVET validation were carried out as previously 
described [69]. 
 
3.2.4. Antibody staining and flow cytometry analysis  
For HSC analysis, whole BM cells were acquired from femurs crushed with a 
mortar and pestle in PBS with 2% fetal bovine serum (FBS) and 2 mM EDTA. Filtered 
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cells then were stained with FcR blocking antibody followed by anti-Lin, anti-c-Kit, anti-
Sca-1, anti-CD48, and anti-CD150 antibodies (Biolegend, San Diego, CA) in PBS 
containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA. HSC was identified by 
the LSK and SLAM markers (CD48- CD150+) as previously described [128]. 
 
For mesenchymal stromal cells (MSC) analysis, crushed femurs were digested 
with 0.25% collagenase IV (Invitrogen, Waltham, MA) in PBS and 10% FBS, 30 min at 
37°C. Cells were stained with FcR blocking antibody followed by anti-CD45, anti-
ter119, anti-CD31, anti-CD51 and anti-PDGFR antibodies (Biolegend, San Diego, CA). 
MSCs were identified as CD45- Ter119- CD31- CD51+ PDGFR+ as previously described 
[131, 269]. Flow cytometry analyses were performed on LSR-II flow cytometer (Becton 
Dickinson Immunocytometry Systems, San Jose, CA) (Andrea Patterson and Pratibha 
Singh in Dr. Pelus’ laboratory provided the bone marrow phenotype analyses). 
 
3.2.5. Colony assay 
The surviving mice of the “young adult” group at day 35 post-TBI were sacrificed 
and 5×104 BM cells acquired from femurs were plated in ColonyGEL Mouse Complete 
Medium (Reach Bio, Seattle, WA) as previously described [131, 135]. After 7 days of 
incubation in a 37°C 5% CO2 incubator, CFC, CFU-GM, BFU-E and CFU-GEMM were 
counted by microscopy. CFC was the total number of all colonies. Colony assay for each 
mouse were done in triplicate. 
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3.2.6. BM cellularity and BM cytokine quantification 
BM supernatants were collected by flushing 2 femurs and 2 tibiae twice with a 
single volume of 500 µl cold PBS, stored at -80°C and thawed on ice before analysis. 
Samples were centrifuged at 16,300 g for 10 min to remove debris and measured in 
duplicate for 32 cytokines/chemokines by Milliplex Map Kit (EMD Millipore, Billerica, 
MA) using a Bio-Plex 200 system with High Throughput Fluidics Multiplex Array 
System (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s 
instructions. Data were analyzed with Bio-PlexTM 6.0 Manager software (Bio-Rad 
Laboratories, Hercules, CA). The 32-plex cytokine panel contained the following 
cytokines: MCSF, GM-CSF, G-CSF, IL-3, IL-7, leukemia inhibitory factor (LIF), IL-15, 
vascular endothelial growth factor (VEGF), IL-1α, IL-1β, tumor necrosis factor alpha 
(TNF-α), IL-2, IL-12 (p40), IL-12 (p70), interferon gamma (IFN-γ), IL-6, IL-17, IL-4, 
IL-5, IL-9, IL-10, IL-13, keratinocyte chemoattractant (KC, CXCL1), macrophage 
inflammatory protein 2 (MIP-2, CXCL2), lipopolysaccharide-induced CXC chemokine 
(LIX, CXCL5) , monokine induced by gamma interferon (MIG, CXCL9), interferon 
gamma-induced protein 10 (IP-10, CXCL10), monocyte chemoattractant protein-1 
(MCP-1, CCL2), macrophage inflammatory protein 1 α (MIP-1α, CCL3), macrophage 
inflammatory protein 1 β (MIP-1β,CCL4), regulated upon activation normal T cell 
expressed and secreted (RANTES, CCL5) and Eotaxin (CCL11).  Since the results of 
Bio-Plex analysis represent the concentration of BM cytokines diluted in 500 µl PBS, and 
the mean BM cavity volume of 2 femurs + 2 tibiae for each mice are 53.1178 µl for 
males and 39.1072 µl for females (personal communication with Dr. Laura Wright who 
did the microcomputed tomography on the BM cavity of young adult mice), the 
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following dilution factor was applied to values from the BioPlex to obtain the actual 
concentration of cytokines as they exist in the BM space: for males, 500 µl /53.1178 µl = 
9.413; for females, 500 µl /39.1072 µl = 12.7854. For example, the concentration of 
cytokine A in Bio-Plex analysis of female mice is 1 pg/ml, so the weight of cytokine A in 
500 µl BM flush is 0.5 pg, and the concentration of cytokine A in BM milieu is 0.5 pg/ 
39.1072 µl = 12.7854 pg/ml. Total BM cells concentration in BM flush was performed on 
HEMAVET 950FS Hematology System (Drew Scientific, Waterbury, CT) as previously 
described in CBC analysis. Similar dilution factor was applied to the BM cellularity. 
 
3.2.7. Statistical analysis 
All data are expressed as mean ± SEM. Binary comparisons between dmPGE2-
treated group and Veh-treated group, or Veh-treated group and NI group were subjected 
to a two-sample unpaired t test using Microsoft Excel 2010 (Microsoft Corp, Redmond, 
WA). The day 30 survival Kaplan-Meier (KM) analyses and log-rank tests were 
performed with SPSS Statistics Version 24 (IBM, Armonk, NY). A p value less than 0.05 
was considered significant. All data shown with error bars represent mean ± SEM. 
 
3.3. Results 
3.3.1. DmPGE2 increases day 30 survival post-IR 
Hoggatt J et al. [135] previously found that a single dose of dmPGE2 acts as a 
radiomitigator when administered +6 hr post-TBI, increasing the day 30 survival rate 
from 5% to 55%. When administered +24 hr post-TBI, the day 30 survival rate was 
increased from 35% to 70% (Figure 20). To test the hypothesis that dmPGE2 may be as 
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effective as a radioprotectant as it is as a radiomitigator and explore the optimal time 
window of dmPGE2 administration, the previously described well-established H-ARS 
mouse model was used [69]. Day 30 survival efficacies of 1 dose of 35 µg dmPGE2 
when given at -24 hr, -3 hr, -1 hr, -30 min, -15 min, +3 hr, +24 hr, or +30 hr relative to 
time of irradiation; or 2 doses of 20 µg at -15 min and -45 min prior to TBI, were tested. 
Survival efficacies were verified by two different irradiation doses, i.e., LD70/30 and 
LD90/30. The results demonstrated that dmPGE2 administration in the -3 hr to -15 min 
time window prior to TBI has the best survival efficacy, which reaches 100% survival in 
LD70/30 and 90-100% in LD90/30. No statistically significant difference was observed 
between the survival rate of one dose of 35 µg dmPGE2 injected at -30 min and two 
doses of 20 µg injected at -15 and -45 min prior to TBI, respectively. Administration of 
dmPGE2 at +24 hr post 8.72 Gy TBI significantly increased day 30 survival, supporting 
previous observation [135]. Now the time frame of radiomitigating dmPGE2 was 
extended to +30 hr.  Interestingly, when dmPGE2 was used as radioprotectant at -24 hr 
prior to TBI or as radiomitigator at +3 hr post TBI, the day 30 survival rates in dmPGE2 
group were the same as Veh group (Figure 21). These results indicated that there exists a 
specific time window pre- and post-TBI at which dmPGE2 is effective.  
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Figure 21 
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Figure 21. Thirty-day survival of lethal-irradiated mice treated with radioprotectant 
or radiomitigator dmPGE2.  
Mice were exposed to 8.72 Gy (LD70/30) or 9.04 Gy (LD90/30) TBI at 12 w/o. Single 
dose of 35 µg dmPGE2 per mouse was injected subcutaneously at -24 hr, -3 hr, -1 hr, -30 
min, -15 min, +3 hr, +24 hr, or +30 hr relative to time of irradiation; or 2 doses of 20 µg 
at -15 min and -45 min prior to TBI. Veh control of same dose was given at same time-
points as dmPGE2. Male and female mice were equally distributed in each group. The 
survival in each group was monitored twice daily for consecutive 30 days after TBI. 
Thirty-day survival rates between the dmPGE2 and Veh group were compared using the 
Kaplan-Meier method and log-rank test. n=19-20 mice per group except LD70/30 +24hr 
where n=60 per group. *p<0.05 comparing to Veh group.  
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3.3.2. DmPGE2 effects are different in pediatric and geriatric mice 
Radiation victims represent a heterogenous population; therefore, age effects of 
treatments need to be taken into consideration to ensure MCMs are suitable and/or 
optimized to use in children and the elderly. Pre-clinical animal studies in young and 
aging mice can be used to determine the impact of age on efficacy when human 
irradiation studies are not ethical. To date, there has been no research on the efficacy of 
dmPGE2 as a radioprotectant or radiomitigator in pediatric or geriatric animals. 
Therefore the efficacy of dmPGE2 was investigated in 6 w/o and 2-year-old mice which 
represent the juvenile and senior human populations, respectively. The 35 µg dose of 
dmPGE2 was tested previously and tolerated well by pediatric and geriatric mice with no 
mortality 24 hr after administration (data not shown). The -30 min and +24 hr Veh-
injected mice were combined into one Veh group in the pediatric or geriatric analysis, 
respectively. In pediatric mice, dmPGE2 given -30 min before TBI (7.41-8.01 Gy) 
protected 95% (p<0.001) of mice compared to 33% survival in vehicle treated mice. 
However, dosing at +24 hr was not radiomitigative in pediatric mice (Figure 22 A). In 
geriatric mice, dmPGE2 given -30 min before TBI (9.47-10.08 Gy) protected 80% 
(p=0.005) of mice compared to 36% survival in vehicle treated mice, and it is an effective 
radiomitigator given at +24 hr, which increased the survival rate to 67% (p=0.008) in 
comparison with 36% survival in vehicle treated mice (Figure 22 B). 
 
3.3.3. EP4 Receptor is the potential target receptor in dmPGE2 radioprotection 
PGE2 interacts with four conserved G-protein receptors: EP1, EP2, EP3 and EP4. 
In order to identify the responsible receptor involved in the survival efficacy of dmPGE2  
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Figure 22 
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Figure 22. Thirty-day survival of lethal-irradiated pediatric or geriatric mice 
treated with radioprotectant or radiomitigator dmPGE2.  
Pediatric mice were exposed to 7.41 Gy for males or 8.01 Gy for females at 6 w/o (panel 
A). Geriatric mice were exposed to 10.08 Gy for males and 9.47 Gy for females at 24 m/o 
(panel B). Radioprotectant dmPGE2 was injected subcutaneously single dose of 35 µg 
per mouse at -30 min prior to TBI, and radiomitigator dmPGE2 was injected with the 
same dose at +24 hr post TBI. Thirty-day survival rates of radioprotectant dmPGE2, 
radiomitigator dmPGE2 and Veh groups were compared using the Kaplan-Meier method 
and log-rank test. In panel A, n=20-21 mice per group. In panel B, dmPGE2 -30 min, 
n=20 mice; dmPGE2 +24 hr, n=33 mice; Veh -30 min and +24 hr groups were combined, 
n=77 mice. *p<0.05 comparing to Veh group; † p<0.05 comparing dmPGE2 +24 hr 
group to dmPGE2 -30 min group. 
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administered as a radioprotectant, agonists highly specific for EP1&3 (17-phenyl trinor 
PGE2; Ki=14/3.7 nM), EP2 (Butaprost-free acid; Ki=11 nM), or EP4 (L-902,688; 
Ki=0.38 nM) were tested for survival efficacies in comparison with dmPGE2 (Table 1). 
Only the EP4 agonist, used as radioprotectant, significantly increased the day 30 survival 
compared with the Veh control (45% in EP4 group vs. 13% in Veh group), although this 
rate was still significantly lower than the day 30 survival with radioprotectant dmPGE2, 
which provided nearly 100% protection. Neither EP1&3 nor EP2 agonist increased the 
day 30 survival rate (Figure 23). Radioprotection appears to be the result of activating the 
signal pathway via the EP4 receptor.  
 
3.3.4. DmPGE2 accelerates hematopoietic recovery post-IR 
Hoggatt, J et al. [135] previously found that dmPGE2 administered +24 hr post-
TBI effectively enhanced the recovery of peripheral blood cells and HPC potential. Here, 
the effects of radioprotectant dmPGE2 (-30 min) on the hematopoietic recovery were 
investigated. The nadir of hematopoietic inhibition post-TBI is around day 7-10, and 
under the protection of dmPGE2, WBC, NE, RBC and PLT started to recover as early as 
day 10 post-TBI, and continuously accelerated the hematopoietic recovery to 38 days 
post-TBI. DmPGE2 treatment had little effect on LY nadir where LY started to recover 
after day 20 post-TBI (Figure 24 A). Analyses of SLAM LSK and MSC phenotypes in 
BM at day 50 post-TBI showed a significant increase in HSCs and niche cells (mainly 
MSC) in dmPGE2-radioprotectant-treated mice compared with mice treated with the Veh 
control (Figure 24 B & C, Andrea Patterson and Pratibha Singh in Dr. Pelus’ laboratory  
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Table 1. Selectivity and sensitivity of EP receptor agonists. 
 
All compounds are commercially available from Cayman Chemical, Ann Arbor, MI and 
data are from Cayman Chemical product sheets. 
  
Compound Receptor Utilization 
Selectivity (Ki) at Receptor (nM) 
    EP1 EP2 EP3 EP4 
PGE2 EP1,2,3,4 20 12 0.85 1.9 
dmPGE2 EP2,3,4 x 17 1.9 43 
17-phenyl trinor PGE2 EP1,3 14 x 3.7 x 
Butaprost-free acid EP2 x 11 x x 
L-902,688 EP4 x x x 0.38 
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Figure 23 
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Figure 23. Thirty-day survival of lethal-irradiated mice treated with dmPGE2 or 
PGE2 receptor agonists at -30 min prior to TBI.  
Mice were exposed to 8.72 Gy TBI at 12 w/o. 17-phenyl trinor PGE2 (EP1+3 agonist), 
Butaprost free-acid (EP2 agonist), L-902,688 (EP4 agonist) or dmPGE2, were injected at 
35 µg per mouse subcutaneously -30 min prior to TBI, respectively. Thirty-day survival 
rates of each group were compared using the Kaplan-Meier method and log-rank test. 
n=20-40 mice per agonist group and n=79-80 mice per dmPGE2 and Veh group. *p<0.05 
comparing to Veh group; † p<0.05 comparing to dmPGE2 group.  
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provided the bone marrow phenotype analyses). The HPC potential analysis (presented as 
CFU-GM, BFU-E, CFU-GEMM, and CFC frequency per femur) at day 35 post-TBI 
demonstrated that dmPGE2 enhanced expansion of myeloid, erythroid, and megakaryoid 
progenitors in the bone marrow when used as a radioprotectant (Figure 24 D, Liqiong Liu 
in Dr. Pelus’ laboratory provided the CFC analysis).  
 
3.3.5. DmPGE2 affects BM cytokines and BM cellularity post-IR 
Irradiation induces cytokine storm where cytokines could play positive or 
negative roles in hematopoiesis post-TBI. Some of them have been proved to be as 
radioprotectant when given before radiation [270]. Considering the key role of BM 
cytokine in hematopoietic regulation [271, 272], cytokine levels in BM milieu post-TBI 
with radioprotectant dmPGE2 treatment were investigated. In order to accurately evaluate 
the cytokine concentration in BM, Dr. Laura Wright used micro computed tomography to 
calculate the volume of femur and tibia marrow cavity in male and female mice 
respectively, in which male had significantly 1.4 times more BM volume than female, 
emphasizing the importance of cytokine analyses in BM milieu in a gender-specific 
manner. The values in the Y-axes of Figure 25 represent the cytokine levels in the BM 
milieu after conversion of the Bio-Plex reads by dilution factor as described in the 
Materials and Methods section. The cytokine levels in mice sacrificed 30 min after 35 µg 
dmPGE2 or Veh injection without sham-irradiation represent the cytokine levels at the 
time of irradiation, in which the hematopoiesis-supporting cytokine KC was significantly 
increased by dmPGE2. KC was equally increased in both dmPGE2 and Veh groups at 6 
hr post-TBI and equally reduced in the two groups at 24 hr post-TBI (Figure 25 A).  
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Figure 24. Hematopoietic recovery of lethal-irradiated mice treated with 
radioprotectant dmPGE2.  
Mice were exposed to 8.72 Gy or 9.04 Gy TBI at 12 w/o and treated with single dose of 
35 µg dmPGE2 or Veh at -30 min prior to TBI. WBC, RBC and PLT were enumerated at 
steady-state before irradiation and at day 2, 7, 10, 20 and 38 post-TBI. n=3-6 mice per 
group per time-point (panel A). In another similar experiment, mice were exposed to 8.72 
Gy TBI at 12 w/o and treated with radioprotectant dmPGE2 or Veh as described above. 
At day 50 post-TBI, the numbers of SLAM LSK and MSC per femur were determined by 
flow cytometry as described in Materials and Methods (panel B & C). At day 35 post-
TBI, 5×104 bone marrow cells were suspended in ColonyGEL Mouse Complete Medium 
for CFC assay. After 7 days of incubation, the frequencies of CFU-GM, BFU-E and 
CFU-GEMM per femur were counted separately and total number of colonies was 
combined as CFC (panel D). n=4 mice per group. Lines and bars represent mean ± SEM. 
*p<0.05 comparing to Veh group. Andrea Patterson and Pratibha Singh in Dr. Pelus’ 
laboratory provided the bone marrow phenotype analyses. Liqiong Liu in Dr. Pelus’ 
laboratory provided the CFC data. 
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Figure 25
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Figure 25. BM cytokines and BM cellularity at 6 and 24 hr post-TBI treated with 
radioprotectant dmPGE2.  
Twelve w/o NI mice were treated with single dose of 35 µg dmPGE2 or Veh 
subcutaneously at -30 min prior to sacrifice. Irradiated mice (8.53 Gy TBI) were treated 
with single dose of 35 µg dmPGE2 or Veh per mouse subcutaneously at -30 min prior to 
TBI and sacrificed at 6 and 24 hr post-TBI. Femurs and tibias were flushed by cold PBS, 
BM cellularity was enumerated and cytokine levels in BM supernatant were measured by 
bead-based multiplex technology as described in Materials and Methods. Bars represent 
mean ± SEM. n=4-5 mice per group per time-point. *p<0.05 comparing dmPGE2 group 
to Veh group at each indicated time-point; † p<0.05 comparing TBI Veh group to NI Veh 
group (0 hr time-point). Huilin Chua and Hailin Feng did the Bio-Plex study; Tong Wu 
did the analyses. 
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 By 6 hr post-TBI, irradiation exposure increased G-CSF and LIF in BM and 
dmPGE2 further increased their concentrations (Figure 25 B & C). IL-6, Eotaxin, IL-4 
and MIP-2 were not influenced by irradiation but increased in dmPGE2 group at 6 hr 
post-TBI (Figure 25 D-G). Radioprotectant dmPGE2 attenuated the irradiation-induced 
decreases of IL-2 and IL-12(p40) (Figure 25 H & I); or attenuated the irradiation-induced 
increase of MIG (Figure 25 H & I).  There were also cytokines which only impacted by 
irradiation but not by dmPGE2, such as M-CSF (Figure 25 L); or neither impacted by 
irradiation nor by dmPGE2 (Figure 25). The BM cell loss induced by irradiation was 
attenuated by dmPGE2 prior to TBI (Figure 25 AF).    
 
By 24 hr post-TBI, most irradiation-induced or dmPGE2-induced cytokine 
production subsided. IL-2 was decreased at 24 hr in dmPGE2 group although it was 
increased at 6 hr (Figure 25 H). MIG and VGEF were lower in dmPGE2 group 
comparing to Veh group at 6 hr and further suppressed at 24 hr (Figure 25 J & K). 
 
3.4. Discussion 
PGE2 could be an inhibitor and a stimulator of hematopoiesis depending on 
regimen and dose [123, 127, 260, 273]. Early studies demonstrated that short-term in 
vitro culture of BM cells with PGE2 stimulated quiescent cells to enter the cell cycle and 
increased colony-forming unit-spleen (CFU-S) following transplantation [273]. However, 
in vivo treatment with PGE2 had little or no impact on hematopoiesis [130, 274]. 
Recently, ex vivo embryonic exposure to dmPGE2 was shown to increase HSC numbers 
in a Zebrafish embryo model, while blocking PGE2 production by indomethacin 
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decreased the HSC number [127]. On the contrary, Gentile P et al. and Hoggatt J et al. 
[123, 260] showed that in vivo repeated treatments (3 or 7 consecutive days) with native 
PGE2 or dmPGE2 decreased bone marrow and splenic cellularity, and CFU-GM 
frequency. Considering that these different studies used different timing and duration of 
exposure, it is reasonable to hypothesize that the administration schedule of dmPGE2 (or 
PGE2) plays a critical role in deciding its stimulatory or inhibitory effect on 
hematopoiesis under the radiation scenario, and certain schedules might be ineffective or 
even deleterious to survival, which makes the optimization of dmPGE2 dosing windows 
important.  
 
Survival analysis indicates that administration of dmPGE2 as radioprotectant 
during -3 hr to -15 min prior to TBI confers almost complete survival but -24 hr schedule 
was not radioprotective (Figure 21). Data from Dr. Pelus’ laboratory show that the 
PGE2’s inhibition on proliferation of HSPC lasts longer than 24 hr after injection [123, 
275]. The potential mechanism that dmPGE2 inhibits cell cycling and thus decrease DNA 
damage brought by irradiation, cannot explain the phenomenon that -24hr schedule is not 
radioprotective. The attenuation of irradiation-induced increase in HSPC cycling by 
dmPGE2 administration at -30 min or earlier prior to TBI is more likely a direct dmPGE2 
signaling response at the time of irradiation. 
 
The dmPGE2 +3 hr administration schedule fails to increase day 30 survival rate. 
Hoggatt J et al. [135] showed that radiomitigator dmPGE2 administrated at +6 hr and +24 
hr post-TBI increases survival, and now the efficacy of +24 hr time-point in another 
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cohort of mice is confirmed and the time window is extended to +30 hr post-TBI. So, the 
time-window for dmPGE2 radiomitigator is +6 to +30 hr post-TBI. This information is 
important for maximizing survival in civilian victims of unexpected lethal radiation when 
radioprotection is impossible. Although Porter RL et al. [276] reported that dmPGE2 
given immediately after sub-lethal irradiation decreased the loss of functional HSPC, 
another survival study reported by Walden TL et al. [134] demonstrated that dmPGE2 
given at either +5, +15, +30, or +60 min after lethal irradiation was not radiomitigative. 
This discrepancy might relate to different mouse stain, different irradiation dose and 
different dmPGE2 dose. These studies indicate that irradiation transient induces unknown 
mechanisms to prevent dmPGE2 to take effect in at least 3 hr post-TBI.  
 
The obtained dmPGE2 survival data in pediatric and geriatric populations are 
important considerations for real-life radiation scenarios. Although there were detailed 
studies about using prostaglandin analogues, most focused on the use of PGE1 in 
maintaining the patency of the ductus arteriosus in neonates [277]. The information from 
these studies could not apply to the radiation scenario because of the different disease 
status and differences between neonates and juveniles. This study, for the first time, 
indicates that radioprotectant dmPGE2 is effective both in pediatric and geriatric 
population, although the survival in geriatric population (80%) is slightly lower than in 
pediatric and adult population (95-100%), which might relate to the underlying 
impairment in aging mice. Radiomitigator PGE2 injected at +24 hr post-irradiation is 
effective in geriatric population but not in pediatric population (Figure 22). Sex 
difference in adolescence where male and female have significantly different sex 
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hormones profile might interfere the dmPGE2 radiomitigation. These results provide 
evidence that the stockpiling of dmPGE2 for use as a radioprotectant for H-ARS might 
benefit more widely diverse populations. 
 
By using specific EP agonists, the potential EP receptor responsible for dmPGE2 
radioprotection was investigated. Survival efficacy was only observed in mice receiving 
an EP4 agonist. However, while strongly suggestive of an EP4 binding effect, the level of 
protection provided by EP4 agonist was less than that by dmPGE2 (Figure 23). Binding 
of PGE2 to EP4 activates the cAMP dependent PKA/GSK3β/β-catenin pathway or cAMP 
independent GPCR kinase/PI3K/GSK3β/β-catenin pathway and then enhances the Wnt 
signaling pathway by stabilizing β-catenin. The nuclear translocation β-catenin activates 
the transcription and translation of CXCR4, Survivin and Cyclin D, thus promotes the 
homing, survival, and proliferation of HSCs [278-280]. When EP agonists given as 
radiomitigators, none of them show survival efficacy (unpublished data from Dr. Pelus’ 
laboratory), which indicates that the mechanisms of radioprotection and as a 
radiomitigation is different. The possible reasons for EP4 agonist not achieving the same 
level of protection as dmPGE2 might be the low agonist potency or dosing regimen, or 
more than one EP receptors activation needed for full survival efficacy. Experiments on 
combination of EP receptor agonists, intensive agonist regimens, EP receptor antagonists 
and genetic knockouts of EP receptors are ongoing to further confirm the responsible EP 
receptors. 
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Enhanced day 30 survival of dmPGE2-treated mice coincided with more robust 
recovery of all CBC parameters (Figure 24 A), indicative of enhanced hematopoietic 
recovery. Enhanced recovery of CBC correlated with increased HPC potential (Figure 24 
D). The result of the colony assay seems be contradictory to an early study that in vivo 
PGE2 administration inhibits the production of CFU-GM [123]. One probable reason is 
that inhibition might not last as late as the time-point of colony assay was taken; another 
reason is that the increased HPC potential came from HSC protection, where SLAM-LSK 
levels were increased in dmPGE2-treated mice (Figure 24 B). The increased number of 
MSCs in dmPGE2 treated mice (Figure 24 C), a critical component of the HSC-
supportive BM microenvironment, indicates the possibility that dmPGE2 influences HSC 
indirectly by protecting the BM microenvironment. It was previously demonstrated that 
PGE2 regulates dendritic cell generation through EP1 and EP3 receptors and the 
downstream STAT3/Survivin pathway [268]. Ikushima et al. found that PGE2 indirectly 
induced hematopoiesis through the activation of mesenchymal progenitor cells, which is 
consistent with finding of increased MSC in dmPGE2-treated mice [281].  
 
BM supernatant is the extracellular fluid component of the BM 
microenvironment, which is rich in cytokines and growth factors. As the BM supernatant 
“bathes” HSCs and HPCs in their specialized niches, the BM cytokine milieu is more 
informative than the peripheral blood cytokine level in determining the effect of 
treatment on hematopoiesis [282]. Cytokines induced by dmPGE2 at the time of 
irradiation may enhance survival and hematopoietic recovery post-TBI. Since straining 
mouse in a limited space during irradiation is a huge pressure on mouse and this 
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procedure itself will impact the cytokine level, the NI mice in this study were not sham-
irradiated, which the levels of BM cytokines at 30 min post-injection represent the 
cytokine levels at the time of irradiation. In NI group, although most cytokines between 
dmPGE2-injected and Veh-injected NI mice were not statistically different, KC 
significantly increased in dmPGE2 group (Figure 25), which play roles in neutrophil 
recruitment [283] and has potent hematopoietic activities in truncated form [284]. Future 
study would need to verify the radioprotective effect of KC.  Some other cytokines, 
which have been proven to be effective radioprotectants in vivo or in vitro, such as TNF-
α [285], LIF [286], VEGF [287], IL-12 [288, 289] and IL-6 [290, 291], had trends of 
increasing in the dmPGE2 group at the time-point of 0 hr although not statistically 
different from the Veh-injected NI group (Figure 25). All these results indicate that 
radioprotectant dmPGE2 enhances survival through up-regulating BM cytokines or 
activating a network of cytokines interaction.  
 
In mice sacrificed at 6 hr and 24 hr post-TBI, the BM cytokine levels reflect how 
dmPGE2 injected before irradiation impacts cytokines post-TBI and hence promotes 
hematopoietic recovery. In cytokines that up-regulated in the dmPGE2 group, some have 
potent effect in stimulating the proliferation of hematopoietic progenitor cells, such as G-
CSF and IL-12(p40) [272]; some others need synergistic actions from other cytokines to 
promote hematopoiesis, such as LIF, IL-6 and IL-4 [292, 293]; and some chemokines 
which do not have directly stimulating effect but can help with the transmigration and 
diapedesis of HSCs or attract inflammatory cells to bone marrow niche to regulate the 
HSCs, such as Eotaxin [294] and MIP-2 [295] (Figure 25). In cytokine down-regulated in 
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the dmPGE2 group, MIG has pleotropic effects, which acts as mediators of chemotaxis 
and as myelosuppressor [296]. The attenuation of HPC inhibition from the down-
regulation of suppressive factors, together with the up-regulation of stimulatory factors, 
might be one of the mechanisms for quick recovery of CBC parameters (Figure 24 A) 
and enhances survival (Figure 21) in dmPGE2 group. DmPGE2 also promotes 
hematopoiesis through regulating the pro-inflammatory vs. anti-inflammatory status of 
BM microenvironment by cytokine such as IL-2. The transient increase and rapid 
decrease of IL-2 in dmPGE2-treated mice indicated that in less than 24 hr post-TBI, the 
stresses and free-radical attacks on HSC from the inflammatory microenvironment were 
attenuated by dmPGE2, which might relate to the immunosuppressive effect of dmPGE2 
[297]. In addition to angiogenesis, VEGF inhibits the maturation of dendritic cells and 
differentiation of lymphocytes through inhibiting the activation of NF-κB in HPC. The 
lower expression of VEGF at 24 hr post-TBI in dmPGE2-treated group indicates that NF-
κB signal pathway was activated by inhibiting VEGF, thus indirectly enhancing 
hematopoiesis [298, 299]. The study on RNA-sequencing and Ingenuity pathway analysis 
(IPA) of these cytokines related gene expression changes in HSC are ongoing and will 
provide more insight on how these cytokines regulate hematopoiesis post-TBI (data 
unpublished).   
 
In summary, these studies characterized the optimum time window for 
administering dmPGE2 as radioprotectant and radiomitigator, showed the survival 
efficacy in pediatric and geriatric populations, investigated the potential receptor for 
dmPGE2’s radioprotective effect, revealed hematopoietic recovery in peripheral blood 
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and bone marrow, and further demonstrated the bone marrow cytokine milieu changes in 
mice received dmPGE2 as a radioprotectant. These studies provide supports for 
developing dmPGE2 as a MCM for H-ARS with FDA approval.  
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Chapter 4. Prostaglandin E2 and Lymphoid Lineage Reconstitution 
4.1. Introduction 
Exposure to a lethal dose of irradiation results in H-ARS and DEARE, as 
previously discussed. Immune involution is an important component of DEARE, mainly 
resulting from defective de novo lymphopoiesis and partially compensated by 
lymphocyte HPE. Thymic and peripheral lymphocytes are highly radiosensitive. The 
“double hit” from radiation and aging accelerates long-term thymic involution and 
immune deficiency. Immune deficiency is linked to the increased incidence of infection, 
cancer, and defective immune surveillance functions in H-ARS survivors [4, 205, 206]. 
Thymic involution in H-ARS survivors can result from: 1) decreased number and/or 
function of bone marrow-derived thymic precursors, 2) inability of these precursors to 
settle in the thymic niches, or 3) disruption of the thymic nurturing niches [4, 40, 56]. 
Currently, there are no effective treatments or preventions for radiation-induced thymic 
involution. 
 
DmPGE2 has demonstrated remarkable radioprotection effect in the H-ARS 
model (discussed in Chapter 3). DmPGE2 is a long-acting analog of PGE2, which has 
similar biological effects to PGE2. PGE2 inhibits T cell activation and proliferation by 
up-regulating cAMP and down-regulating IL-2 [300-302], and thus is considered 
detrimental to T cells. The potential for dmPGE2 to play a positive role in lymphoid 
lineage reconstitution post-IR had not been previously investigated.  
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Dr. Orschell’s laboratory has developed robust murine models of H-ARS in adult 
mice [69], which were used to evaluate thymic involution and immune reconstitution in 
survivors of lethal irradiation and to elucidate potential protective effects of dmPGE2. In 
this chapter, the radioprotection effect of dmPGE2 on radiation-induced thymic 
involution and long-term immune suppression in irradiation survivors is investigated. 
This is the first report of an effective radioprotectant MCM targeting thymic involution 
and lymphoid lineage reconstitution post-IR. 
 
4.2. Materials and Methods 
4.2.1. Mice, radiation, dosimetry, husbandry, and tissue harvest  
Specific pathogen-free C57BL/6 mice (CD45.2+), B6.SJL-PtrcaPep3b/BoyJ mice 
(B6.BoyJ, CD45.1+) and Fgd5-ZsGreen mice were purchased from Jackson laboratory 
(Bar Harbor, ME). F1 hybrids of C57Bl/6 and B6.BoyJ mice (CD45.2+/CD45.1+) were 
bred in-house. Mice were received at 10 w/o and allowed to acclimate for 2-week prior to 
irradiation. Husbandry, irradiation, dosimetry, tissue harvest and process are described as 
in Chapter 2. The TBI dose is either 8.53 (LD50/30), 8.72 (LD70/30) or 9.04 Gy 
(LD90/30) as specified. All studies were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee.  
 
4.2.2. Compounds 
DmPGE2 and EP1-EP4 were purchased from Cayman Chemicals (Ann Arbor, 
MI). The reconstitution, dosage, administration of dmPGE2 and EP agonists were the 
same as in Chapter 3 and were indicated in Figures and Legends.  
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4.2.3. CBC 
Peripheral blood CBC was performed as previously described in Chapter 2. For 
CBC from cardiac puncture, mice were euthanized by CO2 inhalation and laid in dorsal 
position. A 25-G 5/8inch needle was inserted toward the mouse’s left ventricle, under the 
sternum, and into the heart. The plunger of the syringe was slowly pulled and 100-150 μl 
blood was collected. Complete blood count was analyzed by HEMAVET 950FS 
Hematology System (Drew Scientific, Waterbury, CT). 
 
4.2.4. Antibody staining, flow cytometry analysis and flow cytometric cell sorting 
Antibodies used for identifying HSC, HPC, thymocyte subsets, and peripheral 
lymphocyte subsets were described in Chapter 2. In the in vitro lymphoid lineage 
differentiation assay, lysed bone marrow cells were stained with CD11b-FITC, Ter119-
FITC, CD3-FITC, Gr1-FITC, B220-FITC, Sca-1-PECY7 or BV650, c-Kit-APC 
antibodies and sorted for LSK cells to seed on the monolayer stromal cells. The live cells 
harvested from the culture system at different time-points were stained with CD11b-
APCCY7, B220-PE-TEXAS RED, CD4-PECY5, CD8α-PE, CD44-APC, CD25-PECY7, 
CD62L-PerCPCY5-5 antibodies. In bone marrow competitive transplantation study, 
thymi of recipients were processed into single cell suspension and stained with CD45.1-
PE, CD45.2-FITC, CD4-PerCPCy5.5, CD8α-PECy5, CD44-APC and CD25-PECy7 
antibodies to evaluate thymic donor chimerism and thymocyte subgroups reconstitution. 
In short-term thymus homing study, recipient thymocytes were stained with CD45.1-PE 
and CD45.2-FITC antibodies to evaluate the homing efficiency. In TEC analysis study, 
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the single thymocyte suspensions after enzyme digestion were stained with CD45-PE, 
EpCAM-APCCy7, UEA-1-FITC and Ly51-APC antibodies. All antibodies were 
purchased from BD Biosciences (San Jose, CA), Biolegend (San Diego, CA), 
eBiosciences (San Diego, CA) and Vector Laboratories (Burlingame, CA). Analytical 
data were collected on an LSR-II flow cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA). 
 
4.2.5. T and B cell development in vitro and PMA stimulation assay 
To test the ability of progenitor cells to differentiate into B and T lymphoid 
lineages in vitro, I used the OP9 or OP9-DL4 co-culture system, respectively. The co-
culture system and the staining protocol are described by Zuniga-Pflucker et al. [303-
305]. OP9 and OP9-DL4 cell lines were obtained from Zúñiga-Pflücker JC (University of 
Toronto, Canada). The culture medium for OP9 and OP9-DL4 was minimal essential 
medium (HyClone Laboratories Inc., Logan, UT) with 20% FBS and 1% penicillin 
streptomycin (Lonza, Walkersville, MD). OP9 and OP9-DL4 cells were thawed and 
passaged 2-3 times and grown to 80% confluence in a T25 flask, and 4×104 OP9 or OP9-
DL4 cells were plated per well in a 24-well plate 24 hours prior to co-culture at 80-90% 
confluence. Co-culture was carried out with OP9 medium plus 1 ng/ml IL-7 and 5 ng/ml 
FLT3L (both from PeproTech, Rocky Hill, NJ). One thousand sorted LSK cells were 
resuspended with 1 ml co-culture medium and were applied to the stromal monolayer at 
the first day of co-culture. Half of the medium was changed every 3-4 days. The cultured 
cells were demi-depopulated and transferred to new monolayers every 5-7 days after the 
appearance of the first colony (~day 9). Half of the acquired cells were transferred to new 
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monolayer stromal cells and the rest of the cells were used for phenotyping until the end 
of the co-culture [304].  
 
At day 16 or day 32 of co-culture, 5×105 cultured cells from OP9-DL4 co-culture 
system were stimulated with 20 ng/ml phorbol 12-myristate 13-acetate (PMA) (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) plus 500 ng/ml Ionomycin (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) for 5 hr at 37°C with 5% atmospheric CO2. 
Brefeldin A (1 μg/ml; GolgiPlug, BD Biosciences, NJ) was added to inhibit intracellular 
protein transport. After 5 hr of activation, cells were fixed and permeabilized with 
Cytofix and Cytopermb buffers (BD Biosciences, NJ), and stained with intracellular IFN-
γ APC. 
 
4.2.6. Long-term competitive transplantation and short-term thymus homing study 
Donor whole bone marrow cells were flushed from long bones of NI or IR mice 
(C57BL/6, CD45.2+), and 3×105 of these cells were transplanted intravenously along with 
2× 105 congenic competitor bone marrow cells into congenic recipients. The competitors 
and recipients were B6.BoyJ (CD45.1+) or the F1 hybrid of C57Bl/6 and B6.BoyJ mice 
(CD45.1+ and CD45.2+). Recipients had been irradiated with 11 Gy which consisted with 
a split-dose of 5.5 Gy followed by 5.5 Gy four hours later. The use of congenic mice in 
competitive bone marrow transplantation has been previously described [40, 306, 307]. 
Recipient mice were sacrificed at 6 months post-transplantation and thymi were used for 
chimerism analysis. For short-term thymus homing study, 2×107 whole BM cells from 
donor mice (C57Bl/6, CD45.2+) were transplanted intravenously into lethally-irradiated 
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recipient mice (B6.BoyJ, CD45.1+). After 16 hr, recipient thymocytes were analyzed by 
flow cytometry for homing efficiency. 
 
4.2.7. Thymus epithelial cells identification 
Thymi were cut into small pieces with fine scissors and incubated with 0.5 ml 
thymic enzyme solution [RPMI1640 medium with 0.05% (w/v) Liberase TH (Roche 
Diagnostics, Indianapolis, IN) and 100 U/ml DNase I (New England Biolabs, Ipswich, 
MA)] at 37 °C for 20 min. Supernatant was discarded and fresh enzyme solution was 
added to remaining debris until digestion was complete [308]. The cTEC was defined as 
CD45-EpCAM+UEA-1-Ly51+ and mTEC was defined as CD45-EpCAM+UEA-1+Ly51- 
by flow cytometry analysis. 
 
4.2.8. RNA sequencing and IPA analysis of HSC 
Fgd5 mice received one 35 µg dose of dmPGE2 or equivalent Veh injection -30 
min prior to TBI (8.53 Gy, LD50/30) and were sacrificed 24 hr post-TBI. Fgd5 ZsGreen 
was used to enhance the purity of HSCs due to the loss of c-kit expression after radiation 
[309]. HSCs were identified as CD45+SLAM-LSKwideZsGreen+ and sorted by FACSAria. 
RNA was extracted with a RNeasy Plus Micro kit (Qiagen, Hilden, Germany). To obtain 
adequate amounts of high-quality cDNA, due to the low cell number (1,000-6,000 HSCs 
per sample), SMART-Seq v4 Ultra Low Input RNA Kit (Takara Bio, Mountain View, 
CA) was used for cDNA synthesis. RNA sequencing was performed by the Genomics 
Core at Indiana University School of Medicine. To compare gene expression between 
different groups, results were converted to Reads Per Kilobase per Million (RPKM). 
 131 
Significant differences were defined as false discovery rate (FDR) <0.05 and fold change 
>2. IPA analysis was used to evaluate differentially expressed genes. Lymphopoiesis and 
its related genes were identified by IPA cellular function predictions. The RPKM values 
were transformed to Z-scores for visualization purposes.  The Z-score was defined as the 
difference of individual and average RPKM value divided by standard deviation. Blue 
represented lower scores and red for higher scores (Andrea Patterson in Dr. Pelus’ 
laboratory provided the RNA sequencing and IPA analysis). 
 
4.2.9. Bone marrow cytokine analysis 
C57BL/6 mice were treated with one dose of 35 µg dmPGE2 at -30 min or 
equivalent Veh prior to 8.53 (LD50/30) and were sacrificed 9 days post-TBI. The BM 
cytokine detection and analyses were the same as described in Chapter 3. The Z-score of 
each cytokine was calculated as the difference of individual and average cytokine level 
divided by standard deviation. The Z-scores were transferred to color scale with blue for 
low and red for the high expression levels. 
 
4.2.10. Statistical analysis 
Lifespan in DEARE mice were analyzed by Kaplan-Meier analyses and log-rank 
tests using SPSS Statistics Version 24 (IBM, Armonk, NY). Blood parameters 
comparisons between dmPGE2-injected NI and baseline were subjected to unpaired two-
tailed t-tests using Microsoft Excel 2010 (Microsoft Corp, Redmond, WA). Comparisons 
of more than two groups were performed by one-way analysis of variance (ANOVA) 
with post-hoc Tukey-Kramer HSD or Welch ANOVA for unequal variances using JMP 
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14 (SAS Institute, Cary, NC). Fisher’s exact test was used to assess the incidence of 
thymic mass post-TBI and was performed using online Fisher exact test calculator from 
www.socscistatistics.com/tests. The day 30 survival difference between vehicle-treated 
and dmPGE2-treated groups were compared with the Kaplan-Meier (log-rank) test using 
SPSS Statistics Version 24 (IBM, Armonk, NY). P<0.05 was considered significant. All 
data are expressed as mean ± SEM. 
 
4.3. Results 
4.3.1. DmPGE2 extends lifespan and prevents the myeloid skew of DEARE mice 
When used as a radioprotectant, dmPGE2 greatly increased the day 30 survival 
rate of lethally irradiated mice. There was no statistical difference in day 30 survival rates 
between mice received one dose of 35 µg or two doses of 20 µg dmPGE2 at -15 min to -3 
hr time-window prior to TBI (Chapter 3, Figure 21). And there was no statistical 
difference in long-term survival rates between mice exposed to LD50/30, LD70/30 or 
LD90/30 (unpublished data). Data from theses dmPGE2 schedules with different lethal-
irradiation exposure were therefore combined and referred to as radioprotectant dmPGE2 
group in all the following studies unless specifically stated otherwise. Consistent with 
earlier reports [310, 311], lifespan was significantly shortened in Veh mice comparing 
with age-matched NI controls. Radioprotectant dmPGE2 greatly extended the long-term 
survival rate comparing with Veh but still lower than the NI control (Figure 26). 
Complete blood counts in Veh and dmPGE2-treated survivors and NI controls were 
followed up to 12 months post-TBI. At 6 months post-TBI, NE count in the Veh and 
dmPGE2 group were lower than the NI group. No statistical difference among these  
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Figure 26. Long-term survival of lethal-irradiated mice treated with radioprotectant 
dmPGE2.  
Twelve w/o C57BL/6 mice were treated with one dose of 35 µg dmPGE2 at -15 min, -30 
min, -1 hr or -3 hr, or 2 doses of 20 µg dmPGE2 at -15 and -45 min prior to 8.53 Gy, 8.72 
Gy, or 9.04 Gy TBI as previously described. Mice survived over day 30 post-TBI were 
transferred to RBMD study for long-term survival monitor until the end of study (24 
months post-TBI). The survival mice were recorded when found dead, or were 
euthanized when severely moribund or scheduled time-point sacrifices. All the mice 
received radioprotectant dmPGE2 were combined in radioprotectant dmPGE2 group and 
all Veh-treated mice were combined into Veh group. NI mice from multiple studies were 
used as control. Survival is shown as Kaplan-Meier curve. * p<0.05 comparing to Veh 
group; ∆ p<0.05 comparing to NI group. 
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groups remained at 12 months post-TBI. At 6 and 12 months post-TBI, LY count in the 
Veh group was significantly lower than in the NI and dmPGE2 groups, with no 
difference between the NI and dmPGE2 groups (Figure 27 A-C). Myeloid skewing was 
also obvious when expressed as percentages (Figure 27, D & E), where the percentage of 
NE was significantly higher in the Veh group than the NI group, and the percentage of 
LY was significantly lower in the Veh group than the NI group. These differences 
increased as mice aged. DmPGE2 effectively prevented myeloid skew in DEARE mice, 
where the dmPGE2 group had higher LY percentage and lower NE percentage than Veh 
group. NI mice had higher RBC and PLT counts than Veh, and dmPGE2 group had 
higher RBC and PLT than Veh group (Figure 27 F & G).  
 
4.3.2. DmPGE2 transiently decreases lymphocyte level in normal mice 
Lymphocyte recovery post-TBI is relatively later than neutrophil recovery in 
dmPGE2 group, which has been discussed in previous Chapter and in Figure 24), 
whether dmPGE2 itself, in NI scenario, could regulate lymphocyte number, has not been 
tested. Complete blood count was evaluated in non-irradiated mice receiving one shot of 
dmPGE2 or Veh and followed up to 10 days post injection (Figure 28 A-C). The basal 
levels of WBC, NE, LY, RBC and PLT from cardiac puncture were lower than the 
corresponding values from the tail-bled CBC, corresponding with earlier study from 
Hoggatt J et al. [312]. Compared with untreated controls (day 0, Figure 28 A-G), 
dmPGE2-treated mice had rapidly decreasing LY numbers and a relatively higher 
percentage of NE day 1 post-injection, demonstrating the early toxicity of dmPGE2 in 
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Figure 27. CBC profiles in DEARE phase of lethal-irradiated mice treated with 
radioprotectant dmPGE2.  
C57BL/6 mice were treated with radioprotectant dmPGE2 or Veh prior to lethal TBI. 
Complete blood count analyses of WBC (panel A), NE (panel B), LY (panel C), %NE 
(panel D), %LY (panel E), RBC (panel F) and PLT (panel G) were followed up at 6 and 
12 months post-TBI. Lines represent mean ± SEM. n=6-12 mice per group (panel A-G). 
*p<0.05 comparing to Veh; † p<0.05 comparing to NI.  
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Figure 28 
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Figure 28. CBC profiles in NI mice injected with dmPGE2.  
NI C57BL/6 mice were injected with one dose of 35 µg dmPGE2 and CBC analyses of 
WBC (panel A), NE (panel B), LY (panel C), %NE (panel D), %LY (panel E), RBC 
(panel F) and PLT (panel G) were followed up to 10 days post-injection. Lines represent 
mean ± SEM. n=3 mice per group per time-point. *p<0.05 comparing to baseline 
parameters before the injection (day 0 points). Andrea Patterson provided the data; Tong 
Wu did the analyses. 
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lymphocytes. The LY number started to recover at day 2 and had returned to normal at 
day 4 (Figure 28 C and E). There was no significant difference in the absolute values of 
other types of blood cell (NE, RBC and PLT) between dmPGE2-treated and Veh-treated 
mice (Figure 28 B, F & G). The CBC data indicate that the negative effect of dmPGE2 
on peripheral lymphocytes is transient. 
 
4.3.3. Both B and T cells are increased in the spleen of dmPGE2-treated mice 
Since splenic lymphocytes are representative of circulating lymphocytes [248, 
313] and naïve T cell in secondary lymphoid organ is an estimation of RTE [314, 315], 
the lymphocyte subsets in the spleen were analyzed. At 12 months post-TBI, spleens 
were processed into a single cell suspension and phenotyped by flow cytometry. Veh 
group had less CD4+ T cells and naïve CD4+ T cells and B220+ B cells than NI group, 
and radioprotectant dmPGE2 prevented the loss. The differences in CD8+ T and CD8+ 
naïve T cells between NI and Veh group, Veh and dmPGE2 group followed the similar 
trend as CD4+ T cell but were not significant (Figure 29 A-E). Treatment with 
radioprotectant dmPGE2 not only alleviates T lymphocyte involution by increasing 
thymic output, but also increases B lymphocytes, which indicates that dmPGE2 may 
protect the common lymphoid progenitor cells.  
 
4.3.4. DmPGE2 protects thymus from irradiation-induced involution 
Hoggatt J et al. [128] have previously shown that PGE2 protects stem cells from 
apoptosis in vitro and dmPGE2, when used as radioprotectant, accelerates hematopoiesis, 
including lymphopoiesis in H-ARS phase (Figure 24). In DEARE mice model, 
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Figure 29. Spleen T and B cells in DEARE phase of lethal-irradiated mice treated 
with radioprotectant dmPGE2.  
C57BL/6 mice were treated with radioprotectant dmPGE2 or Veh prior to lethal TBI and 
were sacrificed at 12 months post-TBI. Splenocytes from age-matched NI, Veh and 
dmPGE2 group were stained with CD4, CD8, CD44, CD62L and B220 antibodies and 
analyzed by flow cytometry for the absolute number of CD4+ splenocytes (panel A), 
CD8+ splenocytes (panel B), CD4 naïve (CD44-CD62L+) spleen T cells (panel C), CD8 
naïve (CD44-CD62L+) spleen T cells (panel D), B220+ splenocytes (panel E) as described 
in Materials and Methods. Bars represent mean ± SEM. n=3 mice per group. *p<0.05 
comparing to Veh group.  
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radioprotectant dmPGE2 also prevents the decline of lymphocytes and myeloid skew 
(Figure 27). Since the thymus is where T cells are educated and the site of de novo T 
lymphopoiesis, I tracked thymic weight and cellularity post-TBI in NI, Veh-treated, and 
dmPGE2-treated group, from H-ARS to DEARE phase. No difference in thymic weight 
or cellularity was observed between the dmPGE2 and Veh groups at the early time-point 
of H-ARS (day 3 and day 10 post-TBI). The protective effect became apparent at day 20 
post-TBI and extended to the 6 and 12 months post-TBI (Figure 30 A & B). As dmPGE2 
has a minimal effect on body weight change post-TBI, the difference in thymic weight 
between groups was not related to body weight change (the trend of thymic index, which 
is represented by thymus weight/body weight is similar to Figure 30 A & B, data not 
shown).  
 
4.3.5. DmPGE2 protects thymocytes from delay in DN to DP transition induced by 
irradiation 
Differences in thymocyte subpopulation distribution between dmPGE2- and Veh-
treated mice at DEARE phase were analyzed. Thymocytes were measured at 12 months 
post-TBI from the earliest thymic settling cells [CD4-CD8-CD44+CD25- DN1 cells, and 
CD44+CD25+ DN2 cells, CD44-CD25+ DN3 cells, and CD44-CD25- DN4 cells]; to the 
intermediate CD4+CD8+ DP cells and then to the mature CD4 or CD8 single positive 
cells, which are ready to immigrate into peripheral blood. At 12 months post-TBI, the 
percentages of DN2, DN3 and DP in the dmPGE2-treated mice were 5.2, 4.4 and 1.1 
times more than the Veh-treated mice, respectively (p<0.05) (Table 2). Fewer thymocytes 
in the dmPGE2-treated mice were trapped in DN1 stage than Veh-treated mice. The   
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Figure 30. Thymus weight and cellularity in H-ARS and DEARE phases of lethal-
irradiated mice treated with radioprotectant dmPGE2.  
C57BL/6 mice were treated with radioprotectant dmPGE2 prior to lethal TBI. The 
thymus weight (panel A) and cellularity (panel B) were calculated and analyzed up to 1-
year post-TBI. Lines represent mean ± SEM. n=3-10 mice per group per time-point. 
*p<0.05 comparing to Veh; † p<0.05 comparing to NI.  
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Table 2. Comparisons of thymocyte subpopulations at 12 months post-TBI of lethal-
irradiated mice treated with radioprotectant dmPGE2.  
 
%CD4 %CD8 %DP %DN %DN1 %DN2 %DN3 %DN4 
NI vs. Veh 0.96 3.25* 1.10* 1.53 0.64* 7.97* 5.21* 1.05 
dmPGE2 vs. Veh 1.08 1.38 1.11* 1.25 0.79 5.24* 4.39* 0.95 
 #CD4 #CD8 #DP #DN #DN1 #DN2 #DN3 #DN4 
NI vs. Veh 3.51* 12.81* 5.04* 7.35* 4.04* 24.86* 28.67* 9.09* 
dmPGE2 vs. Veh 2.74* 3.69* 3.36* 3.75* 2.97* 9.39* 13.20* 3.64* 
Numbers in the table are the ratio of NI/Veh or dmPGE2/Veh. *p<0.05 comparing to Veh 
group. 
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absolute values of most subpopulations were higher in the NI and dmPGE2-treated mice 
than in the Veh-treated mice due to the increase in the total thymocyte number. The 
distribution of thymocyte subpopulations in dmPGE2-treated mice was similar to NI 
mice. These results suggest that more thymocytes accumulate in the earlier 
undifferentiated stage with fewer differentiating into mature cells in the Veh-treated mice 
than in the dmPGE2-treated mice and dmPGE2 prior to TBI prevents the delay in DN to 
DP transition observed in Veh mice as a consequence of irradiation.  
 
4.3.6. Lymphoid progenitors increase in bone marrow of dmPGE2-treated mice 
T cells in thymus, and B cells in the secondary lymphoid organs, are the progenies 
of committed bone marrow progenitors. The LMPP and CLP are the committed 
progenitors of lymphoid lineage; whereas the CMP, GMP and MEP are the committed 
progenitors of myeloid and erythroid lineages [316]. In order to back-track the influence 
of dmPGE2 on HSPC, HSPC compartments in BM at day 20 post-TBI in H-ARS phase 
and 12 months post-TBI in DEARE phase were analyzed. LT-HSC were identified as 
Lin- c-Kithi Sca-1hi Flt3lo CD34-, ST-HSC were identified as Lin- c-Kithi Sca-
1hi Flt3lo CD34+, LMPP were identified as Lin- c-Kithi Sca-1hi Flt3hi CD34+, CLP were 
identified as Lin- c-Kitint Sca-1int IL7R+ Flt3hi, CMP were identified as  Lin- c-kithi Sca-1lo 
CD34+CD16/32-, GMP were identified as  Lin- c-kithi Sca-1lo CD34+CD16/32+, and MEP 
were identified as  Lin- c-kithi Sca-1lo CD34-CD16/32-. At day 20 post-TBI, dmPGE2 
prevented the decrease of total BM cells and all types of HSPC (Figure 31 A-H). At 12 
months post-TBI, the total BM cells, HSC, CMP, GMP and MEP were completely or 
partially recovered in the Veh mice whereas the lymphoid progenitors, LMPP and CLP, 
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were still severely inhibited (Figure 31 I-P). But the number of LMPP and CLP in the 
dmPGE2-treated group was 5.8 times and 7.9 times higher than Veh group, respectively. 
DmPGE2 effectively prevented the decrease of LMPP and CLP for at least 12 months 
post-TBI (Figure 31 J & K).  
  
4.3.7. Bone marrow cells from dmPGE2-treated mice have higher engraftment and 
lineage reconstitution potential than Veh mice 
Post-TBI HSPCs do not regain full multi-lineage repopulating potential during the 
lifetime of the irradiated survivors [40]. Since T cell development in thymus is dependent 
on the proliferation and differentiation of HSPCs entering into thymus, the ability of BM 
HSPCs to repopulate the thymus was investigated. Whole BM cells isolated from Veh-
treated mice at 6 months post-TBI were found to have <1% of the repopulating potential 
in recipient thymus in comparison with NI mice. BM cells from mice treated with 
radioprotectant dmPGE2 had significantly higher chimerism rate than Veh-treated mice, 
although still significantly lower than in NI mice, indicates that dmPGE2 treatment 
partially protected the thymic repopulating potential of BM HSPCs (Figure 32 A). Donor 
cells from Veh-treated mice showed lower level of DP reconstitution, and higher level of 
DN reconstitution than the NI mice (Figure 32 B). Within the donor-derived DN cells, the 
Veh group showed a significantly higher percentage of DN cells arrested in the DN1 
stage than the NI group (Figure 32 C). Interestingly, the donor cells from mice that 
received radioprotectant dmPGE2 partially corrected the deficiencies, which with more 
cells developed into DP stage and fewer cells stuck in the DN and DN1 stages than Veh-
treated mice (Figure 32 B-D and Table 3).  
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Figure 31. BM cellularity and HSPC phenotypes in H-ARS and DEARE phases of 
lethal-irradiated mice treated with radioprotectant dmPGE2.  
C57BL/6 mice were treated with radioprotectant dmPGE2 prior to lethal TBI and were 
sacrificed at 20 days and 12 months post-TBI. BM cells were enumerated and stained 
with antibodies as described in Materials and Methods. Flow cytometric analyses 
identifies LMPP (panel B & I), CLP (panel C & J), LT-HSC (panel D & K), ST-HSC 
(panel E & L), CMP (panel F & M), GMP (panel G & N) and MEP (panel H & O). Bars 
represent mean ± SEM. n=3-6 mice per group. *p<0.05 comparing to Veh group; † 
p<0.05 comparing to NI group.  
  
 151 
Figure 32 
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Figure 32. Thymic engraftment and thymocyte subpopulation reconstitution of BM 
cells from mice treated with radioprotectant dmPGE2 in competitive 
transplantation assays.  
C57BL/6 mice were treated with radioprotectant dmPGE2 prior to lethal TBI. Survivors 
were sacrificed at 6 months post-TBI, and 3×105 whole bone marrow cells isolated from 
age-matched NI, Veh or dmPGE2 mice, along with 2×105 competitor cells of congenic 
origin were transplanted into congenic recipients conditioned with lethal radiation as 
described in Materials and Methods. Thymocytes from recipients at 6 months post-
transplantation were stained by CD45.1, CD45.2, CD4, CD8, CD44 and CD25 antibodies 
and analyzed by flow cytometry to determine donor chimerism (panel A) and thymocyte 
subgroups reconstitution (panel B and C). Panel D is representing flow plots of 
recipient’s thymocytes in each group. Bars represent mean ± SEM. n=3-13 per group. 
*p<0.05 comparing to Veh group; † p<0.05 comparing to NI group.   
 153 
Donor treatments 
% of donor 
Table 3. Comparisons of thymocyte subpopulation reconstitution in competitive 
transplantation assay of lethal-irradiated mice treated with radioprotectant 
dmPGE2. 
 
DN DP CD4 CD8 DN1 DN2 DN3 DN4 
NI vs. Veh 0.0002 <.0001 0.0023 0.0102 0.0001 NS <.0001 0.0192 
NI vs. dmPGE2 0.0423 0.0172 NS NS <.0001 0.0031 <.0001 NS 
dmPGE2 vs. Veh 0.0105 0.0019 NS NS NS NS NS NS 
Numbers in the table are p values of comparisons. Donor bone marrow cells were from 
NI, Veh and dmPGE2 treated mice at 6 months post-TBI and recipient mice were 
sacrificed at 6 months post-transplantation. NS: Not significant. 
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4.3.8. BM progenitor cells from dmPGE2-treated mice have better lymphoid 
differentiation in vitro than Veh mice 
The HSPC count and competitive transplantation suggest dmPGE2 protects 
against TBI-related defects in primitive cell proliferation and/or differentiation. To test 
this hypothesis, LSK cells were co-cultured with OP9 or OP9-DL4 cells to mimic B cells 
and thymic T cells development in vitro, respectively. The function of the delta-like (DL) 
signal (Notch ligand) and the features of this co-culture system were described by 
Zuniga-Pflucker et al. [303-305].  
 
Cell proliferation in the Veh group was much slower than in the NI and dmPGE2-
treated groups in both OP9 or OP9-DL4 co-culture systems (Figure 33 A & B). In the 
OP9-DL4 co-culture system, the phenotype analysis showed that at early days of co-
culture, the Veh-treated group had higher percentage of T cells arrested at the DN1 stage 
and fewer cells developed to the DN2 and DN3 stage compared with NI and dmPGE2-
treated groups (Figure 33 C-F). As co-culture progressed, the Veh-treated group had a 
lower percentage of T cells in the DP, CD4+ and CD8+ mature stages, and a higher 
percentage in DN the stage than NI and dmPGE2-treated groups (Figure 33 G- J). Mature 
CD8 naïve T cells group grew more slowly in the Veh group than the NI and dmPGE2-
treated groups (Figure 33 K). T cell development in mice treated with dmPGE2 prior to 
TBI was almost indistinguishable from NI mice but apparently better than Veh mice. 
 
In the OP9 co-culture system, B cell progenitors showed a mature phenotype 
(B220) much earlier than T cell progenitors. At day 8, NI and dmPGE2-treated groups 
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had higher B220 expression level than the Veh-treated group, and B220 expression 
quickly increased in all groups and there was no difference between groups in the 
following days (Figure 33 L). These results indicate that HSPCs from DEARE mice are 
deficient in both T and B lineage differentiation, and that treating with dmPGE2 prior to 
TBI partially prevents this deficiency.  
 
4.3.9. Mature T cells generated from OP9-DL4 co-culture system are functional 
In order to further prove that the T cells under dmPGE2 protection are 
functionally intact, IFN-γ production stimulated by PMA and Ionomycin in mature CD4 
and CD8 from OP9-DL4 co-culture system was used to evaluate T cell function. Since 
the difference of IFN-γ positive percentages between day 16 and day 32 was minimal, 
data of these two time-points were combined for analysis. Mature CD4 and CD8 T cells 
in the OP9-DL4 co-culture system from NI and dmPGE2-treated group produced 1.5 to 2 
times more IFN-γ than cells from Veh group (Figure 34). This result indicates that mature 
cells developed from primitive cells that protected by dmPGE2 are functional, rather than 
only increased in number. 
 
4.3.10. DmPGE2 increases chemokine receptors expression on lymphoid progenitors 
but does not increase homing to thymus 
DmPGE2 enhances HSC homing by increasing CXCR4 expression [128, 317]. 
Both CXCR4 and C-C chemokine receptor type 5 (CCR5) mediate the homing of 
primitive BM cells to thymus [318].  Radioprotectant dmPGE2 treated mice were 
sacrificed at 12 months post-TBI and CXCR4 and CCR5 expressions were evaluated  
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Figure 33. In vitro T and B cell lineage differentiation in lethal-irradiated mice 
treated with radioprotectant dmPGE2.  
C57BL/6 mice were treated with radioprotectant dmPGE2 prior to lethal TBI and were 
sacrificed at 12 months post-TBI. BM cells from age-matched NI, Veh and dmPGE2 
group were flushed and 1×103 flow cytometry sorted LSK cells per mouse were co-
cultured with 80-90% confluent OP9 or OP9-DL4 monolayer. Cultured cells were demi-
depopulated and transferred to new monolayers every 5-7 days. Half of the depopulated 
cells were used for phenotyping at the time-points indicated in the plots till to the end of 
the co-culture. Cells were stained with CD11b, B220, CD4, CD8, CD44, CD25 and 
CD62L antibodies and analyzed by flow cytometry.  Panel A and B depict the total 
number of T cell progenies in OP9-DL4 (panel A) and B cell progenies in OP9 (panel B) 
co-culture at different time-points. Panel C-F show the percentages of DN1-4 cells in the 
OP9-DL4 co-culture. Panel G-J show the percentages of DN, DP, CD4+ and CD8+ cells 
in the OP9-DL4 co-culture. Panel K shows the percentages of naïve T cells in the CD8+ T 
cells of OP9-DL4 co-culture system. Panel L shows the percentages of B220+ cells in the 
OP9 co-culture. Lines represent mean ± SEM. n=3-7 per group per time-point. *p<0.05 
comparing to Veh group; † p<0.05 comparing to NI group at different time-points.  
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Figure 34. IFN-γ production in CD4 and CD8 T cells from OP9-DL4 co-culture. 
5×105 cultured cells from OP9-DL4 co-culture system were stimulated by PMA and 
Ionomycin for 5 hr and then stained with intracellular IFN-γ antibodies as described in 
Materials and Methods. Percentage of IFN-γ positive cells after PMA/Ionomycin 
stimulation divided by the percentage before stimulation is the fold increase of IFN-γ in 
Y-axis. Bars represent mean ± SEM. n=4-13 per group. *p<0.05 comparing to Veh 
group.  
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based on the staining of LMPP and CLP. Results showed that CXCR4 and CCR5 
expressions were lower in the Veh-treated group than NI group and radioprotectant 
dmPGE2 increased their expression, albeit still lower than NI group (Figure 35 A & B). 
As the input of KSL or LMPP/CLP cells provided too few homed cells to analyze, 
unfractionated BM cells (CD45.2+) were transplanted into lethally-irradiated congenic 
recipient mice (CD45.1+) in another similar study in which donor mice were sacrificed at 
6 months post-TBI. There was no significant difference in the percentage of homed cells 
at 16 hr post-transplantation among NI, Veh, and dmPGE2-treated groups (Figure 35 C). 
The result indicates that the long-term protective effect of dmPGE2 probably is not 
mediated by increasing the thymic homing in the early stages post-TBI. 
 
4.3.11. DmPGE2 does not increase incidence of thymic mass 
The protective effect of dmPGE2 on HSC raises concerns that it may increase the 
prevalence of malignancies in DEARE. Thymic lymphoma is the most common 
radiation-induced malignancy in C57/BL6 mice, presenting as increased thymic mass, 
variable splenomegaly, and lymphadenopathy [319, 320]. Thymic mass was evaluated in 
mice from previous radioprotectant and radiomitigator dmPGE2 studies at 6 and 12 
months post-TBI with an irradiation dose range of 8.53-9.04 Gy at 12 w/o. There was no 
thymic mass in the NI group. The incidences of thymic mass in both dmPGE2 and Veh-
treated mice increased as aging, consistent with previous reports on thymic mass post-
TBI [321, 322]. The dmPGE2 group had lower thymic mass incidence than Veh group at 
6 months post-TBI (1.8% vs. 14.8%) and 12 months post-TBI (6.6% vs. 20%) (Figure 
36),  
 161 
Figure 35 
  
 
 
 
 
 
 NI
Veh
dmPGE2
B
0
1000
2000
3000
CCR5 CXCR4
 
 
 
 
 
M
FI
 o
f C
CR
5/
CX
CR
4 
in
 C
LP
 
(m
ea
n±
SE
M
)
*
*
A
0
500
1000
1500
2000
CCR5 CXCR4
 
 
 
 
 
 
M
FI
 o
f C
CR
5/
CX
CR
4 
in
 LM
PP
 
(m
ea
n±
SE
M
)
†
*
*†
*
0.000%
0.002%
0.004%
0.006%
0.008%
0.010%
0.012%
NI Veh dmPGE2
 
 
 
C
%
 h
om
ed
 ce
lls
 in
 th
ym
us
(m
ea
n±
SE
M
)
 162 
Figure 35. CXCR4 and CCR5 expression on DEARE lymphoid progenitors and 
homing of DEARE BM cells to thymus.  
C57BL/6 mice were treated with radioprotectant dmPGE2 prior to lethal TBI and were 
sacrificed at 12 months post-TBI. BM cells from age-matched NI, Veh and dmPGE2 
group were stained with LMPP/CLP markers and CXCR4/CCR5 antibodies as described 
in Materials and Methods, and analyzed by flow cytometry for MFI of CXCR4 and 
CCR5 in the LMPP (panel A) and CLP population (panel B). For short-term thymus 
homing study (panel C), donor mice were treated with radioprotectant dmPGE2 prior to 
lethal TBI and were sacrificed at 12 months post-TBI, 2×107 whole bone marrow cells 
from donor mice (C57Bl/6, CD45.2+) were transplanted intravenously into lethally 
irradiated recipient mice (B6.BoyJ, CD45.1+).  After 16 hr, recipient thymocytes were 
stained with CD45.1 and CD45.2 antibodies and analyzed by flow cytometry. The 
thymus homing efficiency was calculated as percentage of CD45.2+ donor cells within 
recipient’s thymocytes. Bars represent mean ± SEM. n=2-7 per group. *p<0.05 
comparing to Veh; † p<0.05 comparing to NI group.  
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Figure 36. Thymic mass incidence in aged irradiation survivors.  
C57BL/6 mice were exposed to 8.53-9.04 Gy irradiation at 12 weeks old and treated with 
radioprotectant or radiomitigative dmPGE2 as described in Chapter 3. Any mice that 
received dmPGE2 treatment were pooled in dmPGE2 group, no matter it is as 
radioprotectant or radiomitigator. The Veh group was the pooled mice received 
equivalent volume of Veh at the same study at the same time. The thymic masses were 
identified at necropsy of 6 and 12 months post-TBI. Thymic mass (lymphoma) incidence 
was calculated as a percentage of thymic mass positive mice over all evaluable mice. 
n=34-89 per group. *p<0.05 comparing to Veh in total number of thymic masses at 6 and 
12 months post-TBI.   
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and there was statistical difference in total thymic mass incidence rate between dmPGE2 
and Veh group (3.7% vs. 17.3%, p<0.05).  
 
4.3.12. DmPGE2 thymic protection effect is time-sensitive and intensive treatment is 
not necessary 
Because the time-point of dmPGE2 injection impacts the day 30 survival rate of 
H-ARS mice (Chapter 3, Figure 21), the impact of different treatment time-points on day 
30 thymic recovery were investigated. Mice received 8.72 Gy TBI (LD70/30) with 1 dose 
of 35 µg dmPGE2 injection at different time [24 hr prior to TBI (-24 hr), 30 min prior to 
TBI (-30 min), 3 hr post-TBI (+3 hr) and 24 hr post-TBI (+d1)]. The result shows that the 
-30 min and +d1 groups had better thymic recovery compared to the Veh group, and there 
was no difference among -24 hr, +3 hr and Veh groups (Figure 37 A), which is consistent 
with the survival efficacies for -30 min and +d1 schedule. Whether intensive treatment 
could further increase the protection effect of dmPGE2 in DEARE mice was also 
investigated. The multiple injection schedule included: dmPGE2 injected at both prior to 
and after TBI (one dose of 35 µg dmPGE2 injected at -30 min, +d1, d2 and d3) , 
dmPGE2 injected at prior to TBI and consolidated by monthly injection post-TBI (one 
dose of 35 µg dmPGE2 injected at -30 min and one dose of 35 µg dmPGE2 injected 
every 28 days beginning on days 92-93 post-TBI), and one dose of 35 µg dmPGE2 
injected at days 1, 2 and 3 post-TBI (Figure 37 B). Thymi were collected at 6 months 
post-TBI. The results showed that one dose of 35 µg dmPGE2, -30 min prior to TBI, is 
sufficient to achieve the thymic protection. Injection of dmPGE2 +d1 post-TBI is not as 
effective as injection at -30 min prior to TBI in maintaining thymus in DEARE phase,  
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Figure 37. Impact of different times and dosing schedule of dmPGE2 injections on 
thymic recovery.  
All mice received one-time TBI dose of 8.72 Gy. Panel A: Mice received 1 dose of 35 µg 
dmPGE2 injection at 24 hr prior to TBI (-24 hr), 30 min prior to TBI (-30 min), 3 hr post-
TBI (+3 hr) or 24 hr post-TBI (+d1). Veh mice in each group were pooled into Veh group 
since no difference in thymus weight between different time-points of Veh injection. 
Thymi were collected at day 30 post-TBI. *p<0.05 comparing to Veh group; † p<0.05 
comparing to -30 min group. In -24 hr group, there was only one mouse survived at day 
30 post-TBI; n=4 mice in other groups. Panel B: Mice received 1 dose of 35 µg dmPGE2 
injection at -30 min prior to TBI (-30 min), 1 dose 30 min prior to TBI and 1 dose on 
days 1, 2 or 3 post TBI (-30 min, +d1,2,3), 1 dose 30 min prior to TBI and monthly 35 µg 
injections beginning on day 92-93 post-TBI(-30 min, +monthly), 1 dose on 24 hr post-
TBI (+d1) or 1 dose on days 1, 2 and 3 post-TBI (+d1,2,3). Thymi were collected at 6 
months post-TBI. Bars represent mean ± SEM. n=6-10 mice per group. *p<0.05 
comparing to Veh group; † p<0.05 comparing to -30 min; ∆ p<0.05 comparing to -30 
min, +d1,2,3 group.   
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and multiple injections after the -30 min or +24 hr injection neither enhance thymic 
recovery nor further increase the protective effect. 
 
4.3.13. DmPGE2 receptors partially involve in the thymic protection 
DmPGE2 has four receptor subtypes, designated EP1, EP2, EP3, and EP4 [323]. 
Hoggatt J et al. demonstrated that regulatory effects of NSAID on HSPC retention 
through the reduction of EP4 receptor signaling [131]. The role of the EP receptors in the 
thymic protection effect of dmPGE2 has not been investigated. Mice were injected with 
one dose of 35 µg dmPGE2 or same dose of EP1+3 agonist (17-phenyl trinor dmPGE2), 
EP2 agonist (butaprost free-acid), or EP4 agonist (L902-688) -30 min prior to 8.72 Gy 
TBI. The thymi analysis at day 30 post-TBI showed that none of the EP agonists were as 
effective as dmPGE2 in protecting the thymus, and that thymocyte subpopulation 
distributions were aberrant in agonist groups compared with the dmPGE2 group (Figure 
38 A & B). Because only one mouse survived to day 30 in the EP1+3 and EP2 groups, 
statistical comparison was not available for these two groups. This result indicates that 
activation of EP1-4 receptors may only be partially responsible for dmPGE2’s thymic 
protection effect; or that simultaneous activation of all or some combination of EP 
receptors is required for the full protection effect; or the currently used agonists are not 
potent enough. 
 
  
 169 
Figure 38 
  
0
0.01
0.02
0.03
0.04
0.05
Veh dmPGE2 EP1+3 EP2 EP4
 
 
*
†
A
Th
ym
us
 w
ei
gh
t (
g)
(m
ea
n±
SE
M
)
0%
20%
40%
60%
80%
100%
Veh dmPGE2 EP1+3 EP2 EP4
 
 
 CD8
CD4
DP
DN%
 o
f t
hy
m
oc
yt
es
(m
ea
n±
SE
M
)
B
 170 
Figure 38. Impact of different dmPGE2 receptors activation on thymic recovery.  
C57BL/6 mice received one dose of 35 µg dmPGE2 or same dose of EP1+3 agonist (17-
phenyl trinor dmPGE2) or EP2 agonist (butaprost free-acid) or EP4 agonist (L902-688) -
30 min prior to 8.72 Gy TBI. Thymi were weighed (panel A) and thymocytes were 
phenotyped for CD4, CD8 single positive, DP and DN subpopulations by flow cytometry 
at day 30 post-TBI (panel B) as previously described. Bars represent mean ± SEM. In 
EP1+3 and EP2 group, there was only one mouse survived at day 30 post-TBI in each 
group; n=4 mice in other groups. *p<0.05 comparing to Veh group; † p<0.05 comparing 
to dmPGE2 group.  
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4.3.14. DmPGE2 does not change the number of thymic stromal cells in DEARE 
mice 
Thymic stromal cells, mainly TECs, support the development of T cell 
progenitors and direct positive and negative selection [324, 325]. DmPGE2 might 
provide thymic protection by indirectly influencing thymic stromal cells. The number of 
cTECs and mTECs at 12 months post-TBI were investigated. The flow cytometry 
analysis showed that there was no significant difference in the numbers of cTECs and 
mTECs between the dmPGE2 and Veh groups (Figure 39 A & B). 
 
4.3.15. Lymphopoiesis related genes are impacted by radioprotectant dmPGE2 
To investigate whether the benefit of radioprotectant dmPGE2 treatment on long-
term immune reconstitution results from its early impact on HSC differentiation, RNA 
sequencing was carried out on highly-purified HSCs from mice that received one dose of 
35 μg dmPGE2 -30 min prior to TBI. Mice were sacrificed 24 hr post-TBI. IPA predicted 
that lymphopoiesis was increased at 24 hr post-TBI in dmPGE2 group with a high 
activation z-score of 4.34 when compared with Veh group, and 115 associated genes 
were identified. Meanwhile, IPA also predicted that lymphopoiesis was decreased in Veh 
group at 24 hr post-TBI with a z-score of 2.01 when comparing with NI group, with 186 
associated genes were identified. Nineteen genes either decreased in Veh but increased in 
dmPGE2 group; or increased in Veh but decreased in dmPGE2 group. The following 
lymphopoiesis-associated genes were up-regulated by radioprotectant dmPGE2: Lepr 
(Leptin receptor), Dntt (DNA nucleotidylexotransferase), Flt3, Smad7 (Mothers against 
decapentaplegic homolog 7), Il6ra (Interleukin-6 receptor Subunit Alpha), Efnb2 (Ephrin  
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Figure 39. Thymic stromal cells in DEARE phase of lethal-irradiated mice.  
C57BL/6 mice were treated with radioprotectant dmPGE2 and were sacrificed at 12 
months post-TBI. Thymi were enzyme-digested and stained with CD45, EpCAM, UEA-1 
and Ly51 antibodies and analyzed by flow cytometry as described in Materials and 
Methods. The absolute cell numbers of cTEC (Panel A) and mTEC (Panel B) were the 
total thymocyte numbers multiplied by the percentage of cTEC and mTEC. Bars 
represent mean ± SEM. n=3-6 mice per group. 
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B2), Cadm1(Cell adhesion molecule 1), Ifngr1 (Interferon gamma receptor 1), Rora 
(RAR related orphan receptor A), Furin (FES upstream region), Stat3 (Signal transducer 
and activator of transcription 3), Cdkn1c (Cyclin dependent kinase inhibitor 1C), Tgfbr1 
(Transforming growth factor beta receptor 1), Myb (MYB proto-oncogene, transcription 
factor), Ets2 (ETS proto-oncogene 2, transcription factor) and Zmiz1(Zinc finger MIZ-
type containing 1). And the following genes which inhibit the lymphopoiesis were down-
regulated by radioprotectant dmPGE2: Prkca (Protein kinase C alpha), Lmo1 (LIM 
domain only 1) and Tk1 (Thymidine kinase 1) (Figure 40). Radioprotectant dmPGE2 
may impact HSC differentiation through these genes as early as 24 hr post-TBI. (Andrea 
Patterson in Dr. Pelus’ laboratory provided the RNA sequencing and IPA analysis). 
 
4.3.16. Cytokines that support lymphopoiesis were prevented from decreasing by 
dmPGE2 
To investigate whether the bone marrow environment helps immune 
reconstitution at early time-points, BM supernatant was collected from NI, Veh, and 
dmPGE2-treated mice at day 9 post-TBI, and 32 cytokines were detected by Millipore 
mouse cytokine/chemokine panel. DmPGE2-treated mice had increase in the average 
levels of growth factor, both anti- and pro-inflammatory cytokines than Veh-treated mice, 
although most differences were not statistically significant. In the growth factor category, 
growth factors that support lymphopoiesis (IL-2 and IL-7) were increased in dmPGE2-
treaed mice compared with the Veh at day 9 (green box labeled at Figure 41). On the 
contrary, growth factors that support myelopoiesis (MGSF, G-CSF, IL-3) were increased  
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Figure 40. Heat map of genes associated with enriched GOTERM_BP: 
lymphopoiesis.  
Fgd5 mice were treated with one dose of 35 µg dmPGE2 or equivalent Veh at -30 min 
prior to 8.53 Gy TBI and were sacrificed at 24 hr post-TBI. 1,000-6,000 HSCs 
(CD45+SLAM-LSKwideZsGreen+) per mouse were sorted from BM by FACSAria and 
were subjected to RNA sequencing. Genes were identified by IPA with FDR <0.05 and 
fold change >2. Lymphopoiesis and its related genes were identified by IPA cellular 
function predictions. Genes up-regulated in HSC are presented in red and genes down-
regulated are in blue. n=7-8 mice per group. *FDR <0.05 in all genes between indicated 
groups. Andrea Patterson provided the RNA sequencing and IPA analysis. 
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Figure 41. BM cytokines in NI mice and irradiated mice at day 9 post-TBI.  
C57BL/6 mice were treated with one dose of 35 µg dmPGE2 or equivalent Veh at -30 
min prior to 8.53 Gy and mice were sacrificed at day 9 post-TBI. Cytokines in BM 
supernatant were analyzed by Bio-Plex multiplex system. Expression level of individual 
cytokine is represented by shades of blue (low value) to red (high value) as described in 
Materials and Methods. n=4 mice per group. *p<0.05 comparing dmPGE2 to Veh group. 
UD: undetectable, values out of range. Huilin Chua and Hailin Feng did the Bio-Plex 
study; Tong Wu did the analyses. 
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in Veh-treated mice at day 9 post-TBI but attenuated by radioprotectant dmPGE2 (black 
box labeled at Figure 41). 
 
4.4. Discussion 
The thymus is the central lymphoid organ for T cell maturation and education. 
Although there are controversies regarding the extent of thymic recovery post-TBI, it is 
generally accepted that an irradiated thymus would be inevitably more involuted than the 
non-irradiated one, and that there is no effective method to prevent or delay this 
involution [186, 218, 219]. Ventevogel MS et al.[75] and Majumdar S et al. [326] 
reported that leuprolide, IL-7, IL-22, keratinocyte growth factor, growth hormone, and 
Ghrelin have thymic-regeneration potential in aged mice. However, none of these has 
been shown to prevent the effect of irradiation. Developing a treatment to protect against 
radiation-induced thymic involution is of significant importance to victims of radiation 
disasters, and to radiotherapy patients.   
 
PGE2, a lipid arachidonic acid derivative, induces lymphocyte apoptosis through 
DNA fragmentation by up-regulating c-Myc expression [327], and suppresses T cell 
activation by down-regulating IL-2 production [300-302]. Since PGE2 has been 
considered a “foe” to lymphoid cells, previous studies about MCMs targeting immune 
recovery post-IR had not considered PGE2 or dmPGE2 as candidate. However, many 
recent studies indicate that PGE2 has both pro- and anti-inflammatory effects [301, 328] 
and its derivative dmPGE2 plays a positive role in hematopoiesis post-TBI [130, 135, 
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276].  To date, no study has evaluated the effect of PGE2/dmPGE2 on the lymphoid 
lineage in the context of irradiation.  
 
Drs. Orschell and Pelus have recently discovered that one dose of dmPGE2 -30 
min prior to TBI greatly increased the day 30 survival rate (Figure 21). Here, I observed 
that radioprotectant dmPGE2 also prevents irradiation-induced thymic involution as early 
as 20 days post-TBI, and that this effect is maintained for at least one-year post-TBI. The 
thymic protection effect is time-sensitive and works best when dmPGE2 is administered 
as a radioprotectant, -30 min prior to TBI. The exact reason for this time sensitivity is 
unclear. 
 
Treatment with radioprotectant dmPGE2 does not demonstrate the thymic 
protection effect until day 20. At day 3 and day 10, there is no difference in thymic 
weight between dmPGE2- and Veh-treated groups. Takada et al. [218] reported that the 
first recovery peak of the thymus, at day 10 post-IR, is due to the proliferation of 
surviving residual thymocytes, and the second recovery peak at day 30 is due to the enter 
and proliferation of progenitor cells from the bone marrow. Here, the hypothesis is that 
the thymic protection from dmPGE2 occurs as a result of protection of early bone 
marrow progenitors as opposed to directly protecting mature T cells. Under protection 
from dmPGE2, lymphoid progenitors with less irradiation damage enter thymus and 
proliferate post-IR. Increases in CXCR4 and CCR5 expression were observed in LMPP 
and CLP of dmPGE2-treated mice group compared with the Veh control, although an 
increase in thymic homing was not observed (Figure 35). This is inconsistent with other 
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studies on chemokine receptors and HSC homing to the bone marrow [22] and may relate 
to a difference in the time at which the “gate” opens post-IR between the bone marrow 
niche and thymic niche. Post-IR and until the second recovery peak, the thymic “gate” is 
not open which does not allow bone marrow progenitors anchor in the thymus. 
 
In in vivo competitive transplantation studies, a better thymic reconstitution is 
achieved by donor cells from dmPGE2 group than Veh group (Figure 32). The Veh mice 
were deficient in thymus repopulation, supporting result from previous report of reduced 
T cell lineage reconstitution in peripheral blood by donor cells from Veh mice [40]. 
These results also supported previous data (Table 2) showing an increased percentage of 
DP thymocytes and decreased percentage of DN1 thymocytes in dmPGE2-treated mice. 
These data indicate that dmPGE2 as a radioprotectant likely protects the thymus through 
the protection of bone marrow HSPCs. 
 
   In further support of the hypothesis that dmPGE2 protects the thymus via the 
“intrinsic mechanism” (HSPC protection) rather than the “extrinsic mechanism” (thymic 
stromal cell protection), I demonstrated that the lymphoid progenitors, LMPP and CLP, 
were decreased in Veh group and attenuated by radioprotectant dmPGE2 at 12 months 
post-TBI, whereas myeloid progenitors were not (Figure 31). Additionally, co-culture 
studies revealed that HSPCs from dmPGE2-treaetd mice had increased proliferation and 
differentiation capabilities compared with cells from Veh-treated mice (Figure 33), and 
the dmPGE2-treated mice did not have significantly higher cTEC and mTEC numbers 
compared with Veh group (Figure 39). These data indicate that HSPCs are protected by 
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radioprotectant dmPGE2, and that these cells have better lymphoid lineage development 
than HSPCs in the Veh-treated mice, although the impact of radioprotectant dmPGE2 on 
bone marrow niche prior to LMPP/CLP entering the thymus cannot be ruled out. 
 
In mice treated with radioprotectant dmPGE2, lymphoid progenies (T and B cells) 
in thymus (Table 2) and spleen (Figure 29) were increased in comparison with the Veh 
control group. In the mature peripheral T cell subsets, naïve T cells were trended higher 
in dmPGE2 group than Veh group although not significant, which is probably because of 
the limited number of mice in each group. There are two mechanisms for T cell 
regeneration: one is thymus-dependent de novo regeneration originated from the 
proliferation of BM-derived progenitors; another is thymus-independent HPE. In normal 
mice, naïve T cells in the spleen are predominantly RTE, which represents the thymus-
dependent de novo regeneration,  as opposed to homeostatic proliferation of naïve T cells 
[314, 315]; in lymphopenic situation, such as post-TBI or post-transplantation, how 
thymic output involves in T cell reconstitution and whether peripheral naïve T cells still 
represent RTE are not clear, but from the consistency of increased thymocytes and 
peripheral naïve T cells in dmPGE2 group, it is highly possible that the increased thymic 
output by dmPGE2 protection comprises, at least involve in, the peripheral T cell 
reconstitution. Further measurement of the ratio of thymic output and HPE in Veh and 
dmPGE2 group would further verify the effect of dmPGE2 on T cell reconstitution post-
TBI. 
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B cells were increased in the spleens of DEARE mice treated with radioprotectant 
dmPGE2 (Figure 29), and HSPCs from dmPGE2-treated mice have enhanced mature B 
cell development in comparison with the Veh mice in OP9 co-culture (Figure 33 L). The 
protective effect of dmPGE2 treatment prior to TBI on B and T lymphocytes ameliorates 
myeloid skewing, which is a sign of immune suppression (Figure 27). Myeloid skewing 
is also seen in geriatric mice with HSPCs that have accumulated DNA damage [329]. The 
prevention of myeloid skewing by radioprotectant dmPGE2 indicates that dmPGE2 may 
successfully prevent radiation-induced DNA damage and that its target stage of 
hematopoietic differentiation is likely before the LMPP and CMP stage, whether it is the 
earlier HSC or the latter MPP stage is not clear.  
 
Although all current evidence indicates that dmPGE2 plays a positive role in 
lymphocyte recovery post-IR. Interestingly, dmPGE2 is also a “foe” to lymphocytes in an 
unirradiated scenario (Figure 28 C). The CBC analysis in unirradiated mice received 
dmPGE2 injection demonstrates that dmPGE2 has quick, transient, toxicity to peripheral 
lymphocytes, which is similar to the reports from Mastino et al. [327, 330] showing that 
PGE2 induces apoptosis of lymphocytes both in vivo and in vitro; and the report from 
Chouaib et al. [331] showing that PGE2 inhibits T lymphocyte proliferation. This effect 
is probably mediated through the activation of EP2 and EP4 since murine mature T cells 
do not express EP1 and EP3 [301, 328]. Other components of the peripheral blood are not 
significantly affected by dmPGE2. The “double hit” from irradiation and dmPGE2 
exposure delays lymphocyte recovery in comparison with neutrophil recovery until the 
cells are replenished by RTEs; however, during the lymphocyte-low period (until day 20 
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post-TBI), the death rate of the dmPGE2-treated group does not increase (Figure 21). 
Considering that infection is the main cause of death during this period [15, 69], the main 
anti-infection effect arises from neutrophils, which are higher in the dmPGE2-treated 
group than Veh-treated group (Figure 24 A). 
 
DmPGE2 represents a simple and effective radioprotectant with the potential to 
provide immense benefits to emergency personnel responding to radiation emergency 
and/or patient receiving radiotherapy. It is known that radiation increases the risk of 
secondary cancers [4, 205], and whether dmPGE2 would exacerbate this situation is 
unknown. In C57BL/6 mice, the most common secondary cancer post-TBI is thymic 
lymphoma [319], which correlates with radiation dosage. In thymic mass study, the 
thymic mass incidence in the dmPGE2-treated group was only 1/5 of that observed in the 
Veh-treated group (Figure 36), indicating that pmPGE2 may protect against secondary 
tumors. The prevention of DNA damage and enhanced immune surveillance in dmPGE2-
treaetd group are potential mechanisms for this finding. This result, however, should be 
interpreted with caution as this study is not designed for estimating thymic mass 
incidence post-TBI, and the total mouse number was relatively low to make a definitive 
conclusion. 
 
Lineage commitment occurs early in the HSC differentiation pathway. As 
myeloid skewing was prevented by dmPGE2 treatment prior to TBI, in order to elucidate 
whether lymphopoietic potential is protected by dmPGE2, RNA sequencing was carried 
out on HSCs +24 hr post-TBI. The IPA analysis indicates that a group of genes that 
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support lymphopoiesis were up-regulated in dmPGE2-treated group and another group of 
genes inhibiting lymphopoiesis were up-regulated in Veh group and attenuated by 
radioprotectant dmPGE2 (Figure 40). Those genes promote lymphopoiesis through 
different mechanisms. Flt3 is a cytokine tyrosine kinase receptor and is one of surface 
markers of LMPP. Flt3-/- and Flt3L-/- mice are deficient in B cell development and earliest 
thymic progenitors [332]. By synergizing with other cytokine defects, such as in Flt3L-/-
Il-7r-/- mice, the thymopoiesis and subsequent T lymphopoiesis are more exacerbated 
[333]. The RNA sequencing shows that Flt3 was significantly up-regulated in dmPGE2 
group comparing to Veh group. IL-7R is the receptor for IL-7 and is an important surface 
mark for CLP. IL-7R gene follows a similar trend as Flt3 with eight times higher 
expression level in dmPGE2 group than Veh group, although this difference was not 
statistically significant (p<0.05 but FDR>0.05), which might be attributed to the limited 
number in this study. The changes in Flt3 and IL-7R gene expression in dmPGE2 group 
accelerate T cell reconstitution post-TBI. Other cytokine receptors in which the ligand-
receptor signal pathways are important for either B cell or T cell development (Lepr, 
Il6ra, Ifngr1 and Tgfbr1) display elevated gene expression in the HSCs from dmPGE2-
treated mice. Additionally, several downstream genes regulating the cell cycle (Stat3, 
Cdkn1c), and genes involving in V(D)J recombination (Dntt) and Notch ligand cleavage 
(Furin) were higher in HSCs from dmPGE2-treated mice than Veh-treated mice. Some 
genes reportedly take action in later lymphopoiesis, such as Zmiz1 coordinates with 
Notch1 to promote thymocyte proliferation [334] and Ets2 promotes thymocyte 
proliferation via inhibition of dexamethasone-induced apoptosis [335].  
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The following BM cytokine analysis represents the bone marrow 
microenvironment difference between dmPGE2 and Veh mice. At day 9 post-TBI, the 
dmPGE2-treated group had a higher average cytokine level than the Veh-treated group in 
growth factor and anti- and pro-inflammatory categories, in which IL-2, IL-4, IL-9 and 
Eotaxin levels were significantly elevated (Figure 41). IL-4 and IL-9 are both produced 
by activated mature T cells, mast cells, and basophils. These cytokines regulate the 
mature T cell response, B cell class switching, and promote B and T cell proliferation. A 
group of growth factors (MCSF, G-CSF and IL-3) that support myelopoiesis (black box 
labeled in Figure 41) were decreased in the dmPGE2-treated group, although not 
significantly. In contrast, the cytokines IL-2 and IL-7, supporting lymphopoiesis (green 
box labeled in Figure 41), increased in dmPGE2-treated group in comparison with Veh 
control group. IL-7-/- or IL-2-/- mice have severe reduction in T and B cells, an involuted 
thymus, and a high incidence of autoimmune disease [336, 337]. Compared with IL-7, 
IL-2 has a broader biological function since the γ chain of the IL-2R is the common 
gamma chain for multiple cytokines such as IL-4, IL-7, IL-9, IL-15 and IL-21 [338]. IL-
2-/- mice, therefore, have several additional hematopoietic defects in addition to 
dysfunctional lymphopoiesis. It has been reported that PGE2 inhibits mature T cell 
function and proliferation by decreasing IL-2 production [10-12]. The cytokine analysis 
indicates that radioprotectant dmPGE2 increases IL-2 shortly after the injection (Figure 
25) and still increases as late as day 9 post-TBI (Figure 41), which further supports the 
“friend or foe” nature of dmPGE2. The change in IL-7 expression also indicates that, as 
early as day 9 post-TBI, the mice under dmPGE2 protection have pro-lymphopoietic 
environment despite peripheral lymphocyte recovery starts to show in CBC analysis 
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around day 20 (Figure 24). This can be explained by the slow process of development 
from LMPP to mature peripheral T cells. The decrease in IL-7 in BM microenvironment 
post-IR and the prevention of this decrease by dmPGE2 corresponds to the RNA 
sequencing findings in which the decrease of IL-7R gene expression in HSC post-IR is 
also prevented by dmPGE2. Determining whether BM cytokines act either in permissive 
(only promote the proliferation and survival of HSC) or instructive (activate a lineage 
differentiation direction) pattern will be helpful to illustrate the mechanism of dmPGE2 
protection [332]. Other cytokine levels, such as FLT3L and CXCL12 which are not 
included in the Millipore mouse 32 cytokines panel, also need to be evaluated in H-ARS 
mouse model in order to investigate other important signal pathways in lymphopoiesis 
under the protection of dmPGE2.  
 
In conclusion, these studies, for the first time, show that radioprotectant dmPGE2 
results in long-lasting protection to the immune system including increased thymic-
settling progenitors in BM, prevention of irradiation-induced thymic involution, 
enhanced differentiation of T and B cells, increased peripheral lymphocyte number, and 
blunted myeloid skewing. DmPGE2 is detrimental to peripheral lymphocytes 
immediately on administration; however, this toxicity is transient, and its pro-
development and pro-differentiation effects rapidly counteract the toxicity, leading to 
lymphoid lineage reconstitution in the long-term post-IR. Further safety test to evaluate 
the effect of dmPGE2 on primary tumor in patients undergoing radiotherapy scenario and 
studies to determine the mechanism of dmPGE2 including the targeted cells and receptors 
and downstream signal pathways are necessary before applying dmPGE2 as a 
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radioprotectant to first responders and military personnel facing radiation disasters and/or 
patients undergoing radiotherapy.  
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Chapter 5. Other stories: Pegylated Hematopoietic Growth Factors and Lisinopril 
as Radiomitigators 
5.1. Introduction 
The majority of clinical symptoms and radiation-related deaths occur early post-
IR in the ARS phase. Treatment development has therefore largely focused on early 
intervention. Irradiation doses higher than two Gy and five Gy induce clinical H-ARS 
and GI-ARS, respectively [2, 35, 339]. H-ARS and GI-ARS are the most common causes 
of radiation-related death. Blood transfusions, supportive care, and administration of 
HGF-based regimens are used to rescue pancytopenia in H-ARS.  
 
G-CSF and GM-CSF have similar signaling pathway and mechanism in 
hematopoiesis, as discussed in Chapter 1. IL-11 belongs to the IL-6 family and has a 
heterodimer receptor composed of IL-11Rα and gp130. IL-11 activates the downstream 
Jak/Stat, RAS/MAPK and PI3K/AKT signaling pathways to promote thrombopoiesis and 
erythropoiesis. It is also an anti-inflammatory cytokine and is cytoprotective for intestinal 
crypt cells [340, 341]. Recombinant human IL-11 (Oprelvekin, Neumega®) is FDA-
approved for the treatment of chemotherapy-induced thrombocytopenia. The most 
common adverse effects of IL-11 are tolerable, including edema and fluid retention. More 
severe adverse effects such as atrial fibrillation occur less frequently [342]. Recombinant 
IL-11 has a longer half-life than natural IL-11, but still requires daily injection [343, 
344]. Dr. Orschell's laboratory and others have shown that long-acting pegylated (peg) 
IL-11 analogs with a 10-fold higher half-life result in a sustained platelet increase for 7-
10 days [74, 345]. Dr. Orschell's laboratory has shown that multiple injections or higher 
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doses of peg-IL-11 did not further increase survival compared to single, lower dose 
schedule (1.0 mg/kg vs. 0.3 mg/kg; three doses at day 1, 3, 5 vs. 1 dose at day 1 post-
TBI) [74]. Similar trends were observed with peg-G-CSF and peg-GM-CSF in the same 
study. This efficacy of a single-dose treatment is of particular significance in treatment of 
victims of nuclear accidents, where daily dosing is complicated by the chaotic aftermath. 
 
Since G-CSF, GM-CSF, and IL-11 interact with different receptors, work through 
different mechanisms, and target different HPCs (as discussed in Chapter 1), the 
combined treatment (double and triple combination of different peg-HGFs) were 
hypothesized to be able to further enhance survival rate and hematopoietic recovery. 
 
Many other potential interventions have been investigated for H-ARS, as 
discussed in Chapter 1. In this study, the efficacy and mechanism of action of lisinopril, 
an ACE inhibitor, were investigated in the well-established H-ARS mouse model. 
Lisinopril decreases Ang II plasma levels by inhibiting ACE and has been approved for 
the treatment of hypertension, congestive heart failure, coronary artery disease, and 
diabetic nephropathy. Ang II receptors express on HSCs, BM stromal cells, erythroid 
progenitors, and mature LY [91, 92]. It has minimal positive effect on hematopoiesis 
when administered alone in the non-irradiated scenario [93, 94, 96], with adverse effects 
including anemia and leukopenia at high dose or when used long-term. This adverse 
effect results from an increase in plasma AcSDKP, an ACE substrate which negatively 
regulates hematopoiesis [99, 104]. The negative regulation of hematopoiesis does not, 
however, rule out the potential of ACEI used as a MCM to radiation. There are many 
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evidences showing that ACE inhibition post-IR is radiomitigating and the increased DNA 
damage repair in HSC due to ACEI-induced quiescence is thought to be a possible 
mechanism [101, 103]. Lisinopril is safe with tolerable adverse effects, and it is 
economical and easily accessible. It neither needs to be injected, nor to be refrigerated 
during the logistics chain. All these advantages make lisinopril an ideal MCM to 
stockpile in case of significant radiation event. Because only using lisinopril alone has 
minimal effect on hematopoiesis, and previous study indicates that there is a synergistic 
response on the hematopoietic recovery when angiotensin (1-7) and G-CSF combined 
[93], the effect of triple HGFs combination therapy in conjunction with lisinopril was 
evaluated in the H-ARS mouse model. 
 
5.2. Materials and Methods 
5.2.1. Mouse husbandry and irradiation 
C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME) at 10 
w/o and housed in microisolators with up to five mice per cage. Extruded chow (Harlan 
2018SXC) and acidified water were provided ad libitum. Mice were irradiated at 12 w/o 
after 2 weeks of acclimatization. At day 0, mice were exposed to single uniform TBI 
doses of gamma radiation a 137Cs radiation source (Mark 1 Irradiator, JL Shepherd, San 
Fernando, CA) at 8.72 Gy (LD70/30), 9.04 Gy (LD90/30) or 9.27 Gy (LD95/30). 
Autoclaved acidified water and wet feed were provided from day 4 to day 30 post-TBI. In 
the competitive transplantation study, recipients and competitors were congenic 
PtrcaPep3b/BoyJ (B6.BoyJ; CD45.1+) or the F1 hybrid of C57Bl/6 and B6.BoyJ mice 
(CD45.2+/CD45.1+). B6.BoyJ and F1 hybrid mice were bred in-house and used between 
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8-12 w/o. Morbidity and mortality of irradiated mice was monitored twice daily for the 
duration of the H-ARS study (day 30). Mice were evaluated daily using a scale system 
incorporating body posture, activity level, and eye appearance to determine when 
euthanasia was required as previously described [69]. Day 30 post-TBI, surviving mice 
were transferred to the RBMD study. All studies were approved by the Indiana 
University School of Medicine Institutional Animal Care and Use Committee (IACUC 
protocol 10689). 
 
5.2.2. Compounds 
The manufacturing process of pegylated-HGFs have been described [74]. All 
pegylated-HGFs (subsequently referred to as “peg-HGFs” or “HGFs”) were administered 
by subcutaneous injection (SQ) 24±4 hr post-TBI at the following doses: peg-huG-CSF 
(BBT-015, subsequently referred to as “G”), 1.0 mg/kg; peg-muGM-CSF (BBT-007, 
subsequently referred to as “GM”), 1.0 mg/kg; peg-huIL-11 (BBT-059, subsequently 
referred to as “IL-11”), 0.3 mg/kg) were obtained from Bolder Biotech and formulated in 
10 mM sodium phosphate, 4% mannitol, 1% sucrose pH 6.2 before use. The final volume 
of HGFs (~100 µl) was adjusted by mouse weight resulting in a dose of 6 µg of peg-IL-
11, 20 µg of peg-G-CSF or 20 µg of peg-GM-CSF per mouse. An equivalent volume of 
vehicle (10 mM sodium phosphate, 4% mannitol, 1% sucrose, subsequently referred to as 
Veh) was delivered to the control group. The doses were chosen based on the previous 
efficacy study [74]. The different regimens of HGFs are summarized in Table 4. 
Lisinopril was supplied by Dr. Medhora at Medical College of Wisconsin and 
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Table 4. Dose and combination regimens of pegylated HGFs. 
     Group ID Treatment 
1 Vehicle (Veh) 
2 peg-G-CSF (1.0 mg/kg) (G) 
3 peg-GM-CSF (1.0 mg/kg) (GM) 
4 peg-IL-11 (0.3 mg/kg) (IL-11) 
5 peg-G + peg-IL-11 (G+IL-11) 
6 peg-GM + peg-IL-11 (GM+IL-11) 
7 peg-G + peg-GM (G+GM) 
8 peg-G + peg-GM + peg-IL-11 (triple combo, TC) 
9 Non-irradiated controls (NI) 
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dissolved into 60 mg/L in autoclaved acidified water for dosing on days 7-30 post-TBI. 
Lisinopril was delivered at a dose of 9 mg/kg (180 µg/20 g mouse) based on a previous 
finding that mice consume ~3 ml water per day in the absence of wet chow [69]. 
 
5.2.3. CBC and tissue harvest 
Mice were tail-bled for CBC, which was performed at baseline and repeated 
throughout the study. NI, Veh-treated, and MCM-treated mice were assessed at various 
time-points at H-ARS and DEARE stage for CBC, bone marrow cellularity, and thymus 
weight/cellularity as previously described in Chapter 2. For the brain hemorrhage study, 
mice were sacrificed immediately at day 10 post-TBI. The scalp was cut in a sagittal 
direction with a scalpel from the forehead to the neck and the skull was broken between 
the eyes with scissors. A scoop was used to extract the cerebrum and cerebellum from the 
brain stem for counting macroscopic petechiae on the brain surface. 
 
5.2.4. Antibody staining and flow cytometry analysis 
Twelve w/o C57BL/6 mice were injected with different HGF regimens 24 hr post-
TBI as described above. At day 2 post-TBI, peripheral blood cells were harvested by tail 
snip. Erythrocytes were lysed, and leukocytes (“total cells” in figures) were stained with 
antibodies for T cells (CD3-PE), B cells (B220-FITC), and myeloid cells (Gr-1-
PerCPCy5.5). Annexin-V-APC was used as an apoptosis marker and 7-AAD as a 
viability stain. Apoptotic rate in each white blood cell subpopulation was evaluated by 
flow cytometry. Expression of c-Kit was rapidly down-regulated post-IR at cell numbers 
were very low at myelosuppressive nadir. Therefore, for bone marrow stem cell 
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population analysis, lineage-, Sca-1+ and CD150+ (SLCD150+ cells) markers were used 
to identify the enriched population in HSCs at day 2, 7, 10 post-TBI in the H-ARS study 
to gain sufficient cells for flow cytometry analysis. The gating strategy used in DEARE 
stage was different from in the H-ARS stage since hematopoiesis had almost or partially 
recovered at the DEARE time-points. Therefore, in the DEARE study, lineage-, c-Kit+, 
Sca-1+, CD150+ and CD48- (KSLCD150+CD48-) markers were used to identify the 
enriched population in HSCs at 6 and 12 months post-TBI. Thymocyte subgroup staining 
and analysis was as described in Chapter 2. For cell cycle analysis in the lisinopril study, 
bone marrow cells were stained at day 10 post-TBI for the SLCD150+ marker, or 6 
months post-TBI for KSL CD150+CD48-, as described above. Cells were fixed overnight 
in 1% (v/v) formaldehyde and stained with 4’,6-diamidino-2-phenylindole (DAPI, 
Invitrogen, Eugene, OR). All antibodies were purchased from BD Biosciences (San Jose, 
CA), Biolegend (San Diego, CA), eBiosciences (San Diego, CA), or R&D Systems 
(Minneapolis, MN). Staining procedures and flow cytometric analyses were as previously 
described [40]. 
 
5.2.5. CFC assays and competitive transplantation 
Twelve w/o C57BL/6 mice were exposed to 9.27 Gy (LD95/30) and treated with 
different HGF regimens at 24 hr post-TBI as previously described. In H-ARS phase, four 
mice per treatment group were euthanized at day 5, 7, 14, and 30. BM cells were flushed 
from eight bones (humeri, pelvis, femurs, and tibias) and pooled together because cell 
number was very low at days 5, 7, and 14. Three quarters of the total cells were 
transplanted into three recipient mice (one aliquot number of cells per recipient, total of 
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three recipients per group); remaining cells were used for the colony assay. In H-ARS 
CFC assays, one aliquot of BM cells was suspended in 1 ml semi-solid methylcellulose 
media supplemented with murine SCF, murine IL-3, recombinant human IL-6, and 
recombinant human EPO (Methocult M3434, Stem Cell Technologies, Vancouver, BC, 
Canada) and incubated for 7 days (37°C, 5% CO2) prior to quantification of CFU-GM, 
BFU-E and CFU-GEMM. In H-ARS transplantation studies, one aliquot of BM cells was 
transplanted into one recipient along with 2×105 competitor cells. Peripheral blood was 
analyzed monthly for donor-derived chimerism for 1-5 months post-transplantation. In 
DEARE CFC assays, 2.5×104 whole BM cells were cultured in duplicate in similar 
procedures as in H-ARS CFC studies. In DEARE transplantation studies, donor mice 
were sacrificed at 12 months post-TBI, and BM cells were flushed from pelvis, femurs, 
and tibias, and 3×105 whole BM donor cells were transplanted intravenously with 2×105 
competitor cells into congenic recipient. Peripheral white blood cells were stained with 
CD45.1, CD45.2, Gr-1, B220, CD4 and CD8 antibodies for chimerism and lineage 
reconstitution at 6 months post-transplantation. Similar studies were also carried out on 
TC ± lisinopril study.  
 
5.2.6. Plasma and bone marrow cytokine analysis 
Plasma samples were obtained by cardiac puncture. BM supernatants were 
obtained from 2 femurs and 2 tibiae flushed twice with 500 µl cold PBS. Plasma samples 
were acquired after centrifuging EDTA-anticoagulant whole blood from cardiac puncture 
at 956 g for 4 min. BM supernatants and plasma samples were stored at -80°C and 
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thawed on ice before analysis. The cytokine detection and analysis were described in 
Chapter 3.  
 
5.2.7. Statistical analysis 
Thirty-day survival in H-ARS studies and lifespan in DEARE studies were 
analyzed by KM analyses and log-rank tests using SPSS Statistics Version 24 (IBM, 
Armonk, NY). Unpaired two-tailed t-tests were performed on Microsoft Excel 2010 
(Microsoft Corp, Redmond, WA) to compare the parameters between “with xx” and “no 
xx” as the combined analysis strategy, or between female and male in lisinopril studies, 
where at least three mice of either gender were analyzed. In rest studies, when comparing 
more than two groups, one-way ANOVA with post-hoc Tukey-Kramer HSD or Welch 
ANOVA for unequal variances were performed by JMP 14 (SAS Institute, Cary, NC). 
Data were expressed as mean ± SEM. P<0.05 was considered significant. 
 
5.3. Results 
5.3.1. Peg-HGFs increase post-TBI day 30 survival rate 
Dr. Orschell’s laboratory recently reported a significantly increased day 30 
survival rate in mice treated with SQ injections of single-dose individual peg-HGFs +24 
hr post-TBI [74]. In the current study, the efficacy of combined HGFs strategy on day 30 
survival was investigated. The difference between LD90/30 and LD95/30 is minimal so 
mice were combined. The day 30 survival rate in mice receiving the Veh injection was 
7.5%, consistent with the expected LD. The day 30 survival rate significantly increased in 
mice receiving a single individual dose of G, GM, or IL-11 (50%, 32.5%, and 62.5%, 
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respectively), consistent with previous report [74] (Figure 42 A and Table 5). Mice 
receiving combinations of two or three HGFs had higher day 30 survival rates than mice 
treated with individual HGFs. Treating with G+IL-11, GM+ IL-11, G+GM, and 
G+GM+IL-11 (triple combination, TC) increases day 30 survival to levels of 65%, 
72.5%, 55%, and 80%, respectively. TC-treated mice had a significantly higher survival 
than G, GM, and G+GM groups; however, no statistical difference was found in 
comparison with IL-11-containing regimens (IL-11, G+IL-11, GM+IL-11) (Figure 42 A 
and Table 5). Comparable results were obtained in a subsequent study with a lower dose 
of irradiation (8.72 Gy, LD70/30; data not shown). 
 
To further understand how combining HGFs contributes to increased survival, 
different HGF-treated mice were pooled together for analysis. Mice treated with G, G + 
GM, G + IL-11, or TC were pooled as G-CSF regimens (“with G” in figures) and 
compared with a pooled group of mice treated with GM, IL-11, or GM + IL-11 (“no G” 
in figures). The pooling criteria were applied to mice treated with GM-CSF regimens and 
IL-11 regimens. To compare the use of multiple HGFs vs. a single HGF, the G+IL-11, 
GM+IL-11, G+GM, and TC groups were combined into one group (“combined” in 
Figures and Legends) and the G, GM and IL-11 groups into one group (“single” in 
Figures and Legends). To compare HGFs vs. Veh, all HGF-treated groups were 
combined (“HGFs” in figures) and compared with the Veh group. The analyses showed 
that the “with IL-11” and “combined” groups had a higher day 30 survival rate than the 
“no IL-11” and “single” groups, respectively (Figure 42 D & E). However, there were no 
differences in the day 30 survival rates between “with G” and “with GM” groups in 
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comparison with the “no G” and “no GM” groups, respectively (Figure 42 B & C). All 
HGF-treated groups had significant higher day 30 survival rates than the Veh group 
(Figure 42 A & F). 
 
5.3.2. Peg-HGFs accelerate recovery of peripheral blood cells 
To examine the relationship of hematopoietic recovery to survival, CBC with 
differential counts were performed at baseline as well as at day 2, 4, 7, 10, 21, and 30 
post-TBI. The fluctuation in animal number during the course of the study is due to the 
fact that these are retrospective analyses that combined data from several MCM screening 
studies. At day 2 post-TBI, LY level was at a low level approaching their nadir at day 7-
10, whereas NE level only decreased to 33-50% of normal (Figure 43 B & C, Table 7 & 
8, for comparisons of other CBC parameters, please see Table 6-10). As expected, the 
declines of RBC and PLT were delayed in comparison with NE and LY. RBC and PLT 
decreased at day 10 and at day 7 post-TBI, respectively, in comparison with NI mice. The 
nadirs of WBC, LY and NE occurred at day 7-10, whereas RBC and PLT reached nadir 
around day 21. At the time-points around the nadirs (day 4, 7, and 10), almost all HGF-
treated groups had no significant differences in WBC, NE, and LY compared with Veh-
treated mice. All irradiated mice (both HGF-treated and Veh-treated mice) had significant 
differences in these parameters in comparison with NI mice. At day 30, NE levels had 
recovered to normal in all irradiated mice with no difference to NI mice; in contrast, 
WBC and LY numbers remained significantly lower in IRR mice than in NI mice. No 
HGF treatment rescued this low LY count at day 30. At day 21, the nadir time-point of 
RBC and PLT, mice receiving HGF treatments had higher numbers of these cells than  
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Figure 42 
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Figure 42. Thirty-day survival of lethal-irradiated mice treated with pegylated 
HGFs.  
Mice were exposed to 9.04 Gy or 9.27 Gy TBI and treated with pegylated HGFs in 
single, double, or triple combination (TC) 24 hr later. Survival on day 30 is shown as 
Kaplan-Meier survival curve. n=39-41 mice in each group (panel A). P values of 
comparisons in panel A were summarized in Table 5. The day 30 survival data were also 
analyzed in the method of combining different HGF groups into “with G” vs. “no G” 
(panel B), “with GM” vs. “no GM” (panel C), “with IL-11” vs. “no IL-11” (panel D), 
“single” vs. “combined” (panel E), or combining all HGF groups into one “HGFs” group 
and compared with Veh group (panel F). *p<0.05 comparing to Veh group. ∆ p<0.05 
comparing to “no IL-11” group (panel D) or comparing to “single” group (panel E). 
Sasidhar Vemula acquired the data; Tong Wu did the analyses. 
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Table 5. Comparisons of day 30 survival rates of lethal-irradiated mice treated with 
pegylated HGFs. 
Treatment Veh G GM IL-11 G+IL-11 GM+IL-11 G+GM TC 
Veh  <.0001 0.002 <.0001 <.0001 <.0001 <.0001 <.0001 
G <.0001  NS NS NS 0.027 NS 0.005 
GM 0.002 NS  0.011 0.027 0.001 NS <.0001 
IL-11 <.0001 NS 0.011  NS NS NS NS 
G+IL-11 <.0001 NS 0.027 NS  NS NS NS 
GM+IL-11 <.0001 0.027 0.001 NS NS  NS NS 
G+GM <.0001 NS NS NS NS NS  0.025 
TC <.0001 0.005 <.0001 NS NS NS 0.025  
Numbers in the table are p values of comparisons. NS: Not significant 
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Veh-treated mice. This difference no longer existed by day 30, though RBC and PLT in 
mice treated with most HGF regimens were lower than NI control mice (Figure 43 D & 
E, Table 9 & 10). 
 
To reduce the number of comparisons and identify which HGF or which 
combination regimen promoted hematopoietic recovery, data were analyzed as “with IL-
11” vs. “no IL-11”, “with G” vs. “no G”, “with GM” vs. “no GM”, “single” vs. 
“combined”, and “HGFs” vs. “Veh”(Figure 44-48). The “with IL-11” group had higher 
NE numbers than “no IL-11” group at day 2 post-TBI (Figure 44). The “with G” group 
had higher NE, RBC and PLT numbers, but not LY number, than “no G” group at day 21 
post-TBI (Figure 45). The “with GM” group had lower WBC and LY numbers at day 21 
post-TBI than “no GM” group (Figure 46). These analyses indicate that the three 
different HGFs took effect at different time-points and affect different cell types. 
Regimens containing G-CSF increase NE, RBC and PLT levels at day 21 post-TBI, 
which is when most Veh-treated mice die from infection and hemorrhage. This was not 
observed in mice treated with GM-CSF or IL-11-containing regimens. The “single” vs. 
“combined” analysis indicated that combining HGFs increased WBC and NE at day 2 
post-TBI; RBC and PLT at day 21 post-TBI. However, LY at day 21 post-TBI was lower 
with combined treatment than treatment with single HGF (Figure 47). Analyzing all 
HGF-treated groups together in comparison with the Veh group (Figure 48) revealed that 
the most significant increases in CBC parameters were at day 21, where WBC, NE, LY, 
RBC, and PLT counts were higher in HGF-treated mice than in Veh-treated mice. 
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Figure 43 
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Figure 43. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
pegylated HGFs.  
Mice were exposed to 9.04 Gy or 9.27 Gy TBI and treated with pegylated HGFs in 
single, double, or TC 24 hr later. Peripheral blood CBCs were performed at different 
time-points as indicated in panels. n=3-21 mice in each group (panel A). P values of 
comparisons were summarized in Table 6-10. Sasidhar Vemula acquired the data; Tong 
Wu did the analyses.  
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Table 6. Comparisons of WBC at different time-points of lethal-irradiated mice 
treated with pegylated HGFs. 
WBC  
Treatments Day2 Day4 Day7 Day10 Day21 Day30 
NI vs. Veh <.0001 <.0001 <.0001 <.0001 <.0001 0.0072 
NI vs. G <.0001 <.0001 <.0001 <.0001 0.0002 0.0001 
NI vs. GM <.0001 <.0001 <.0001 <.0001 <.0001 0.0001 
NI vs. IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 0.0001 
NI vs. G+IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 0.0112 
NI vs. GM+IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. G+ GM <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. TC <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
Veh vs. G NS NS NS NS 0.0047 NS 
Veh vs. IL-11 NS NS NS NS 0.0102 NS 
Veh vs. G+IL-11 NS NS NS NS 0.0062 NS 
Veh vs. GM+IL-11 NS NS NS NS 0.0208 NS 
Veh vs. G+GM NS NS NS NS 0.008 NS 
Veh vs. TC NS NS NS NS 0.0052 NS 
G vs. GM+IL-11 NS 0.0441 NS NS NS NS 
G vs. TC NS NS NS NS 0.0181 NS 
GM vs. GM+IL-11 NS 0.0441 NS NS NS NS 
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Numbers in the table are p values of comparisons. If a comparison has no significant 
difference at any time-points, it will not be shown in the table. NS: Not significant   
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Table 7. Comparisons of NE at different time-points in H-ARS phase of lethal-
irradiated mice treated with pegylated HGFs. 
NE  
 Treatments Day2 Day4 Day7 Day10 Day21 Day30 
NI vs. Veh 0.0386 <.0001 <.0001 <.0001 <.0001 NS 
NI vs. G NS <.0001 <.0001 <.0001 0.0295 NS 
NI vs. GM 0.0109 <.0001 <.0001 <.0001 <.0001 NS 
NI vs. IL-11 NS <.0001 <.0001 <.0001 <.0001 NS 
NI vs. G+IL-11 NS <.0001 <.0001 <.0001 0.0004 NS 
NI vs. GM+IL-11 NS <.0001 <.0001 <.0001 <.0001 NS 
NI vs. G+ GM NS <.0001 <.0001 <.0001 0.0005 NS 
NI vs. TC NS <.0001 <.0001 <.0001 <.0001 NS 
Veh vs. G NS NS NS NS 0.0059 NS 
Veh vs. IL-11 NS NS NS NS 0.0361 NS 
Veh vs. G+IL-11 NS NS NS NS 0.0078 NS 
Veh vs. GM+IL-11 NS NS NS NS 0.0203 NS 
Veh vs. G+GM NS NS NS NS 0.0101 NS 
Veh vs. TC NS NS NS NS 0.0063 NS 
G vs. GM NS NS NS NS 0.0114 NS 
G vs. IL-11 NS NS NS NS 0.0555 NS 
G vs. GM+IL-11 NS 0.0441 NS NS NS NS 
GM vs. IL-11 0.0211 NS NS NS NS NS 
 209 
GM vs. G+IL-11 NS NS NS NS 0.0087 NS 
GM vs. GM+IL-11 0.0296 0.0441 NS NS NS NS 
GM vs. G+GM NS NS NS NS 0.0243 NS 
GM vs. TC NS NS NS NS 0.0388 NS 
IL-11 vs. G+IL-11 NS NS NS NS 0.0238 NS 
Numbers in the table are p values of comparisons. NS: Not significant 
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Table 8. Comparisons of LY at different time-points in H-ARS phase of lethal-
irradiated mice treated with pegylated HGFs. 
LY  
Treatments Day2 Day4 Day7 Day10 Day21 Day30 
NI vs. Veh <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. G <.0001 <.0001 <.0001 <.0001 0.0018 <.0001 
NI vs. GM <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. G+IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. GM+IL-11 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. G+ GM <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
NI vs. TC <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 
Veh vs. G NS NS NS NS 0.0045 NS 
Veh vs. GM NS NS NS NS 0.0269 NS 
Veh vs. IL-11 NS NS NS NS 0.0043 NS 
Veh vs. G+IL-11 NS NS NS NS 0.0101 NS 
Veh vs. GM+IL-11 NS NS NS NS 0.0078 NS 
Veh vs. G+GM NS NS NS NS 0.0057 NS 
Veh vs. TC NS NS NS NS 0.0031 NS 
G vs. GM+IL-11 NS 0.0445 NS NS NS NS 
G vs. TC NS NS NS NS 0.0084 NS 
GM vs. GM+IL-11 NS 0.0445 NS NS NS NS 
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Numbers in the table are p values of comparisons. NS: Not significant 
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Table 9. Comparisons of RBC at different time-points in H-ARS phase of lethal-
irradiated mice treated with pegylated HGFs. 
RBC  
Treatments Day2 Day4 Day7 Day10 Day21 Day30 
NI vs. Veh NS NS 0.0312 <.0001 <.0001 NS 
NI vs. G NS NS NS <.0001 <.0001 0.0303 
NI vs. GM NS NS NS <.0001 <.0001 0.0093 
NI vs. IL-11 NS NS NS <.0001 <.0001 NS 
NI vs. G+IL-11 0.0131 NS NS <.0001 0.0003 NS 
NI vs. GM+IL-11 NS NS NS <.0001 <.0001 0.0009 
NI vs. G+ GM 0.0174 NS NS <.0001 0.001 0.0072 
NI vs. TC NS NS NS <.0001 <.0001 0.0009 
Veh vs. G NS NS NS NS 0.0047 NS 
Veh vs. IL-11 NS NS NS NS 0.0115 NS 
Veh vs. G+IL-11 NS NS NS NS 0.0047 NS 
Veh vs. GM+IL-11 NS NS NS NS 0.0038 NS 
Veh vs. G+GM NS NS NS NS 0.006 NS 
Veh vs. TC NS NS NS NS 0.0025 NS 
G vs. GM NS NS NS NS 0.023 NS 
GM vs. G+IL-11 NS NS NS NS 0.0045 NS 
GM vs. G+GM NS NS NS NS 0.0155 NS 
GM vs. TC NS NS NS NS 0.0072 NS 
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IL-11 vs. G+IL-11 NS NS NS NS 0.0486 NS 
IL-11 vs. G+GM NS NS NS NS 0.0473 NS 
Numbers in the table are p values of comparisons. NS: Not significant   
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Table 10. Comparisons of PLT at different time-points in H-ARS phase of lethal-
irradiated mice treated with pegylated HGFs. 
PLT  
 Treatments Day2 Day4 Day7 Day10 Day21 Day30 
NI vs. Veh NS NS <.0001 <.0001 <.0001 NS 
NI vs. G NS NS <.0001 <.0001 <.0001 0.0009 
NI vs. GM NS 0.0172 <.0001 <.0001 <.0001 0.0059 
NI vs. IL-11 NS NS <.0001 <.0001 <.0001 0.001 
NI vs. G+IL-11 NS 0.0481 <.0001 <.0001 <.0001 NS 
NI vs. GM+IL-11 NS 0.0459 <.0001 <.0001 <.0001 0.0356 
NI vs. G+ GM NS 0.0413 <.0001 <.0001 <.0001 0.004 
NI vs. TC NS 0.0204 <.0001 <.0001 <.0001 0.0104 
Veh vs. G NS NS NS NS 0.0047 NS 
Veh vs. GM NS NS NS NS 0.0135 NS 
Veh vs. IL-11 NS NS NS NS 0.004 NS 
Veh vs. G+IL-11 NS NS NS NS 0.0047 NS 
Veh vs. GM+IL-11 NS NS NS NS 0.0262 NS 
Veh vs. G+GM NS NS NS NS 0.006 NS 
Veh vs. TC NS NS 0.0464 NS 0.0026 NS 
G vs. GM NS NS NS NS 0.0016 NS 
G vs. IL-11 NS NS NS NS 0.0072 NS 
GM vs. G+IL-11 NS NS NS NS 0.003 NS 
 215 
GM vs. G+GM NS NS NS NS 0.0129 NS 
GM vs. TC NS NS NS NS 0.0015 NS 
IL-11 vs. G+IL-11 NS NS NS NS 0.0039 NS 
IL-11 vs. TC NS NS NS NS 0.0034 NS 
Numbers in the table are p values of comparisons. NS: Not significant   
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Figure 44. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
“with IL-11” or “no IL-11” regimen.  
Mice in Figure 43 were re-grouped as mice received any regimens containing IL-11 were 
combined into “with IL-11” group and mice received regimens containing other HGFs 
were combined into “no IL-11” group. n=21-71 mice per time-point per group. * p<0.05 
comparing “with IL-11” group (light blue) to “no IL-11” group (purple) at time-points as 
marked. Sasidhar Vemula acquired the data; Tong Wu did the analyses. 
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Figure 45 
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Figure 45. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
“with G” or “no G” regimen.  
Mice in Figure 43 were re-grouped as the method of “with G” vs. “no G” as previously 
described. n=21-72 mice per time-point per group. *p<0.05 comparing “with G” group 
(light blue) to “no G” group (purple) at time-points as marked. Sasidhar Vemula acquired 
the data; Tong Wu did the analyses. 
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Figure 46 
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Figure 46. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
“with GM” or “no GM” regimen.  
Mice in Figure 43 were re-grouped as the method of “with GM” vs. “no GM” as 
previously described. n=21-71 mice per time-point per group. * p<0.05 comparing “with 
GM” group (light blue) to “no GM” group (purple) at time-points as marked. Sasidhar 
Vemula acquired the data; Tong Wu did the analyses. 
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Figure 47 
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Figure 47. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
“single” or “combined” regimen. 
Mice in Figure 43 were re-grouped as the method of “single” vs. “combined” as 
previously described. n=21-72 mice per time-point per group. *: p<0.05 comparing 
“combined” group (light blue) to “single” group (purple) at time-points as marked. 
Sasidhar Vemula acquired the data; Tong Wu did the analyses. 
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Figure 48 
  
  
 
    
NI
Veh
HGFs
0
1
10
0 5 10 15 20 25 30
W
BC
 (K
/u
l)
(M
ea
n 
±
SE
M
) 
Days  post Irradiation 
WBC
*
0
1
2
3
4
5
0 5 10 15 20 25 30
NE
 (K
/u
l)
(M
ea
n 
±
SE
M
) 
Days  post Irradiation 
NE
*
0
300
600
900
1200
0 5 10 15 20 25 30
PL
T 
(K
/u
l)
(M
ea
n 
±
SE
M
) 
Days  post Irradiation 
PLT
*
0
3
6
9
12
0 5 10 15 20 25 30
RB
C 
(M
/u
l)
(M
ea
n 
±
SE
M
) 
Days  post Irradiation 
RBC
*
0
4
8
12
16
0 5 10 15 20 25 30
LY
 (K
/u
l)
(M
ea
n 
±
SE
M
) 
Days  post Irradiation 
LY
*
B
C
A
D
E
 225 
Figure 48. CBC profiles in H-ARS phase of lethal-irradiated mice treated with 
“HGFs” or “Veh” regimen.  
Mice in Figure 43 were re-grouped as the method of “HGFs” vs. “Veh” as previously 
described. n=52-121 mice per time-point per group. *p<0.05 comparing “HGFs” group 
(purple) to “Veh” group(red) at time-points as marked. Sasidhar Vemula acquired the 
data; Tong Wu did the analyses. 
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To summarize, HGF treatments do not increase WBC, NE, and LY counts at their 
nadirs. Instead, significant recovery of the hematopoietic system occurs around day 21 
post-TBI, where HGFs increase all CBC parameters. G-CSF-containing regimens 
increase NE, RBC, and PLT counts at day 21; polypharmacy regimens increase WBC 
and NE at day 2, and increase RBC and PLT at day 21. These results support the use of 
HGFs in a lethal irradiation scenario, and are consistent with the increased survival of 
HGF-treated mice. 
 
5.3.3. Peg-HGFs does not reduce peripheral blood cell apoptosis 
Previous findings show that “combined” HGFs regimens treated mice had higher 
WBC and NE count at day 2 post-TBI and lower WBC count at day 4 than mice treated 
with individual HGFs, indicating that WBC and NE decrease more rapidly in mice 
receiving “combined” HGFs regimens (Figure 47). Comparable results were observed in 
the “with IL-11” vs. “no IL-11” analysis. The effect of HGF treatment on radiation-
induced apoptosis was evaluated, as a potential mechanism for the observed CBC 
parameter changes. Peripheral blood was collected at day 2 post-TBI (24 hr post-HGFs 
injection). WBCs were stained with CD3 (T cells), Gr-1 (myeloid cells), Annexin-V 
(apoptosis marker), and 7-AAD (viability stain), and analyzed by flow cytometry. There 
was no statistical difference between HGFs treatment and Veh treatment; as expected, 
apoptosis in NI mice was lower than in IR mice, although not statistically different, in all 
cell types (Figure 49 A-F).  
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Figure 49 
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Figure 49. Apoptosis of peripheral white blood cells at day 2 post-TBI.  
Mice were exposed to 9.04 Gy TBI and injected with pegylated HGFs in single, double, 
or TC 24 hr later. Mice were euthanized on day 2 post-TBI and PB collected via cardiac 
puncture. PB cells were stained with CD3, B220, Gr-1, Annexin (apoptosis marker), and 
7AAD (viability stain). Expression of Annexin-V+7AAD- (apoptotic cells) was assessed 
on total white blood cells, B220+ cells (B cells), CD3+ cells (T cells) and Gr-1+ 
(neutrophils) (panel A). Data were combined and analyzed in the methods as “with G” vs. 
“no G” (panel B), “with GM” vs. “no GM” (panel C), “with IL-11” vs. “no IL-11” (panel 
D), “single” vs. “combined” (panel E), “HGFs” vs. “Veh” (panel F). Bars represent mean 
± SEM. n = 3-4 mice per group. P values of percentage of apoptotic cells between 
different groups were summarized in Table 8 (all p values > 0.05, only show the 
comparisons with p values <0.1). Artur Plett acquired the data; Tong Wu did the 
analyses. 
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5.3.4. Peg-HGFs increase HSPC count early post-TBI 
To determine whether the enhanced survival and hematopoietic recovery of 
combined HGF regimens results from altered HSPC numbers in the bone marrow, bone 
marrow cellularity and HSPC numbers were analyzed up to 30 days post-TBI. Bone 
marrow inhibition persisted until day 21 post-TBI and recovered at day 30. At day 30, 
only G-CSF-treated mice had higher total bone marrow cell counts than IL-11 treated 
mice, there was no statistical difference between any irradiated groups and the NI control, 
and there was no statistical difference between any HGF-treated group and the Veh 
control. Up to day 21, all irradiated groups had significantly lower bone cell counts than 
the NI group and there was no significant difference between different irradiated groups 
(Figure 50 A). When analyzed in a manner similar to “with xx” vs. “no xx” in the CBC 
analysis, there was no statistical difference in total bone marrow cell numbers between 
any “with xx” and “no xx” groups at any time-points. (Figure 50 B-F). HPC numbers 
were slightly higher in mice receiving combined HGF regimens than in mice receiving a 
single HGF at day 5 and 7 post-TBI, although difference was not statistically significant 
(Figure 51). 
 
In a similar study, HSC counts were phenotyped by flow cytometry post-TBI. No 
statistical significance in HSC (Lin-Sca+CD150+) numbers was observed comparing 
HGF-treated groups with Veh group, or comparing different HGF-treated groups, at day 
2, 7, 10 and 21 post-TBI (Figure 52). Combining all HGF-treated groups together, HSC 
counts were significantly increased in comparison with the Veh control at day 10 post-
TBI (Figure 52 E). The differences between “single” and “combined”, “with G” and “no 
 230 
G”, “with GM” and “no GM”, “with IL-11” and “no IL-11” were minimal (Figure 52 F-
I). 
 
Competitive transplantation studies at day 5, 7, and 14 post-TBI with donor bone 
marrow cells from mice treated with different HGF regimens or the Veh control did not 
show statistical differences in chimerism rate up to 5 months post-transplantation (Figure 
53 A-C). When analyzed as “HGFs” vs. “Veh”, at four months post-transplantation in 
day-14 post-TBI transplant recipients, chimerism was significantly lower in the “HGFs” 
group than in the Veh control. There was no statistical difference between Veh control 
and “HGFs” group at any other time-points (Figure 53 D-F). When analyzed as “single” 
vs. “combined”, the chimerism rate of “combined” group was only transiently higher than 
the “single” group at 1 month post-transplantation (Figure 53 I). There was no statistical 
difference among the “single”, “combined” or Veh groups at day 5 or day 7 post-TBI 
(Figure 53 G & H). When analyzed in the pattern of “with G” vs. “no G” (Figure 53 J-L), 
“with GM” vs. “no GM” (Figure 53 M-O), and “with IL-11” vs. “no IL-11” (Figure 53 P-
R), there was no significant difference between “with xx” and “no xx”. In mice 
transplanted at day 14, both “with xx” and “no xx” groups had lower chimerism rates 
than Veh group. 
 
5.3.5. Peg-HGFs do not extend lifespan of DEARE mice 
Radiomitigator peg-HGFs successfully increased the survival rate of lethally-
irradiated mice in H-ARS phase, whether the early administration can extend lifespan or 
alleviate DEARE symptoms in survivors is unknown. In the current study, mice surviving  
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Figure 50. Total BM cell count in H-ARS phase of lethal-irradiated mice treated 
with pegylated HGFs.  
Mice were exposed to 9.04 Gy or 9.27 Gy TBI and treated with pegylated HGFs. Mice 
were sacrificed on day 2, 4, 7, 10, 21 and 30 post-TBI, and BM cells were flushed from 
femurs, tibias, pelvis, and humeri (8 bones), and counted for total BM cells per mouse 
(panel A, insert is the bar graph of day 21 data, no statistical difference among different 
irradiated groups). Data were combined and analyzed in the methods as “with IL-11” vs. 
“no IL-11” (panel B), “with G” vs. “no G” (panel C), “with GM” vs. “no GM” (panel D), 
“single” vs. “combined” (panel E), “HGFs” vs. “Veh” (panel F). Lines represent mean ± 
SEM. n=3-12 per group per time-point in panel A. ∆ p<0.05 comparing IL-11 to G group 
in panel A. * p<0.05 comparing “HGFs” to “Veh” group in panel F. Artur Plett and 
Sasidhar Vemula acquired the data; Tong Wu did the analyses. 
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Figure 51. Recovery kinetics of HPCs in H-ARS phase of lethal-irradiated mice 
treated with pegylated HGFs.  
Mice were exposed to 9.27 Gy TBI and treated with pegylated HGFs as previously 
described. Four mice in each HGF treated group were euthanized on days 5, 7, 14 and 30 
post-TBI separately and BM cells were flushed from femurs, tibias, pelvis, and humeri (8 
bones). BM cells from the 4 mice were pooled and ¼ were used into colony assay. In 
panel A-D, n=1 in each group. Data were analyzed in method as “single” vs. “combined” 
(panel E-H). n=3-4 in “single” and “combined” group. Sasidhar Vemula acquired the 
data; Tong Wu did the analyses. 
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Figure 52. Recovery kinetics of hematopoietic stem cells in H-ARS phase of lethal-
irradiated mice treated with pegylated HGFs.  
Mice were exposed to 9.04 Gy TBI and treated with pegylated HGFs as previously 
described. Mice were sacrificed on days 2, 7, 10 and 21 post-TBI. Flushed BM cells were 
stained with Lin markers, Sca-1 and CD150 antibodies, and then assessed by flow 
cytometry. The number of Lin-Sca-1+CD150+ (LS CD150+) cells per mouse were 
analyzed in each HGF treated group (panel A-D). Data were analyzed in methods as 
“HGFs” vs. “Veh” (panel E), “single” vs. “combined” (panel F), “with G” vs. “no G” 
(panel G), “with GM” vs. “no GM” (panel H) and “with IL-11” vs. “no IL-11” (panel I). 
Bars represent mean ± SEM. n=4 per group per time-point in panel A-D. *p<0.05 
comparing to Veh group. Artur Plett acquired the data; Tong Wu did the analyses. 
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Figure 53. BM competitive transplantation for donor cells at H-ARS phase from 
lethal-irradiated mice treated with pegylated HGFs.  
Mice were exposed to 9.27 Gy TBI and treated with pegylated HGFs as previously 
described. Four mice in each HGF treated group were euthanized on day 5, 7 and 14 post-
TBI and BM cells were flushed from femurs, tibias, pelvis, and humeri (8 bones). BM 
cells from the 4 mice were pooled and pooled sample then was split into 4 equal aliquots. 
Three aliquots were used for transplantation into 3 recipient mice (one aliquot per 
recipient, the rest one aliquot was used in colony assay as describe in Figure 51). For 
transplantation, the whole bone marrow fraction, regardless of the number of cells, was 
transplanted via the retro orbital sinus into one irradiated (5.5 + 5.5 Gy) recipient BoyJ 
mouse, along with 2 × 105 whole bone marrow competitor cells. Donor chimerism rates 
of peripheral white blood cells were tracked monthly till to 5 months post-transplantation. 
Data were presented as line graphs in each HGF treated group (panel A-C) and bar 
graphs in “HGFs” vs. “Veh” (panel D-F), “single” vs. “combined” (panel G-I), “with G” 
vs. “no G” (panel J-L), “with GM” vs. “no GM”(panel M-O) and “with IL-11” vs. “no 
IL-11” (panel P-R). Lines and bars represent mean ± SEM. n=3 per group per time-point 
in panel A-C. ∆ p<0.05 comparing to Veh group. *p<0.05 comparing to “single” group in 
panel I. Artur Plett acquired the data; Tong Wu did the analyses. 
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the H-ARS stage (day 30 post-TBI; 4 months of age) were transferred to the RBMD 
study and observed until 24 months post-TBI. Mice were euthanized when severely 
moribund or were sacrificed at scheduled time-points for DEARE studies. Kaplan-Meier 
lifespan analyses were performed in SPSS. Consistent with earlier reports [310, 311], a 
significantly shortened lifespan was observed in Veh-treated irradiated mice in 
comparison with NI mice. No significant difference was observed between HGF-treated 
and Veh-treated groups, with the exception of the G+GM group (significantly lower than 
Veh group), and the differences between different HGF-treated groups were minimal 
(Figure 54 A and Table 11). When analyzed as “HGFs” vs. “Veh”, “with IL-11” vs. “no 
IL-11”, and “single” vs. “combined”, there was  no difference between “HGFs” vs. 
“Veh”, “with IL-11” vs. “no IL-11”, and “single” vs. “combined” groups (Figure 54 B-
D);  “no IL-11” group had significantly lower survival rate than Veh group, whereas 
“with IL-11”group had not (Figure 54 C). 
 
5.3.6. Peg-HGFs do not alleviate body weight loss in DEARE mice 
Pegylated HGFs do not increase survival rate of DEARE mice, whether HGFs at 
24 hr post-TBI impact DEARE markers is still unknown. Weight loss is one of the 
significant markers of DEARE [40]. The body weights at 6 and 12 months post-TBI were 
measured. There was no statistical difference between different irradiated groups either at 
6 or at 12 months post-TBI, no matter what treatments mice received (Figure 55 A). 
When analyzed as “HGFs” vs. “Veh”, “single” vs. “combined”, or “with IL-11” vs. “no 
IL-11”, the “HGFs” and Veh mice had lower body weights than NI mice at 12 months 
post-TBI (Figure 55 B), but there was no difference in “single” vs. “combined” and “with  
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Figure 54. Long-term survival of day 30 survived mice treated with pegylated 
HGFs.  
Mice were exposed to 9.27 Gy TBI and treated with pegylated HGFs as previously 
described. Mice survived over day 30 post-TBI were transferred to RBMD study for 
long-term survival monitor until the end of study (24 months post-TBI). The survival 
mice were recorded when found dead, or were euthanized when severely moribund, or 
scheduled time-point sacrifices. Survival is shown as Kaplan-Meier curve. n=60-109 
mice in each group (panel A). P value of comparisons for panel A were summarized in 
Table 11. Survival data were analyzed in the manner of “HGFs” vs. “Veh” (panel B), 
“with IL-11” vs. “no IL-11” (panel C), “single” vs. “combined” (panel D). “with G” vs. 
“no G” and “with GM” vs. “no GM” comparisons were not shown since no statistical 
difference between the two types of comparison. *p<0.05 comparing to NI group in panel 
B-D. ∆p<0.05 comparing to Veh group in panel C. Artur Plett and Sasidhar Vemula 
acquired the data; Tong Wu did the analyses. 
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Table 11. Comparisons of long-term survival of lethal-irradiated mice treated with 
pegylated HGFs. 
Treatment G G+GM G+IL-11 GM GM+IL-11 IL-11 NI TC Veh 
G  NS NS NS NS NS <.0001 NS NS 
G+GM NS  NS 0.029 0.023 NS <.0001 0.033 0.01 
G+IL-11 NS NS  NS NS NS <.0001 NS NS 
GM NS 0.029 NS  NS NS <.0001 NS NS 
GM+IL-11 NS 0.023 NS NS  NS <.0001 NS NS 
IL-11 NS NS NS NS NS  <.0001 NS NS 
NI <.0001 <.0001 <.0001 <.0001 <.0001 <.0001  <.0001 <.0001 
TC NS 0.033 NS NS NS NS <.0001  NS 
Veh NS 0.01 NS NS NS NS <.0001 NS  
Numbers in the table are p values of comparisons. NS: Not significant 
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Figure 55. Body weight in DEARE phase of lethal-irradiated mice treated with 
pegylated HGFs.  
Mice were exposed to 9.04 Gy TBI and treated with pegylated HGFs as previously 
described. Body weights were assessed at 6 and 12 months post-TBI (panel A). Data 
were analyzed by “HGFs” vs. “Veh” (panel B), “single” vs. “combined” (panel C), “with 
IL-11” vs. “no IL-11” (panel D) as previously described. Bars represent mean ± SEM. n= 
5-8 mice for each group in panel A. *p<0.05 comparing to NI group. Artur Plett acquired 
the data; Tong Wu did the analyses. 
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IL-11” vs. “no IL-11” comparisons. (Figure 55 C & D). This indicates that HGF 
administration 24 hr post-TBI does not alleviate weight loss in DEARE mice. 
 
5.3.7. Peg-HGFs do not reverse myeloid skewing in DEARE mice 
Hematopoiesis is severely defective in DEARE mice following exposure to lethal 
radiation at young age [40, 147]. Dr. Orschell's laboratory has already proved that HGFs 
treatment at 24 hr post-TBI accelerates hematopoietic recovery at the H-ARS phase, 
whether it would alleviate defective long-term hematopoiesis is not clear. The CBC 
changes at 6 and 12 months post-TBI in the survivor mice of lethal radiation were 
investigated. At 12 months post-TBI, WBC, LY, and RBC were significantly decreased 
in most irradiated mice in comparison with age-matched NI controls. No significant 
difference in NE number was observed between irradiated and NI control mice at 6 or 12 
months post-TBI. Myeloid skewing was apparent 12 months post-TBI in most irradiated 
groups, but no significant difference between HGF-treated and Veh-treated mice was 
observed. (Figure 56 A-G). When analyzed as “HGFs” vs. “Veh”, “single” vs. 
“combined”, or “with xx” vs. “no xx”, all the significant differences were from the 
comparisons to NI group, there was no statistical difference between “HGFs” and “Veh”, 
“single” and “combined”, or “with xx” and “no xx” (Figure 56 H-AI). 
 
5.3.8. Peg-HGFs do not increase HSC number and function in DEARE mice 
While HGF treatment does not alleviate peripheral blood defects in DEARE mice, 
the possibility of beneficial effects in HSPC cannot be excluded. Mice were irradiated at 
12 weeks LD90/30 and received HGFs treatments 24 hr post-TBI as previously 
 246 
described. Survivors were sacrificed 6 and 12 months post-TBI and bone marrow 
cellularity, LSK cell number, and LSK CD150+CD48- cell number were assessed by flow 
cytometry. There was no statistical difference between different HGF groups and Veh 
control (Figure 57 A-C). Consistent with the previous report, LSK and LSK 
CD150+CD48- cell numbers were generally higher at 12 months post-TBI than at 6 
months [40]. When analyzed as “HGFs” vs. “Veh”, “single” vs. “combined”, or “with 
xx” vs. “no xx”, there was no statistical difference in these comparisons (Figure 57 D-O). 
 
To test HSC function, transplantation studies were done at 12 months post-TBI. 
One hundred and fifty KSL CD150+ cells were transplanted into the congenic recipients 
and recipients were sacrificed 6 months post-transplantation. The donor chimerism rates 
and donor-derived lineage reconstitution of peripheral blood Gr-1+ NE, CD8+ T cells, 
CD4+ T cells, and B220+ B cells were measured by flow cytometry. KSL CD150+ cells 
from irradiated mice had significantly lower repopulation capacity than the cells from 
age-matched NI controls. There was no significant difference between the Veh control 
and HGF-treated mice (Figure 58 A) or “HGFs” vs. Veh (Figure 58 C), or “with IL-11” 
vs. “no IL-11” (Figure 58 E), or “single” vs. “combined” (Figure 58 G). As previously 
observed [147], recipients of KSL CD150+ cells from irradiated donors exhibited 
imbalanced lymphoid-myeloid reconstitution. Myeloid (Gr-1+) percentages were higher 
in all irradiated groups than in the NI control, explaining the myeloid skewing observed 
in the peripheral blood. No HGF treatment improved this HSC defect (Figure 58 B, D, F 
& H). HGF treatment 24 hr after TBI, therefore does not alleviate HSC deficiencies 
despite improving survival in the H-ARS stage. 
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Figure 56 
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Figure 56 continue 
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Figure 56. CBC profiles in DEARE phase of lethal-irradiated mice treated with 
pegylated HGFs.  
Mice were exposed to 9.04 Gy TBI and treated with pegylated HGFs as previously 
described. Survived mice were tail-bled at 6 and 12 months post-TBI and assessed for 
CBC parameters including WBC (panel A), NE (panel B), LY (panel C), %NE (panel D), 
%LY (panel E), RBC (panel F), and PLT (panel G). Data were analyzed in the method as 
“single” vs. “combined” (panel H-N), “with IL-11” vs. “no IL-11” (panel O-U), “with G” 
vs. “no G” (panel V-AB), “HGFs” vs. “Veh” (panel AC-AI). Bars represent mean ± 
SEM. n=5-8 mice per group in panel A-G. *p<0.05 comparing to NI group. Artur Plett 
acquired the data; Tong Wu did the analyses. 
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Figure 57. BM cellularity and HSPC in DEARE phase of lethal-irradiated mice 
treated with pegylated HGFs.  
Mice were exposed to 9.04 Gy TBI and treated with pegylated HGFs as previously 
described. Mice were sacrificed at 6 and 12 months post-TBI. BM cells were flushed 
from pelvis, femur and tibia; red blood cells were lysed and nucleated cells were 
enumerated. BM cells were stained with Lin markers, c-Kit, Sca-1, CD48 and CD150 
antibodies, and then assessed by flow cytometry. Cellularity and HSPC numbers were 
analyzed in each HGF treated group (panel A-C). Data were analyzed in the method as 
“single” vs. “combined” (panel D-F), “with IL-11” vs. “no IL-11” (panel G-I), “with G” 
vs. “no G” (panel J-L), “HGFs” vs. “Veh” (panel M-O). “with GM” vs. “no GM” plots 
were not shown since there was no difference between groups and the plot was similar to 
others. Bars represent mean ± SEM. n=5-8 per group per time-point in panel A-C. 
*p<0.05 comparing to NI group. Artur Plett acquired the data; Tong Wu did the analyses. 
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Figure 58. BM competitive transplantation for donor cells at DEARE phase from 
lethal-irradiated mice treated with pegylated HGFs.  
Mice were exposed to 9.27 Gy TBI and treated with pegylated HGFs as previously 
described. Survivors were euthanized at 12 months post-TBI and 3×105 of donor whole 
bone marrow cells were transplanted intravenously along with 2×105 congenic competitor 
cells into lethal-irradiated (5.5 + 5.5 Gy) congenic recipients. Recipient mice were 
sacrificed at 6 months post-transplantation. The donor chimerism and lineage 
reconstitution were evaluated by flow cytometry as described in the Materials and 
Methods. Data were analyzed in each HGF treated group separately (panel A & B) and in 
the method as “HGFs” vs. “Veh” (panel C & D), “with IL-11” vs. “no IL-11” (panel E & 
F), and “single” vs. “combined” (panel G & H). Bars present as mean ± SEM. n=6-9 per 
group in panel A & B. *p<0.05 comparing to NI group. Artur Plett acquired the data; 
Tong Wu did the analyses. 
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5.3.9. Peg-HGFs enhance early thymic recovery post-TBI but do not alleviate thymic 
involution in DEARE mice 
Peg-HGFs treatment 24 hr post-TBI increases LY count at day 21 (Figure 48). LY 
HPE is a physiological reaction to radiation-induced lymphopenia, consisting of G-CSF-
driven immune reconstitution [346]. HPE is the predominant source of T cells after 
thymic involution [347]. The potential of HGFs treatment to promote thymic regeneration 
and hence boost de novo T cell generation were investigated. First, the main components 
of peripheral blood cells at day 21 post-TBI in selected HGFs-treated groups were 
assessed by flow cytometry. Consistent with previous reports, the stimulating effect of 
peg-G-CSF was most prominent in Gr-1+ neutrophils [74, 203, 348]. Additionally, peg-
G-CSF treated mice had higher B220+ B cell count, CD4+ and CD8+ T cell counts 
compared with Veh-treated mice at day 21 post-TBI. Combining peg-HGFs did not 
further increase cell numbers (Figure 59). 
 
Twelve w/o mice were irradiated LD90/30 and treated with peg-HGFs 24 hr post-
TBI as previously described. Thymic weight and cellularity were measured at different 
time-points up to 12 months post-TBI. At all time-points (day 2, 7, 10, and 12 months 
post-TBI), thymus weight and cellularity were lower in irradiated mice in comparison 
with NI mice, no matter what treatments received. At day 21, peg-HGFs-treated mice had 
higher thymic weight and cellularity than Veh mice, although ANOVA analysis of all 
irradiated groups revealed no statistical difference (Figure 60 A & B). This trend was 
significant when combined all HGFs-treated groups together as a “HGFs” group and 
compared it to Veh group. The HGFs-treated mice had significantly higher thymus 
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weight and cellularity than the Veh-treated mice at day 21 (Figure 60 C & D). At 12 
months post-TBI, the peg-HGFs-treated mice had slightly lower thymic weight and 
cellularity than Veh-treated mice, though the difference was not significant. When 
analyzed as “single” vs. “combined”, “with G” vs. “no G”, “with GM” vs. “no GM”, and 
“with IL-11” vs. “no IL-11” as previously described, there was no statistical difference 
between any of these two groups at any time-point (Figure 60 E-L). 
 
When analyzed the phenotype of thymocyte subpopulations, since there was no 
significant difference between different HGF groups at each time-point and the trends 
were similar to the thymus cellularity plot, for the easy of readers, the plots of each HGF 
comparison were not presented but only the combined analysis plots were presented as in 
the method of “HGFs” vs. “Veh” (Figure 61 A-H) and “single” vs. “combined” (Figure 
61 I-P). The rest comparisons including “with G” vs. “no G”, “with GM” vs. “no GM”, 
and “with IL-11” vs. “no IL-11” were not presented because the similarity to the plots of 
“single” vs. “combined”. In the plots of “HGFs” vs. “Veh” (Figure 61 A-H), DP and 
DN3 percentages in irradiated mice were decreased at day 2 compared to NI mice, and 
the percentages of CD4+, CD8+, DN, and DN1, DN2, and DN4 groups were relatively 
increased or not change. Thymi of irradiated mice began to recover with DN3 level 
restored to normal by day 7 and DP by day 10 respectively. No significant difference of 
subpopulation distribution between HGFs-treated mice and Veh-treated mice was 
observed at day 2, 7 or 10, consistent with the thymocyte number changes at these time-
points (Figure 60 C & D). At day 21, the HGFs-treated mice had a higher percentage of 
DP cells than Veh-treated mice, which was significant when all HGFs-treated mice were 
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combined together for analysis (Figure 61 B). DN2 and DN3 followed similar trends, 
with no statistical difference (Figure 61 F & G). Again, at 12 months post-IR, the 
percentages of DP, DN2, and DN3 were lower in HGFs-treated mice than Veh mice, 
though the difference was not statistically significant (Figure 61 A-H). When analyzed 
“single” vs. “combined” as previously described, there was no statistical difference at any 
time-point (Figure 61 I-P). HGFs treatment therefore promotes early thymic recovery 
post-TBI but does not alleviate thymic involution in DEARE mice. Polypharmacy 
strategy does not further enhance the effect on thymic recovery. 
 
5.3.10. Adding lisinopril to the TC regimen further alleviates irradiation damage  
Combining all three peg-HGFs (peg-G-CSF + peg-GM-CSF + peg-IL-11, TC) 
results in the highest day 30 survival rate (Figure 42), and evidence suggests that ACEI is 
an effective radiomitigator when used alone or in combination with HGFs [93, 101, 103]. 
Here, radiomitigating potential of lisinopril (Liso) was evaluated on the TC-treated H-
ARS mouse model. TC was administrated as previously described 24 hr post-TBI and 
Liso was added to drinking water (60 mg/L) from day 7-30 post-TBI. Some mice were 
euthanized on day 10 to evaluate bone marrow HSC content, HPC number, HSC 
function, and BM cytokines. Brains were examined on day 10 for petechiae as ACE 
inhibition is a known mitigator of brain hemorrhage post-TBI [103]. CBC parameters 
were analyzed at day 10 and 20. Surviving mice over day 30 were transferred to the 
RBMD study and monitored for long-term survival. 
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Figure 59. WBC phenotype at day 21 post-TBI of mice treated with G-CSF or TC. 
Mice were exposed to 8.72 Gy TBI and treated with pegylated G-CSF or TC at 24 hr 
post-TBI. Mice were tail-bled at day 21 post-TBI and the expression levels of Gr-1, 
B220, CD4 and CD8 on peripheral nucleated cells were assessed by flow cytometry. Cell 
number was the product of WBC number in CBC analysis at day 21 and the percentage 
of each population acquired by flow cytometry. Bars present mean ± SEM. n=2-4 per 
group. *p<0.05 comparing to Veh group; ∆p<0.05 comparing to NI group. 
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Figure 60 
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Figure 60. Thymus weight and cellularity of lethal-irradiated mice treated with 
pegylated HGFs.  
Mice were exposed to 8.72, 9.04 or 9.27 Gy TBI and treated with pegylated HGFs as 
previously described. Thymus weight and cellularity were analyzed at day 2, 7, 10, 21 
and 12 months post-TBI (panel A & B). Data were analyzed in the method as “HGFs” vs. 
“Veh” (panel C & D), “single” vs. “combined” (panel E & F), “with G” vs. “no G” (panel 
G & H), “with GM” vs. “no GM” (panel I & J) and “with IL-11” vs. “no IL-11” (panel K 
& L). Bars present mean ± SEM. n=3-21 per group per time-point in panel A & B. 
*p<0.05 comparing to NI group; ∆p<0.05 comparing to Veh group. 
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Figure 61 
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Figure 61 continue 
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Figure 61. Thymus subpopulation of lethal-irradiated mice treated with pegylated 
HGFs.  
Mice were exposed to 8.72, 9.04 or 9.27 Gy TBI and treated with pegylated HGFs as 
previously described. At day 2, 7, 10, 21 and 12 months post-TBI, thymocytes were 
stained with CD4, CD8, CD44 and CD25 antibodies and percentages of different 
thymocyte subpopulations were assessed by flow cytometry as described in Materials and 
Methods. Plots of each HGF comparison and the comparisons of “with G” vs. “no G”, 
“with GM” vs. “no GM”, and “with IL-11” vs. “no IL-11” were not presented because no 
significant difference was observed; and for the easy of readers, only “HGFs” vs. “Veh” 
(panel A-H) and “single” vs. “combined” (panel I-P) plots were presented. Bars present 
mean ± SEM. n=16-28 in NI group, 3-8 in Veh group, and 14-45 in HGFs group, per 
time-point, respectively. *p<0.05 comparing to NI group. ∆p<0.05 comparing to Veh 
group. 
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All treatment groups [Liso, TC, and TC + lisinopril (TC+L)] significantly 
increased the day 30 survival rate compared with the Veh control, and this effect was 
most pronounced TC+L group. There was no significant difference between TC and Liso 
treatments alone (Figure 62 A). Interestingly, TC+L significantly increased survival rate 
in female mice but not in male mice (Figure 62 B & C). 
 
Complete blood count analysis at day 20 revealed that TC+L group had higher 
NE numbers than TC group and Veh group only in females. Female TC+L-treated and 
TC-treated mice had higher RBC counts than Veh-treated mice, though the difference 
between TC+L and TC treatment was not significant. Male mice followed the similar 
trends but did not reach statistical significance (Figure 63). At day 10, there was no 
significant difference in total bone marrow cell number or HSC number when comparing 
irradiated mice to Veh mice, regardless of treatments received or gender of mice. 
However, cell cycle analysis revealed that female TC+L-treated mice had significantly 
more quiescent HSCs than males (Figure 64). The colony-forming ability of cells from 
TC+L-treated mice was slightly increased in comparison with cells from TC or Veh-
treated mice, but this difference was not statistically significant and there were no sex 
differences in colony-forming ability between TC+L and TC-treated mice (Figure 65). 
 
TC+L-treated mice had lower levels of the pro-inflammatory cytokines RANTES 
(in bone marrow supernatant) and IL-3 (in plasma) than Veh-treated mice. No significant 
difference between TC- and TC+L-treated mice, or between females and males, was 
observed (Figure 66). No difference in other cytokines was observed. TC+L-treated mice 
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had fewer petechiae in the brain than Veh-treated mice, whereas TC-treated mice were 
similar to Veh controls (Figure 67). Reduced brain hemorrhage in TC+L-treated mice 
correlates with the enhanced day 30 survival rate and is also consistent with its higher 
PLT level than TC-treated and Veh controls at day 10, although the difference is not 
statistically significant (Figure 63). The impact of TC+L on thymic recovery was also 
evaluated at day 10 (Figure 68). No statistically-significant differences were observed 
between TC, TC+L, and Veh treatment indicating that Liso is not involved in thymic 
recovery at day 10. The only sex difference observed was the higher percentage of DN1 
in males in the Veh and TC+L groups (Figure 68). 
 
 H-ARS survivors were transferred to the RBMD study. The KM estimation of 
long-term survival showed no statistical difference among groups regardless of treatment, 
and the sex difference observed in the H-ARS study was not maintained long-term. 
(Figure 69). Complete blood count analysis at 6 months post-TBI showed lower WBC 
and LY numbers in irradiated mice but no statistical difference between Veh, TC and 
TC+L treated mice. No sex differences were found in CBC parameters at 6 months post-
TBI (Figure 70). Cells were flushed from the bone marrow and stained for SLAM-LSK 
including cell cycle analysis at 6 months post-TBI. Since there was no male mouse in 
Veh group and only 1 female mouse in Veh group at 6 months post-TBI time-point, 
ANOVA test was not available; and t-test comparisons between TC and TC+L group and 
between male and female in the two groups was used instead. There was no significant 
difference in bone marrow cell number, HSC number and HSC cell cycle status between 
TC and TC+L groups. Male mice had higher total bone marrow cell count than female 
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mice in TC-treated group, and female mice had higher Lin- cells than male mice in the 
TC+L-treated group. There were no sex differences in HPC (LSK) and HSC (SLAM-
LSK) cells (Figure 71). To assess HSC function, 0.3×106 donor cells from TC- or TC+L-
treated mice were injected into each recipient with 0.2×106 competitor cells, and 
recipients were monitored for donor chimerism monthly up to 4 months post-
transplantation. Although the average chimerism rates were higher in TC+L group than 
TC group, no statistically significant difference was observed when males and females 
were combined (Figure 72 A). Separately, however, the TC+L male mice had 
significantly higher donor chimerism rates than TC+L female mice, and also higher than 
male and female TC-treated mice. There were no sex differences in TC-treated mice 
(Figure 72 B). 
 
In summary, TC+L further slightly increased day 30 survival rate than TC (not 
significant, Figure 62) mice and this was consistent with no significant difference 
between TC and TC+L groups in hematopoietic recovery markers (CBC parameters, BM 
cell numbers, HSC/HPC numbers, etc.). Dr. Orschell's laboratory also found a sex 
difference where TC+L regimen was especially effective in female population which 
might relate to the higher CBC parameters and less HSC in proliferation status than male 
mice, although the causal relationship has not been verified. Same as peg-HGFs, adding 
lisinopril to the mitigator regimens did not help to alleviate the DEARE effect.  
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5.4. Discussion 
Impacts of different peg-HGFs regimens on survival and hematopoiesis were 
investigated from the H-ARS to the DEARE stage. The increased day 30  
Figure 62  
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Figure 62. Thirty-day survival of lethal-irradiated mice treated with TC, Lisinopril 
or TC+L.  
Mice were exposed to 9.04 Gy TBI and treated with TC or Veh 24 hr later. Lisinopril was 
dissolved into water for ad libitum at days 7-30 post-TBI. Thirty-day survival is shown as 
Kaplan-Meier curves. Total n=50-123 mice in each group (panel A). Female n=29-101 
mice in each group (panel B). Male n=10-22 mice in each group (panel C). *p<0.05 
comparing to Veh; ∆p<0.05 comparing to Liso; †p<0.05 comparing to TC. Sasidhar 
Vemula and Tong Wu acquired the data; Tong Wu did the analyses. 
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Figure 63 
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Figure 63. CBC profiles in H-ARS phase of lethal-irradiated mice treated with TC 
or TC+L.  
Mice were exposed to 9.04 Gy TBI and treated with TC or TC+L as previously 
described. Mice were tail-bled on and assessed for CBC parameters were evaluated at 
baseline, day 10 and day 20 post-TBI. WBC (panel A & F), NE (panel B & G), LY 
(panel C & H), RBC (panel D & I), PLT (panel E & J) were analyzed in male (panel A-
E) and female (panel F-J) separately. Lines present mean ± SEM. n=2-10 per group per 
gender per time-point. *p<0.05 comparing to Veh; ∆p<0.05 comparing to TC. Sasidhar 
Vemula and Tong Wu acquired the data; Tong Wu did the analyses. 
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Figure 64. HSC number and HSC cell cycle in H-ARS phase of lethal-irradiated 
mice treated with TC or TC+L.  
Mice were irradiated and treated as previously described. Mice were sacrificed at day 10 
post-TBI. Flushed BM cells were stained with Lin markers, Sca-1 and CD150 antibodies 
(panel A-D); and after fixed overnight in 1% formaldehyde, 0.042% DAPI was added for 
cell cycle analysis (panel E). Bars present mean ± SEM. n=5-7 per gender per group. 
*p<0.05 comparing to NI; ∆p<0.05 comparing male to female. 
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Figure 65. HPC in H-ARS phase of lethal-irradiated mice treated with TC or TC+L. 
Mice were irradiated and treated as previously described. Mice were sacrificed at day 10 
post-TBI and CFC assay was done as described in Materials and Methods. Bars present 
mean ± SEM. n=5-7 per gender per group. *p<0.05 comparing to NI; ∆p<0.05 comparing 
male to female. 
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Figure 66. BM and plasma cytokine in H-ARS phase of lethal-irradiated mice 
treated with TC or TC+L.  
Mice were irradiated and treated as previously described. Mice were sacrificed at day 10 
post-TBI and plasma was obtained by cardiac puncture. BM supernatants were obtained 
by flushing 2 femurs and 2 tibias twice with 500 ul PBS. Cytokine detection and analysis 
were followed as in Materials and Methods of Chapter 3. Bars present mean ± SEM. n=4-
6 per gender per group. *p<0.05 comparing to NI; †p<0.05 comparing to Veh.  
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Figure 67. Brain hemorrhages in H-ARS phase of lethal-irradiated mice treated 
with TC or TC+L.  
Mice were irradiated and treated as previously described. Mice were sacrificed at day 10 
post-TBI and cerebrum and cerebellum were scooped out of brain and petechiae were 
counted macroscopically on the surface on brain. Bars present mean ± SEM. Figures in 
panel B were the representative brain images taken from superior and base views. The 
representative petechiae were circled out in black colors. n=5-7 per gender per group. 
*p<0.05 comparing to Veh.  
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Figure 68. Thymus weight, cellularity and thymocyte subpopulations in H-ARS 
phase of lethal-irradiated mice treated with TC or TC+L.  
Mice were irradiated and treated as previously described. Mice were sacrificed at day 10 
post-TBI and the thymus weight, cellularity and thymocyte subpopulation analyses were 
followed as in Materials and Methods of Chapter 2. Bars present mean ± SEM. n=4-6 per 
gender per group. *p<0.05 comparing to NI; ∆p<0.05 comparing male to female. 
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Figure 69. Long-term survival of day 30 survived mice treated with Liso, TC or 
TC+L.  
Mice were exposed to 9.27 Gy TBI and treated with Liso, TC or TC+L as previously 
described. Mice survived over day 30 post-TBI were transferred to RBMD study for 
long-term survival monitor until the end of study (15 months post-TBI). The survival 
mice were recorded when found dead, or were euthanized when severely moribund or 
scheduled time-point sacrifices. Survival is shown as Kaplan-Meier curves. Total n=8-41 
mice in each group (panel A). Female n=7-29 mice in each group (panel B). Male n=1-14 
mice in each group (panel C). Sasidhar Vemula and Tong Wu acquired the data; Tong 
Wu did the analyses. 
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Figure 70. CBC profiles in DEARE phase of lethal-irradiated mice treated with TC 
or TC+L.  
Mice were exposed to 9.27 Gy TBI and treated with TC or TC+L as previously 
described. Survivors were tail-bled at 6 months post-TBI and assessed for the WBC 
(panel A), NE (panel B), LY (panel C), RBC (panel D), and PLT (panel E). Bars present 
mean ± SEM. n= 6-10 mice per group. *p<0.05 comparing to NI. Sasidhar Vemula and 
Tong Wu acquired the data; Tong Wu did the analyses. 
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Figure 71. HSC number and HSC cell cycle in DEARE phase of lethal-irradiated 
mice treated with TC or TC+L.  
Mice were exposed to 9.27 Gy TBI and treated with TC or TC+L as previously 
described. Survivors were sacrificed at 6 months post-TBI. Flushed BM cells were 
stained with Lin markers, c-Kit, Sca-1, CD48 and CD150 antibodies for SLAM LSK 
analysis (panel D); and after fixed overnight in 1% formaldehyde, 0.042% DAPI was 
added for cell cycle analysis (panel E). Bars present mean ± SEM. n=2 per gender in NI 
group, only one female in Veh group, n=4-7 per gender in TC and TC+L groups. *p<0.05 
comparing to female to male. 
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Figure 72. Long-term engraftment potential of BM cells in DEARE phase from 
lethal-irradiated mice treated with TC or TC+L.  
Mice were exposed to 9.27 Gy TBI and treated with TC or TC+L as previously 
described. Survivors were euthanized at 6 months post-TBI and 3×105 of donor whole 
BM cells were transplanted intravenously along with 2×105 competitor cells into 
congenic recipient. Peripheral blood was monitored for donor chimerism monthly till to 4 
months post-transplantation. Data were analyzed as male + female (gender of donors) 
combined in each treatment group (panel A) or male and female separately (panel B). 
Lines present mean ± SEM. n= 9-15 recipients per group per gender. *p<0.05 comparing 
to female TC+L group; ∆p<0.05 comparing to male TC group; †p<0.05 comparing to 
female TC group. Sasidhar Vemula and Tong Wu acquired the data; Tong Wu did the 
analyses. 
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survival rates with single or combined peg-HGFs regimens are similar to multiple daily 
injections of nonpegylated HGFs [69, 349]. One injection of peg-HGFs has logistical 
advantage over multiple daily administrations in the chaos scenario of nuclear plant 
disasters and nuclear warfare and has less possibility to develop neutralizing antibodies 
comparing to multiple injections. Besides, the risk of spleen rupture reported in 
chemotherapy patient who received multiple injections of G-CSF for treatment of 
neutropenia [350] is less likely to happen in single dose of peg-HGF scenario; especially 
considering there is a portion of patients receiving HGF treatment after nuclear accident 
whose radiation exposure might be very low but cannot be identified because of the 
limitation of dosimetry methods, the risk of spleen rupture might be even higher in those 
immune-intact population if they receive multiple injections of HGFs.  
 
The increased day 30 survival rate of mice treated with peg-HGFs correlates with 
the increased CBC parameters, including WBC, NE, RBC, and PLT, mainly at day 21 
post-TBI (Figure 42 & 50). The most pronounced differences observed were between 
peg-HGFs-treated and Veh-treated, with few differences observed between groups treated 
with different combinations of peg-HGFs (Figure 44-48). The CBC analyses indicate that 
some peg-HGFs regimens, such as “with IL-11” and “combined” regimens increase NE 
level at day 2 post-TBI. The lifespan of NE is short, generally fewer than 24 hours; and 
the cells are constitutively committed to apoptosis after leaving the bone marrow. G-CSF 
and GM-CSF have been reported to delay NE apoptosis in an unirradiated scenario in 
vivo and in vitro by regulating the activity of caspase family proteases [351-353] and IL-
11 is known to prevent intestinal crypt cell apoptosis after radiotherapy and 
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chemotherapy [354]. Pegylated HGFs might increase the CBC parameters at day 2 post-
TBI through the protection from apoptosis. The in vivo experiment shows that irradiation 
increases NE and LY apoptosis at day 2 post-TBI as expected; however, peg-HGFs did 
not protect NE and LY from apoptosis 24h after injection, where there is no difference in 
the apoptotic rate between peg-HGFs-treated and Veh groups (Figure 49). There are 
several possible reasons for the inconsistencies between the CBC data and apoptosis 
study. First, RBC lysis and staining during the apoptosis study might impact WBC 
integrity, obscuring any anti-apoptotic effects of peg-HGFs treatment. Secondly, a 
protective effect may occur earlier than 24 hr, making the 24 hr post-injection (day 2 
post-TBI) time-point too late to observe differences. Third, the higher NE numbers in 
“combined” and “with IL-11” groups may result from stronger progenitor stimulation in 
these groups compared with the “single” and “no IL-11” groups. However, this 
explanation is not supported by the lack of sustained high NE numbers at day 4 and 7. 
 
 Since mature peripheral blood cells differentiate from immature HPCs and HSCs 
in the BM, the HPC function was evaluated by CFU assay at different days post-TBI. 
Because of the scarcity of BM cells post-TBI, BM cells from four mice were pooled. 
Three quarters of the cells were used for the transplantation study, and the remainder for 
the CFU assay (Figure 51 A-D). Although statistical comparison to Veh is not available 
(Veh was pooled form four mice), the peg-HGFs treated groups had higher average CFU 
number than Veh-treated group as early as day 5 post-TBI and prominent at day 14 post-
TBI (Figure 51). In another similar study to evaluate the HSC number in BM, peg-HGFs 
treated group had significantly higher HSC number (LSCD150+) than Veh-treated group 
 291 
at day 10 post-TBI (Figure 52 E). These results indicate that peg-HGFs stimulate the 
proliferation of the remaining committed hematopoietic progenitor cells after radiation 
exposure, whether peg-HGFs also have indirect effect on the bone marrow niche cells 
remains to be determined in future study. 
 
Mice received “combined” regimens had slightly higher, but not significantly 
different, CFU number and HSC number than “single” regimens at early days post-TBI 
(Figure 51 E-H & Figure 52 F), and this hematopoietic recovery in bone marrow is 
consistent with the hematopoietic recovery in peripheral blood at later day (day 21) post-
TBI (Figure 47), which indicates that the extra benefit in hematopoietic recovery brought 
from polypharmacy strategy is limited. Similar results were observed for “with IL-11” 
and “no IL-11” analysis. These results indicate that there is possibility that “combined” or 
“with IL-11” regimens have positive effects on non-hematopoietic systems, such as in 
gastrointestinal system [341, 355], and thus enhance the day 30 survivals in mice 
received these regimens (Figure 42). Future studies will investigate the broad 
systems/organs effects other than hematopoietic system of the peg-HGFs. 
 
Next, transplantation study was used to evaluate the repopulation capacity of 
HSCs, monitoring peripheral blood chimerism for five months post-transplantation. In 
general, recipients had higher chimerism when transplanted at day 7 post-TBI than at 5, 
and higher at day 14 than days 7 and 5, meeting the expectation that HSC dysfunction 
gradually recovers over time following irradiation. Overall, the donor chimerism of 
irradiated mice was transient, no matter which treatments the donor mice received, which 
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indicates the loss of HSC long-term repopulating potential in irradiated mice. There were 
no statistically significant differences in chimerism rate between different peg-HGFs 
regimens (Figure 53 A-C). In order to increase the number of N in each group, all peg-
HGFs-treated groups were combined into the “HGF” group and compared with Veh 
group. No statistical difference between these groups at any time-point in mice 
transplanted at day 5 or day 7 post-TBI. The average chimerism in the “HGF” group was 
generally lower than in the Veh group in mice transplanted 14 days post-TBI. This 
difference was statistically significant at four months post-transplantation (Figure 53 D-
F). When “single” vs. “combined” were compared, at 1-month post day 14 
transplantation study, donor cells from mice receiving “combined” regimens had 
significantly higher chimerism than those from mice that received “single” regimens. 
This trend was sustained over the subsequent months but without statistical difference 
(Figure 53 G-I). When analyzed in the pattern of “with G” vs. “no G” (Figure 53 J-L), 
“with GM” vs. “no GM” (Figure 53 M-O) and “with IL-11” vs. “no IL-11” (Figure 53 P-
R), there was no significant difference comparing “with xx” to “no xx”. These results 
indicate that peg-HGFs did not rescue the loss of HSC repopulating potential brought by 
radiation exposure and even exacerbate the loss at certain time-point post-TBI. Peg-HGFs 
likely enhance hematopoietic recovery by promoting proliferation and differentiation of 
short-term repopulating progenitors at early time post-TBI but at the expense of self-
renewal and long-term repopulating potential of HSC, which may aggravate RBMD. This 
is consistent with the previous report from Li et al.[356] in which the donor receiving G-
CSF treatment had lower chimerism than the donor receiving Veh treatment 1-month 
post-TBI. The “combined” regimen transiently increase the chimerism rate indicates that 
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“combined” regimen preserves the HSC short-term repopulating potential better than 
“single” regimen. The effect of irradiation and peg-HGFs on self-renewal capacity of 
stem cells need to be tested by secondary transplantation which is beyond the scope of 
this study. 
 
Many studies have reported similar survival benefit of early administration of 
HGFs or peg-HGFs [74, 267], but long-term survival studies are rare due to prohibitive 
costs in long-term animal husbandry and monitoring. Most RBMD studies used sublethal 
radiation exposure or only monitored mice a few months post-TBI and did not use peg-
HGFs as MCM [40, 357, 358]. In this study, survivors of H-ARS were transferred to 
RBMD study with time-point sacrifices to observe delayed effects and evaluate long-term 
survival. Survival analyses showed that the survival benefit of peg-HGFs treatments in 
H-ARS phase did not sustain in DEARE. All irradiated mice had significantly lower 2-
year survival rates than NI mice, and no any peg-HGFs-treated group had significant 
higher survival rate than Veh-treated mice (Figure 54 A and Table 11). Combining 
different groups into “HGF” vs. “Veh” (Figure 54 B), “with IL-11” vs. “no IL-11” 
(Figure 54 C) and “single” vs. “combined” (Figure 54 D) as previously described, there 
was no significant difference between any of these comparisons. This result contradicts to 
the survival superiority of peg-HGFs in H-ARS phase, but it is consistent with the 
transplantation chimerism study at day 14 post-TBI (Figure 53 F) which highlighted the 
detrimental effect of peg-HGFs on HSC function post-TBI.  
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In DEARE markers studies including the body weight, CBC parameters, bone 
marrow HSC number and function at 6 and/or 12 months post-TBI, the results followed 
the similar trend in DEARE survival study, where the differences between peg-HGFs- 
and Veh-treated mice were minimal and there was no significant difference between 
“with xx” and “no xx” comparisons, or between “combined” and “single” comparison 
(Figure 55-58). The difference between irradiated mice and NI mice are generally more 
apparent in 12 months post-TBI than in 6 months post-TBI, such as body weight and 
myeloid skewing in peripheral blood, which reflects the “double hits” of aging and 
irradiation on the DEARE mice. The bone marrow LSKCD150+ cells followed the 
opposite trend where the number per mouse was higher in the 12 months NI and DEARE 
mice than the 6 months NI and DEARE mice, respectively (Figure 57). Dr. Orschell's 
laboratory has previously confirmed that the LSKCD150+ cells from irradiated survivor 
represent the long-term repopulating HSCs, the same as LSKCD150+ cells from NI mice 
[147]. The increased CD150 on KSL population of the irradiated mice has been reported 
by Simonnet AJ et al. [359] and by Chua HL et al. [40, 147]. Whether the increased 
CD150 expression represents the enhanced long-term repopulating ability is unknown, 
the lack of 6 months post-TBI transplantation data makes the comparison to 12 months 
post-TBI transplantation impossible. There is a possibility that more LSKCD150+ cells in 
DEARE mice represent a compensatory mechanism to try to maintain the increased 
hematopoietic demand, which is through the enhanced proliferation of HSCs, but the 
repopulating function of these HSCs is still defective [360-362]. From the result of 12 
months post -TBI HSC phenotyping study and the result of transplantation study at the 
same time, peg-HGFs have limited effect on either increasing the HSC number or 
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enhancing long-term repopulating progenitors, comparing to the Veh-treated control. The 
lower levels of donor-derived lymphoid differentiation in both peg-HGFs- and Veh-
treated mice than in NI mice (Figure 58) were consistent with the lower lymphocyte 
percentages in peripheral blood in these two groups than the NI group (Figure 56). This 
result indicates that the long-term immune deficiency roots in the HSCs whose 
multilineage differentiation ability is defective, rather than the direct effects of radiation 
exposure on mature lymphocytes.  
 
DNA damage and epigenetic changes are induced by irradiation and aging, 
leading to downregulation of lymphoid genes and upregulation of myeloid genes, which 
shifts the differentiation potential of the HSC pool to the myeloid lineage. Wang et al. 
found that irradiation-induced G-CSF/STAT3/BATF upregulation bypasses the lymphoid 
differentiation checkpoint, impairs the self-renewal potential of HSCs, and depletes 
lymphoid-biased HSCs [363]. Potentially, BATF activation is G-CSF dependent and 
needs continuous stimulation with G-CSF sustain activated status and maintain HSC self-
renewal inhibition [363]. Irradiation-induced apoptosis or cell cycle arrest [364] in HSCs 
cannot explain the myeloid skewing observed in normal aging mice and DEARE mice 
[363]. This model perfectly explains that LY number partially recovers at day 21 post-
TBI, especially apparent in the peg-G-CSF group (Figure 45). It also raises the concern 
that administration of HGFs would impair HSC self-renewal and exacerbate the myeloid 
skewing. The transplantation study shows that a decreased chimerism rate at 4 months 
post-transplantation in the peg-HGFs group comparing with Veh group (Figure 53 F). 
This result indicates the possibility that administration of peg-HGFs as MCM rescues the 
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irradiated mice by inducing the differentiation of short-term repopulating progenitors and 
impairs the HSC long-term repopulating potential at an early time-point post-TBI, 
whether this impairment relates to the G-CSF/STAT3/BATF pathway needs further 
investigation. 
 
The day 21 peripheral blood analysis indicated that T and B cells increase in the 
peg-G-CSF treated group compared to Veh group, albeit to a less extent than the 
increased Gr1+ neutrophils (Figure 59). Adding more peg-HGFs into the regimen does 
not increase lymphocytes and neutrophils. The differentiation of T lymphocytes is 
different from B lymphocytes and neutrophils since T cells require thymic education and 
maturation. The atrophy of thymus is a hallmark of aging and contributes to the loss of 
immune function in senior mammals, including humans and mice. The involution of 
thymus post-TBI has been reported [186, 218, 219], but rarely discussed in an MCM 
scenario. In this section, the thymic involution and recovery post-TBI in H-ARS and 
DEARE phases, and the impact of peg-HGFs on the thymus, were investigated. Thymus 
is extremely sensitive to radiation, reaching the first nadir at day 2 post-TBI, followed by 
the first recovery peak at day 10, and then second nadir at around day 21 and second peak 
at around day 30-40. Subsequently, the thymus gradually involutes under the double hits 
of aging and irradiation (Figure 60 A & B). The first recovery results from the 
proliferation and expansion of radioresistant thymocytes and the second recovery is from 
the proliferation and expansion of ETPs which are generated de novo from HSC in bone 
marrow [218, 365]. 
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 Administration of peg-HGFs at 24 hr post-TBI did not change the thymic weight 
and cellularity at the first nadir and peak. When combining all peg-HGFs-treated groups 
together, the “HGFs” group had statistically higher thymus weight and cellularity than 
Veh group at day 21 post-TBI (Figure 60 C & D). Analysis of thymic subpopulations at 
day 21 reveals that the “HGF” group had a statistically higher percentage of DP cells 
which indicates peg-HGFs enhance the de novo thymus regeneration. Previous studies 
have shown that G-CSF, GM-CSF or IL-11 enhance hematopoiesis mainly by promoting 
the proliferation and differentiation of myeloid-megakaryoid progenitor cells [366, 367]. 
Current studies indicate that peg-HGFs treatment 24 hr post-TBI enhances immune 
recovery in both the myeloid and lymphoid lineage. Thymus-dependent de novo 
regeneration originated from BM-derived progenitors and thymus-independent HPE are 
the two ways of T cell reconstitution. The effect of peg-HGFs on HPE has not been 
evaluated; however, the G-CSF receptor has expression on some mature B and T 
lymphocytes [368, 369] and G-CSF enhances the proliferation of these cells [346, 369]. 
Although the expression of GM-CSF and IL-11 receptors have not been reported on the 
surface of peripheral lymphocytes, it is possible that GM-CSF or IL-11-taregeted cells 
such as monocytes have an indirect influence on lymphocyte proliferation [370, 371]. 
Lymphocyte recovery at day 21 following peg-HGF administration post-TBI involves 
both the thymus-dependent and thymus-independent T cell recovery pathways. 
Lymphocyte with thymus education provide a more comprehensive immune protection 
than lymphocyte generated from HPE. Interestingly, at 12 months post-TBI, the peg-
HGFs-treated mice had lower thymic weight and cellularity than Veh group (Figure 61 J, 
N & O). It is consistent with the lower chimerism rate in bone marrow of peg-HGFs 
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group comparing with Veh control in the transplantation study (Figure 53 F). The lower 
thymus repopulating potential of the ETPs might be similar to the lower bone marrow 
repopulating potential HSCs in the irradiated mice. Further study is needed to identify 
whether peg-HGFs impair the homing of ETPs to thymus or impair the proliferation and 
differentiation of ETPs. 
 
Except peg-HGFs, other MCMs are also investigated to see if there is space to 
further increase survival in H-ARS and alleviate DEARE effects. ACE is part of the 
classic RAS system, which converts angiotensin I to angiotensin II. ACEI is widely used 
in the treatment of hypertension. Recent research found that HSCs express ACE 
throughout the hematopoietic ontogeny from embryo to adulthood [372]. HPCs exhibit 
transient cell cycle arrest after two days of captopril (a classic ACEI) administration in 
vivo. When used as a radiomitigator instead of a radioprotectant, captopril significantly 
decreases radiation-induced lethality by accelerating hematopoietic recovery. The cell 
cycle pause leads to side effects in hypertension patients including agranulocytosis, 
anemia, or pancytopenia [373-375]. Based on previous findings, Liso was added to TC 
regimen to determine whether this new combination (TC+L) more effectively alleviates 
H-ARS and DEARE than TC alone. The results show that the day 30 survival rate 
slightly increased in the TC+L group in comparison with the TC group, and there was a 
sex difference in this effect. TC+L was more effective in female than in male mice 
(Figure 62 A-C). In the HSC cell cycle analysis at day 10 post-TBI (3 days after Liso 
treatment), more quiescent HSCs were present in female TC+L-treated mice than in male 
TC+L-treated mice; and in female mice, the percentage of HSCs in quiescent status was 
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slightly higher in the TC+L group than the TC and Veh group, although not statistically 
different (Figure 64 E). This result indicates that sex difference in cell cycle pause is a 
possible mechanism for the higher survival rate in female TC+L group. This is consistent 
with a report from Davis et al., showing an increased percentage of HSCs in quiescent 
status in captopril-treated female mice [103]. The transient cell cycle pause allowing 
more time for repair of radiation-induced DNA damage in HSCs. Cautions are needed for 
the interpretation of these results because there was no statistical difference in cell cycle 
between TC+L and TC group; and in TC group, there was similar trend of sex difference 
although not statistically different, which was not seen in other TC studies. The possible 
reasons could relate to the small size of N (5-7 mice per group) or relate to the time of 
sacrifice, day 10 post-TBI (3 days after Liso treatment) might be too short to observe the 
full effect of Liso, which also explains that why there was no significant difference 
between TC+L and TC groups in BM cellularity, HSC and HPC number, BM cytokines 
and brain petechiae studies at this time-point. Because the cell cycle arrest is transient 
and followed with more cells entering the G1 to G2 transition [103], it is possible that the 
higher neutrophil number at day 20 in the female TC+L group than TC group correlates 
with the earlier cell cycle pause on progenitors. In summary, there are several possible 
mechanisms to explain the survival benefit and the sex difference for TC+L regimen, 
further studies are needed to investigate other time-points after Liso treatment and 
increase the sample size.  
 
In the DEARE study, TC+L group did not improve long-term survival, myeloid 
skewing, or HSC number (Figure 69-71). However, analysis of HSC function at DEARE 
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mice (6 months post-TBI) with competitive transplantation revealed that TC+L-treated 
male mice had significantly higher donor chimerism rate than TC+L-treated female mice 
and significantly higher than TC-treated mice in both genders (Figure 72). Although the 
long-term survival rate in TC+L-treated male mice was higher than the TC-treated male 
mice and was higher than TC- and TC+L-treated female mice, which is consistent with 
the transplantation results, the differences were not statistically significant and this might 
relate to the limited number of mice survived to the DEARE phase. The reason for why 
female TC+L-treated mice had higher day 30 survival rate than male mice in H-ARS 
phase, but lower long-term survival rate and HSC repopulation ability in the DEARE 
phase, is not clear. Further evaluation of sex hormone status at these time-points may 
provide insights into the observed sex difference.  
 
To summarize, one shot of single or multiple combined peg-HGFs at 24 hr post-
TBI enhances the day 30 survival rate and alleviates H-ARS, including thymus recovery, 
which promotes the de novo regeneration of T cells. The effects of peg-HGFs on DEARE 
are minimal when compared to Veh-treated mice in terms of long-term survival, body 
weight, myeloid skewing, HSPC number, and HSC function. Adding lisinopril from day 
7 post-TBI further increases the day 30 survival rate and shows a sex difference in TC+L 
group. Future studies with large sample size and more mechanism studies such as sex 
hormone status in H-ARS and DEARE phases are needed.  
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Chapter 6. Future Directions  
6.1. Time-window and dosage-window of dmPGE2 efficacy 
As described in Chapter 3, dmPGE2 administrated at -24 hr prior to irradiation 
does not enhance survival; whereas dmPGE2 schedules administrated within 3 hr time 
window prior to irradiation are all effective and -1 hr prior to irradiation conferred a little 
better survival than -3 hr prior to irradiation, though not statistically significantly (day 30 
survival rate of 90% vs.100% respectively; Figure 21). Previous studies reported that the 
closer to irradiation, the more effective the dmPGE2 protection and suggested that -1 hr 
prior to irradiation is the time limit [134]. Current studies show the similar trend and 
extend the time-window to -3 hr prior to irradiation. There is a specific time-window in 
which dmPGE2 must be administered for a protective effect to be achieved. Since the -24 
hr time-point is the only earlier time-point tested than -3 hr, whether other time-points 
early than -3 hr will still be effective and where is the upper limit of the time window for 
radioprotection are unknown. Further studies at time-points between -3 hr and -24 hr 
prior to irradiation would help to reveal when PGE2 signaling pathway to start and end 
its effects in hematopoietic system. 
 
One dose of 35 µg or two doses of 20 µg dmPGE2 were tested in the survival 
studies. According to previous reports, the closer of the time-point of dmPGE2 
administration to the time-point of irradiation, the lesser dmPGE2 dose is needed for 
providing an adequate protection. Walden TL et al. reported that 1 µg of dmPGE2 
injected -5 min prior to TBI (10 Gy) results in ~90% survival [134]. The side effects of 
dmPGE2 injection include diarrhea and decreased ambulation, which are dose-dependent 
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[134], and these side effects are one of the main obstacles that prevent its wide usage. 
The severity and duration of these side effects with a 1 µg dmPGE2 treatment would be 
significantly lower than the 35 µg schedule. Investigating the potential to use this smaller 
dose is of importance if dmPGE2 is to be used as a radioprotectant for first responders 
and military personnel as they will be required to work in a radioactive material-
contaminated environment and thus require treatment which is not associated with side 
effects that will affect their ability to work. 
 
Another limitation of current studies is that the highest irradiation dose tested is 
9.04 Gy (LD90/30) and therefore it is not known whether the dmPGE2 schedule tested 
render the mice capable of tolerating a higher radiation dose. In previous studies, a 
similar dmPGE2 regimen (40 µg at -30 min prior to TBI) increased the LD50/30 from 
9.39 Gy to 16.14 Gy, with the survival curve beginning to decline after 10 Gy [134]. A 
probit analysis in well-defined mouse model would provide information on to how to 
adjust the dmPGE2 regimen according to the predicted level of radiation exposure. 
 
As for the dmPGE2 radiomitigation, although +3 hr schedule fails to increase the 
survival rate and +6 hr schedule is effective and the time-window is extended to +30 hr 
post-TBI, whether earlier time-points than the +3 hr, especially the time-points very close 
to irradiation, will be effective or not, is still unknown. Although a previous study [276] 
indicated that dmPGE2 given immediately after irradiation could decrease the loss of 
functional HSPC, another survival study [134] demonstrated that mice received dmPGE2 
at either 5, 15, 30, or 60 post-irradiation were all dead. This discrepancy might relate to 
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different mouse stain (C57BL/6 vs. CD2F1), different irradiation dose (6.5 Gy from 137Cs 
vs. 10 Gy from 60Co) and different dmPGE2 dose (2 µg/g, around 40 µg per mouse vs. 10 
µg per mouse). Since Walden TL et al. [134] in the survival study only used 10 µg 
dmPGE2, whether the result will be different if higher dosage applied, such as 35 µg, is 
unknown. And since in radioprotection studies, the protective effect is dmPGE2 dosage-
dependent, it is reasonable to assume that radiomitigation effect might also be dosage-
dependent.  
 
In summary, further investigations into the limits of the use of dmPGE2 as a 
radioprotectant are required for optimizing the timing of injection, the dose of dmPGE2, 
and the effect of the dose of irradiation on efficacy. These studies will be beneficial 
curating an optimal regimen according to predicted radiation exposure, and will be 
meaningful to the potential recipients of dmPGE2 protection, especially to first 
responders and military personnel facing a radiation threat. 
 
6.2. Mechanism of dmPGE2 protection 
It is not known whether the protection effect of dmPGE2 is dependent on the 
presence of dmPGE2 at the time of irradiation, or whether non-dmPGE2 components 
mediate the protection effect. The metabolism of endogenous PGE2 occurs rapidly via 
pulmonary circulation and has a half-life of ~30 s [376]. DmPGE2 has two methyl groups 
at position 16, rendering it resistant to 15-hydroxy PGDH degradation [377] and 
extending its half-life to 20-25 min (unpublished data). Although dmPGE2 has a longer 
half-life than regular PGE2, the half-life of dmPGE2 is still much shorter than the 
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dmPGE2 radioprotectant time-window (3 hr prior to TBI). It is possible that dmPGE2 
protection is not dependent on a specific lowest presence level or a threshold of dmPGE2 
in bone marrow or peripheral blood. Another early study also indicate this possibility by 
detecting the dmPGE2 concentration in plasma, spleen and BM after injection, where 
they found that dmPGE2 concentrations in BM and spleen are higher in 1 hr post-
injection than 5 min post-injection, whereas the -5 min dmPGE2 protection effect is 
better than -1 hr administration [134]. The lack of correlation between drug concentration 
and protection effect indicates that dmPGE2-induced activities are receptor mediated. 
 
There are several potential mechanisms for dmPGE2 radioprotection. First, free 
radical scavenger is supposed to be the mechanism for protectants with sulfhydryl (thiol) 
group such as amifostine or glutathione [378]. However, dmPGE2 does not have 
sulfhydryl (thiol) group and at 30 min after injection most dmPGE2 in tissue are still in 
unmetabolized status, so at least it seems not a direct scavenger effect. Future study 
would focus on the detection of intracellular sulfhydryl containing compounds, such as 
glutathione, induced by the radioprotectant in a relative short time (considering the time-
window for radioprotectant dmPGE2 could be as short as -5 min to -15 min prior to 
irradiation). Second, inhibiting cell cycling or redistributing cell cycle to late S phase 
could decrease the DNA damages brought by irradiation and thus increase survival. 
However, as described in previous chapter, the dmPGE2 suppression on HSPC 
proliferation is longer than 24 hr after injection but the -24 hr dmPGE2 schedule is not 
radioprotectant, which challenge the cell cycle inhibition theory; what’s more, 
considering as short as -5 min prior irradiation could provide radioprotection [134], it is 
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almost impossible to redistribute cell cycle to late S phase in such short time. Last, 
changing microenvironment, such as hypoxia environment, is also a potential mechanism 
for radioprotectant and this is also a mechanism for radioresistant cancer cells. Although 
lack of direct evidence that dmPGE2 could induce hypoxia, considering one of its 
physiological effect is vasodilation, which means bring more oxygen to tissues, 
challenges this hypothesis [132]. Among all these mechanisms, the future studies 
focusing on accumulated intracellular sulfhydryl compounds [132] and/or elevated cAMP 
[379] induced by PGE2 receptor activation are promising. 
 
Here, results suggest that EP4 agonist increases day 30 survival compared to Veh 
and other EP agonists (Figure 23), but the survival rate with was considerably lower than 
observed with dmPGE2 treatment. Although EP1, 2, and 3 agonists fail to show similar 
protection, it cannot be ruled out that the protective effect is mediated through a 
combination of all three or four agonists. In order to further verify the responsible EP 
receptor, future experiments need to include an EP 2+3+4 agonist combination group, or 
use EP agonist which hits all EP receptors (such as misoprostol), or seek a more potent 
EP4 agonist, or test an intensive EP4 agonist regimen. 
 
In bone marrow, non-dmPGE2 components such as KC (Figure 25), may be 
regulated by dmPGE2 shortly after dmPGE2 injection. The contribution of these 
cytokines to the radioprotective activity of dmPGE2 will be assessed in future 
experiments by injecting the cytokines prior to TBI. The potential for dmPGE2 to 
regulate non-protein components, such as the sulfhydryl compounds as observed with 
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PGE2 gastric cytoprotection, cannot be ruled out [380, 381]. Considering the complexity 
of the role of PGE2 in normal physiological processes, it is highly possible that dmPGE2 
radioprotection involves multiple molecules or pathways. The RNA sequencing and IPA 
analysis on the LMPP and CLP population, which under the protection of dmPGE2, 
would be helpful in identifying more lymphoid-related genes and reveal which 
differentiation stage dmPGE2 protection targets on. 
 
6.3. Polypharmacy of peg-HGFs and dmPGE2 
Peg-HGFs are effective radiomitigators, treatment with multiple peg-HGFs 
increases the survival rate following TBI (Figure 42). Although mice receiving peg-HGFs 
had accelerated CBC recovery at around day 20 post-TBI (Figure 48), the treatment did 
not ameliorate low WBC, NE, and LY counts at their nadir (day 10 post-TBI). DmPGE2 
similarly increased the day 30 survival rate when used as a radioprotectant, and increased 
WBC and NE levels at day 10 post-TBI. DmPGE2 did not increase LY levels at day 10 
post-TBI, and prolonged LY recovery until day 30 (Figure 24). DEARE mice receiving 
peg-HGF treatment at young age showed a trend of a more involuted thymus than Veh-
treated mice (Figure 60), whereas mice receiving dmPGE2 treatment had better thymic 
reconstitution than Veh-treated mice (Figure 27). The lower WBC, NE, or LY post-TBI 
in H-ARS mice and involuted thymus in DEARE mice contribute to the higher 
opportunistic infection rate and death rate. A polypharmacy strategy combining dmPGE2 
as radioprotectant and peg-HGFs as radiomitigator will be investigated in the future, 
which may further enhance hematopoiesis post-TBI. Additionally, this combined therapy 
may reduce the required dose of dmPGE2, alleviating the side effects associated with a 
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higher dose. Combining the dmPGE2 radioprotective protection of HSCs from radiation 
damage and peg-HGF radiomitigating promotion of HPC proliferation and differentiation 
may result in a beneficial synergistic effect.  
 
6.4. DmPGE2 used in the scenarios of chemotherapy or radiotherapy 
Patients undergoing chemotherapy or radiotherapy for malignancy or bone 
marrow transplantation have been successfully treated with HGFs and peg-HGFs. There 
are a limited number of FDA-approved radioprotectants. The only FDA-approved 
cytoprotectant for chemotherapy and radiotherapy is Amifostine. Although dmPGE2 as a 
radioprotectant greatly enhances day 30 survival, accelerates hematopoiesis recovery, and 
prevents myeloid skewing in DEARE mice, there is a concern that dmPGE2 may protect 
cancer cells and thus increase recurrence rate. 
 
Recently, endogenous PGE2 has been shown to play an important role in 
tumorigenesis. COX-2, a key enzyme in the prostaglandin synthesis pathway, is 
overexpressed in 80-85% of adenocarcinomas [382]. Prostaglandin E synthase 2 
(PTGES2), the enzyme catalyzing the final step of PGE2 synthesis, has a higher 
expression level in endometrial cancer tissue than in normal tissue [383]. The 
concentration of PGE2 is increased five-fold in breast cancer tissue compared with 
normal tissue [384]. The expression level of 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH), an important enzyme responsible to the degradation of PGE2, is lower in 
colorectal cancer than in normal tissue [385]. Administration of a COX-2 inhibitor or 
EP4 antagonist inhibits cancer growth and metastasis through inhibiting 
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lymphangiogenesis and angiogenesis in a breast cancer mouse model [386]. Clinically, 
celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for the treatment 
of familial adenomatous polyposis (FAP) [387]. Clinical trials on celecoxib or aspirin for 
cancer primary prevention are ongoing [388]. 
 
In addition to studies suggesting that PGE2 is a driver of cancer, a few studies 
indicate that it may also play an anti-cancer role. Wilson et al. reported that weekly 
injections of dmPGE2 for 12 weeks in APCMin/+ mice reduced the size and number of 
GI adenomas in comparison with control-treated mice. Although this study’s result is the 
opposite to other findings, it indicates that the effects on cancer cells from PGE2 are 
more complicated than initially thought, and the effect of exogenous vs. endogenous 
PGE2 might be different [389, 390]. 
 
In most PGE2 studies indicating a pro-cancer effect, the focus was on 
endogenous, long-lasting exposure to PGE2. A one-time injection of dmPGE2 would be 
metabolized quickly and thus may not drive tumorigenesis. Considering the 
hypovascularity and low PH in the cancer microenvironment, which is different from 
normal tissue, the amount of PGE2 exposure in cancer compared with in normal tissue 
following dmPGE2 treatment is likely to be considerably different. Since the 
concentration of endogenous PGE2 in the cancer microenvironment is elevated in 
compared with normal tissue [384], the increase brought about by a one-time dmPGE2 
injection might be negligible in cancer tissue, but sufficient to provide radioprotection in 
normal tissue. 
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Future studies will therefore investigate the impact of dmPGE2 on tumorigenesis 
and using dmPGE2 before radiotherapy in a tumor-bearing mouse model. If dmPGE2 
increases survival and boosts immune reconstitution, but does not impact the effect of 
radiotherapy and increase the cancer relapse rate in the long-term, it will be a strong 
candidate for preventing radiation effects in cancer patients.  
 
However, the double-hit to lymphoid cells from dmPGE2 and radiotherapy may 
prolong the lymphoid cell inhibition period. Whether the risk for infection will increase, 
especially opportunistic viral infection, needs further evaluation. Additionally, the 
lymphocyte percentage in humans (20-30%) and mice (60-90%) is different, and the 
observation of initial inhibition and later recovery of lymphopoiesis in dmPGE2 injected 
mice might not appear in humans. A non-human primate study is necessary before 
progressing to human clinical trial. 
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